

Therapeutic (“normal”), toxic, and comatose-fatal blood-plasma concentrations (mg/L) in man

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Abacavir (ABC)	0.9-3.9 ³⁰⁸			appr. 1.5	[1,2]
Acamprosate	appr. 0.25-0.7 ²³¹	1 ³¹¹		13-20 ²³²	[3], [4], [5]
Acebutolol ¹	0.2-2 (0.5-1.26) ¹		15-20	3-11	[6], [7], [8]
Acecaïnide	see (N-Acetyl-) Procainamide				
Acecarbromal(um)	10-20 (sum)	25-30			
Acemetacin	see Indomet(h)acin				
Acenocoumarol	0.03-0.1 ¹⁹⁷	0.1-0.15		3-11	[9], [3], [10], [11]
Acetaldehyde	0-30	100-125			[10], [11]
Acetaminophen	see Paracetamol				
Acetazolamide	(4-) 10-20 ²⁶⁷	25-30		2-6 (-13)	[3], [12], [13], [14], [11]
Acetohexamide	20-70	500		1.3	[15]
Acetone	(2-) 5-20	100-400; 2000 ⁸	550	(6-)8-31	[11], [16], [17]
Acetonitrile			0.77	32	[11]
Acetyldigoxin	0.0005-0.0008 ³	0.0025-0.003	0.005	40-70	[18], [19], [20], [21], [22], [23], [24], [25], [26], [27]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Acetylsalicylic acid (ASS, ASA)	20-200 ²	300-350 ²	(400-) 500 ²	3-20 ^{2, 37}	[28], [29], [30], [31], [32], [33], [34]
Acitretin	appr. 0.01-0.05 ¹¹²			2-4 ⁶	[35], [36]
Acrivastine	-0.07			1-2	[8]
Acyclovir	0.4-1.5 ²⁰³			2-5 ⁸³	[37], [3], [38], [39], [10]
Adalimumab (TNF-antibody)	appr. 5-9			14 ⁶	[40]
Adipiodone(-meglumine)	850-1200			0.5	[41]
Äthanol	see Ethanol			-.139	
Agomelatine	0.007-0.3 ³¹⁰	0.6 ³¹¹		1-2	[4]
Ajmaline	(0.1-) 0.53-2.21 (?)		5.5 ⁸	1.3-1.6, 5-6	[3], [42]
Albendazole	0.5-1.5 ⁹²			8-9 ⁹²	[43], [44], [45], [46]
Albuterol	see Salbutamol				
Alcuronium	0.3-3 ³⁵³			3.3±1.3	[47]
Aldrin	-0.0015	0.0035		50-167 ⁶ (as dieldrin)	[11], [48]
Alendronate (Alendronic acid)	< 0.005 ³²²			-.6	[49], [50], [51]
Alfentanil	0.03-0.6 ⁴			0.6-2.3 ⁹⁶	[52], [53], [54], [55]
Alfuzosine	0.003-0.06			3-9	[8]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Alimemazine (Trimeprazine)	0.05-0.4	0.5	1-3.2	8	[56], [57]
Alizapride	0.1-2			2-3	[15]
Allobarbital	2-5	10	20	40-48	[47], [11], [58]
Allopurinol ³⁵⁴	2-19			0.5-3	[11]
Almotriptan	0.05-0.07			3-4	[47]
Alphaprodine	0.87-1			1.6-2.6	[11]
Alprazolam	0.005-0.05 (-0.08) ⁶⁵	0.1-0.4	²⁵²	6-20	[56], [3], [59], [60], [61], [62], [63]
Alprenolol ⁴⁸	0.025-0.14	1-2	40-48	2-7	[7]
4-Hydroxyalprenolol	0.04-0.06				[8]
Aluminium	< 0.005 ²³⁴	0.05-0.15	4.4 ⁸	appr. 0.5	[64], [65], [66], [11]
Amantadine	(0.06-) 0.2-0.6 (-1)	1; 2.4 ⁸	2.1-4.8; 21 ⁸	9-15	[48]
Amfebutamone	see Bupropion				
Amikacin	10-25 ⁷⁶	30		2-3	[67]
Aminobenzoic acid	300-600	600			[66]
Aminoglutethimide	(0.05-) 7.5-25			10-15	[3], [8], [11]
Aminophenazone	10-20			appr. 2-4	[15]
4-Aminopyridine (Fampridine)	0.025-0.075	0.14 ⁸ ; 0.2		3-3.5	[68], [10], [11]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
5-Aminosalicylic acid (5-AS, 5-ASA)	see Mesalazine				
Amiodarone ²⁶¹	(0.5-) 1-2 (-2.5)	2.5-3		30-120 ⁶	[69], [64], [3], [70], [71]
Amisulpride	0.1-0.4	0.64 ³¹¹	9.3 ⁸ ; 41.7 ⁸	12-20	[4], [72], [15], [8]
Amitriptyline ^{7; 48}	0.05-0.3	0.5-0.6	1.5-2	30-50	[73], [74], [56], [75], [76], [77], [78], [79], [80], [81], [82], [83]
Amlodipine	0.003-0.015	0.088 ^{8; 165}	0.1-0.2 ^{8; 166}	34-50	[84], [85], [86]
Ammonia	0.5-1.7				[11]
Amobarbital	1-5	(5-6) 10-30	13-96	15-30	[87], [48]
Amodiaquine	-0.05 ²⁷⁰			- ²⁷⁰	[88]
Amoxapine	0.18-0.6 ¹⁵¹	3	5	8	[9]
Amoxicillin	0.5-1 (5-15)			1-2	[15]
Amphetamine	0.02-0.1	0.2	0.5-1	4-8 (7-34) ³⁴⁴	[89], [66]
Amphotericin B	(0.1-) 0.2-3	(3-) 5-10		24-48 ¹¹⁰	[47], [90], [91], [92], [93]
Ampicillin	0.02-2 (2-20)			1	[67]
Amrinone	1-2 (-4)			3-12	[3], [94], [95]
Amsacrine	(0.1-) 1-5.5			5-7	[96]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Anileridine	< 0.5		0.9 ⁸		[11], [48]
Aniline	-0.02 ³²⁸ (urine)	0.13 ^{8; 355}	6	(2-) 3-4 (-7)	[11], [48], [97], [47], [98], [99]
Antimony	-0.01 ³²⁹	0.2			[64], [100]
Antipyrine	see Phenazone				
Apomorphine	0.002-0.02 ²⁰⁴			appr. 0.75	[3], [10]
Aprindine ⁴⁸	1-2	2-3		13-50	
Aprobarbital	4-20	30-40	50	14-34	[47], [11], [58]
Aripiprazole	0.15-0.5	1 ^{311; 345}		60-80	[101], [4], [102]
Arsenic	0.002-0.07 ²⁸³	0.05-0.25	9-15		[103], [64], [87], [11], [100]
Asenapine	0.002-0.005	0.01 ³¹¹		24	[4]
Articaine	< 1.5-2 (?)			0.3 (-1)	[104]
Ascorbic acid (Vitamin C)	4-15			-. ⁶	[105], [3], [106], [107],[108]
Astemizole	0.002-0.05 ⁴³	14 ⁸		appr. 20 ^{6; 42; 43}	[47], [3], [109]
Atazanavir (ATV)	> 0.15 ²⁹³			6.5-8.6	[110], [2], [111]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Atenolol	0.1-1 (-2) ⁷⁷	2-3	27 ⁸	4-14 ⁹	[3], [42], [7], [112], [64]
Atomoxetine	0.2-1 ³¹⁷	2 ³¹¹		appr. 4 ³⁵⁶	[4]
Atovaquone	13.9 ± 6.9 (> 15)			2-3 ⁶	[113]
Atracurium(besylate)	0.1-0.5 (-5)			appr. 0.5	
Atropine	0.002-0.025 ¹⁵⁵	0.03-0.1	0.2	2-6.5, 13-38	[66], [114], [11]
Azapropazone (Apazone)	40-90			8-24	
Azathioprine ¹⁰	0.05-2			1-4 ¹¹	
Azelastine	0.002-0.003(-0.01)			22-25	[15]
Azithromycin	appr. 0.04-1			50-60 (2-4 ⁶)	[115], [116], [117], [118], [119]
Aztreonam	1-10 (50-250)			1.5-2	[11]
Baclofen	0.08-0.4 (-0.6)	1.1-3.5	6-9.6	6.8±0.7	[47], [9], [11]
Bambuterol	see Terbutaline				
Barbexalone	active metabolite = phenobarbital (see Table)				[12]
Barbital	2-20	20-50	50	57-120	
Barium	-0.001			10-18	[47]
Bendrofluazide	0.05-0.1			appr. 3	[42]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Benoxapfen	-50			19-39	[3]
Benperidol	0.001-0.01	0.02 ³¹¹		4-8	[4], [15], [8]
Benzbromarone	2-10			2-4	
Benzene	-0.0002 ²⁷¹		0.95	9-24	[47], [58]
Benzonatate		2.5		appr. 1-3	[8]
Benzoyllecgonine ³⁵⁷	-0.1		1	4-5	[8]
Benzphetamine	0.025-0.5	0.5	14 ⁸		[47], [8], [11]
Benztropine	0.01-0.18	0.05	0.2-0.7		[15], [8], [11]
Benzyl alcohol		18 ⁸ , 19 ⁴		.1 ⁹⁵	[3], [120], [121]
Benzylpenicillin	1.2-12			1	[67], [41]
Bepridil	0.6-2.5			33-42 (30-130)	[122], [8]
Beryllium	-0.0003				[58]
Betacarotene	4-6 ¹⁹⁶				[123], [124]
Betaxolol	0.005-0.05		36 ⁸	14-22	[47], [125], [7]
Bethanidine	0.02-0.5			9-10	[3], [58]
Bevantolol	0.2-2			2	[15], [8]
Bezafibrate	-15			2	[3]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Bicalutamide	1.5-17.5 (-25) ¹⁶³			(3-) 7-10 ⁶	[126]
Biperiden	0.05-0.1?		0.25 ⁸	18-24	[56]
Bismut(h)	< 0.05 (-0.1)	0.05-0.1		. ⁶	[47], [64]
Bisoprolol	0.01-0.1			10-12	[7]
Bopindolol	0.001-0.015 ⁵⁴			4-8 ⁵⁴	[7]
Borate	0-7	20	200	12-27	[47], [66]
Boron	0.8-6	20-50	50-150		[58]
Bornaprine	0.0007-0.0072 ³¹³	0.014 ³¹¹		appr. 30	[4]
Brallobarbital (Brallobarbitone)	4-8	8-10	15	20-40	
Bretylum	0.8-2.4			6-11	[3]
Brodifacoum		0.02	0.03-0.17; acute: 3.9 ⁸	20-60 ⁶	[58], [127]
Bromadiolon		0.02		3-6 ⁶ (early), 10-24 ⁶ (late phase)	[11], [58]
Bromazepam	(0.05-) 0.08-0.2	0.3-0.4	(1-) 2	8-22	[59]
Bromide	75-100 (-300)	500-1500; 3000 ^{8; 242}	2000	12-13 ⁶	[58], [128], [129], [130]
Bromisoval	10-20	30-40		appr. 4 ^{28, 105}	
Bromocriptine	0.0001-0.0003 (-0.004) ³¹⁴	0.008 ³¹¹		appr. 38	[4]
Bromoxynil		20			[58]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Bromperidol	0.012-0.02	0.03 ³¹¹		20-36	
Brompheniramine	0.005-0.015	0.2 ⁸		2-10 (-20)	[15]
Brotizolam	0.001-0.01 (-0.02)	0.02 ³¹¹	0.01-0.03 ⁸	4-10	[47], [131]
Budipine	appr. 0.1-0.3			30	[15]
Buflomedil	appr. 0.2-0.5 (-1.0)	15-25	25-50; 275 ⁸	2-4	[42], [11], [58]
Bunitrolol	0.001-0.015			2-6	[7]
Bupivacaine	(0.25-) 0.5-1.5 (-2)	2-4		0.5-3	[123], [132], [133], [134]
Bupranolol	-.44			2-4	[7]
Buprenorphine ³⁴⁰	0.0005-0.005 (-0.01) ²⁸⁵	0.03-0.1 ³³⁹	0.008-0.029	3-5 (i.v.); 18-49 (sublingual); appr. 19 (buccal)	[47], [135], [123], [136], [137], [138], [139], [140], [141]
Bupropion (Amfebutamone)	0.01-0.02; 0.05-0.1 ¹⁵²	1.2-2 ²⁴⁶	4 ⁸ ; 4.2 ⁸ ; 7.3 ⁸	(4-) 10-20	[47], [142], [143], [4], [144], [145], [146], [80], [147], [148]
Buspirone ³¹²	0.001-0.004	0.008 ³¹¹		2-3	[4]
Busulfan	> 0.9 ²⁹¹			2-4	[149], [150], [151], [152], [153], [154]
Butabarbital	see Secbutabarbital				

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Butalbital	1-5	10-15	15-30	30-40	[58]
Butanone	-10	500			
Butaperazine	0.02-0.3 (-0.7)			12	[15]
Butorphanol	0.0006-0.002			4-9	[15], [8]
Butriptyline	0.07-0.15	0.4-0.5			[15]
Butylscopolamine	-0.7			4-5	[8]
Cabergoline	58-144 pg/mL ³¹⁵	390 pg/mL ³¹¹		63-68	[4]
Cadmium	<0.0003-0.0065	0.015-0.05		appr. 16 years	[47], [58], [100]
Caffeine (Coffein)	(2-) 4-10	15-20	80-180	2-10	[47], [123], [155], [156], [157], [64]
Calcifediol	0.01-0.05				[66]
Camazepam	0.1-0.6	2		20-24	[59]
Camphor		0.3-0.4	1.7	2-8	[47], [15], [8], [158]
Candesartan	0.08-0.18			5-7	[15]
Canrenone	see Spironolactone				
Captopril	0.05-0.5 (-1)	5-6	60	1-2	[159], [84], [42]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Carazolol ²³	-0.015			9	[7]
Carbachol	appr. 0.01?		3.6 ^{8; 287}		[3], [160]
Carbamazepine ¹²	2-8 (4-12)	10	20	12-60 (7-35) ¹⁴⁰	[161], [162], [56], [163], [164], [165], [166], [12]
Carbaryl		5	6-27		[47], [167]
Carbenoxolone	appr. 5-30			8-20	[66]
Carbidopa	0.02-0.2 ³¹⁶	0.4 ^{311; 316}		2	[4]
Carbimazole	0.5-3.4 ⁹⁵			3-6 ⁹⁵	
Carbinoxamine	appr. 0.02-0.04			appr. 10-15	[168]
Carboc(h)romene	0.8-2.4 (-3)			0.2-1.5	
Carbon monoxide	~200	25-30 %	50-60 %		[123], [10], [58]
Carbon tetrachloride	-0.07	0.12 ⁸ ; 7.1 ^{8; 269} ; 11 ⁸ ; 10-50	100-200	Appr. 24 ; 42.6 ⁸	[169], [58], [170], [171], [172], [173]
Carboplatin	max. 10-25			2.5-6 ¹⁰⁶	
Carbromal(um) ¹³	2-10	15-20	40	7-15	
Carisoprodol	10-30	40; 30-50 ¹⁰⁴	50 ⁸ ; 110 ¹⁰⁴	8	[56], [58]
β-Carotene	see Betacarotene				

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Carteolol	0.01-0.1			3-7	[7]
Carvedilol	appr. 0.02-0.15 (-0.3)			6-10	[3], [95], [8]
Cathine	appr. 0.71 ³⁷⁰			3-8	[47]
Cefaclor	13-35 (i.v. -900)			0.5-1 (-2)	[3], [8], [11]
Cefadroxil	-30			1-2	[8]
Cefalexin	-65			1-1.5	[41]
Cefaloridine	20-80			1.5	[41]
Cefalotin	See Cephalotin				
Cefamandole	1-5 (10-40-150)			0.5-1.2	[41], [58]
Cefazolin	-150			1.5-2	[67], [41]
Cefdinir	-4			16	[8]
Cefepime	-160			2	[8]
Cefetamet	-7			2-3	[8]
Cefixime	-7			3-4	[8]
Cefmenoxime	-200			1-2	[8]
Cefodizime	-400			2-4	[8]
Cefoperazone	-250			1-2 (-5)	[174]
Cefotaxime	0.5-2 (10-50; i.v. -225)			1-1.5	[67]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Cefotetan	65-90			3.5	[41]
Cefotiam	-150 ⁷¹			0.7-1.5 (-2)	[41], [175]
Cefoxitin	-150			0.7-1	[41]
Cefpodoxime	-7			2-3	[8]
Cefsulodin	20-100			1.6-1.9	[3], [8], [11]
Ceftazidime	20-40 (50-200)			1-4	[3], [8], [11]
Ceftibuten	appr. 3-20			2-4	
Ceftizoxime	40-160			6-9	[41]
Ceftriaxone	15-75			6.5-8.5	[67]
Cefuroxime	0.5-1 (10-60 ; i.v. -180) ²⁴³			1.1-1.3	[3], [176], [177], [10], [58]
Celecoxib ⁴⁸	0.36-0.8 ³⁷¹			11-16	[47]
Celiprolol	0.05-0.5 (-1)			3-6	[58]
Cephalothin (Cefalotin)	-30			0.5-0.6	[3], [41]
Cerivastatin	0.002-0.04			1.5-3	[15], [8]
Cetirizine	appr. 0.02-0.3	2-5		7-9	[47], [15], [8]
Chinidine	see Quinidine				
Chinine	see Quinine				

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Chloralhydrate ¹⁴	1.5-15	40-50	60-100	8-30	
Chlorambucil	0.15-0.3 (-1.0)			1.5-3	[15]
Chloramphenicol	5-10 (-15) ⁵⁹	25		2-6	[178], [11], [58]
Chlordane	-0.001	0.0025	1-7	88 ⁶	[11], [58]
Chlordecone		0.5		63-148 ⁶	[47]
Chlordiazepoxide ¹⁵	0.4-3	3.5-10 (-15); 20.5 ⁸	20 ⁸ ; 26 ⁸	6-27	[179], [47], [56], [180], [11], [58]
Chlormethiazole	see Clomethiazole				
Chlormezanone	(3-) 5-9 (-14)	appr. 20	18 ⁸ ; 53 ⁸	20-30	[43], [56], [181]
Chlorobutanol		75			[66]
Chloroform	20-50	appr. 70	33 ⁸ ; 64 ⁸ ; 69 ⁸ ; 91 ⁸	1.5	[47], [11], [58], [182]
Chlorophacinone		0.1		6-23 ⁶	
Chloroquine	0.02-0.5	1	3	dose-dependent ⁶	[183], [56], [30]
Chlorothiazide	appr. 6			0.5-2	[3], [11], [58]
Chlorphen(ir)amine	0.003-0.017		1.1 ⁸	(12-) 15-25 (-43) ³⁵⁸	[47], [3], [11], [58]
Chlorpromazine ⁶⁶	0.03-0.1 (-0.5)	1-2	3-4	10-30	[56], [3], [184],

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
					[185]
Chlorpropamide	30-150	200-750		25-60	[66], [58]
Chlorprothixene	0.02-0.3	0.4	0.8	8-12	[47], [4]
Chlorpyrifos		0.2	1.3 (0.4-3.5) ²⁷⁶	27	[47], [186]
Chlortalidone	0.15-0.3 (-1.4)	appr. 2		44-48 (35-70)	[47]
Chlortetracycline	1-5 (-10)	30		5-6	[9], [13], [14]
Chromium	-0.00035		32 ⁸	3-4 years	[47]
Cibenzoline	0.2-0.4 (-0.9)	(0.5-) 1		7-8 ⁸³	[3], [187]
Cicletanine	appr. 1-2			5-23	[3], [8]
Ciclosporine A (CsA)	< 0.1-0.15-0.25	0.3-0.4 ¹⁶		10-27 ¹⁶⁹	[188], [189], [190], [191], [192], [193]
Cidofovir	appr. 7-43			2.5	[8], [3]
Cilazapril(-)at	0.003-0.09			30-50	[8]
Cimetidine	0.25-3 (0.75-4)	30-50	110 ⁸	1.5-4	[194], [195]
Cinnarizine	0.04-0.33	7.4 ⁸		12-34	[47]
Cinoxacin	appr. 15			1.5-4	
Ciprofloxacin	2.5-4	11.5 ⁸		3-6	[196], [197], [198], [199]
Cisaprid	0.04-0.08			6-12	[8]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Citalopram	0.05- 0.11	0.22 ³¹¹	5-6 ¹⁶⁰	appr. 33 ¹⁷⁰	[8], [200], [201], [202], [4], [203], [204], [205],[206], [207]
Cladribine	appr. 0.006			0.1-0.2 (6.4-19.7)	[208], [209], [210]
Clarithromycin	appr. 0.2-2			3-7 ²¹⁷	[115], [211], [8], [118], [212], [213]
Clemastine	appr. 0.001-0.002 (?)			appr. 8	[8], [214]
Clenbuterol	0.0003-0.0006	0.003 ⁸		30-35	[47]
Clindamycin	appr. 0.5			2-3	
Clobazam ¹⁷	0.03-0.3	0.5 ³¹¹		18-42	[47], [4], [59], [215]
Clobutinol	appr. 0.05-0.2			23-34	[3], [8]
Clodronate (Clodronic acid)				.6	[49]
Clofibrate	50-250			10-18	
Clomethiazole (Chlormethiazole)	0.1-5	(2.8-) 4-15	50	3-7	[3], [4], [216], [9], [13],[217]
Clomipramine ^{48, 85}	(0.02-) 0.09-0.25 (-0.4) ²²⁶	0.4-0.6	1-2	20-26 ⁸⁶	[218], [219], [220], [76], [221], [222], [80], [223]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Clonazepam	(0.004-) 0.02-0.08 ¹⁵⁰	0.1		20-60	[161], [60], [224]
Clonidine	0.001-0.002 (-0.004)	0.025-0.05 (0.009 ⁸)	0.23 ⁸	5-20	[47], [225], [226], [227]
Clopentixol	0.002-0.015	0.1-0.3		15-25	[8], [11]
Clopidogrel	0.001-0.006			1.4-3.6	[47]
Clorazepate ¹⁵	see Nordazepam			1-2	[164]
Clotiazepam	0.1-0.7			3-15	
Cloxacillin	5-30 (-85)			0.5-1 (0.3-2)	
Clozapine ¹³⁶	(0.1-) 0.35-0.6 (>0.35 ?)	0.6-1 (9.5 ⁸)	1.2 ⁸ ; 2 ⁸ ; 5.2 ⁸	6-14	[101], [228], [229], [230], [231], [232], [233], [234], [72], [235], [236], [237], [238], [239], [240]
Cobalt	0.0001-0.0022			2 (early); 38 (late phase)	[47], [11], [58]
Cocaine	0.05-0.3	(0.25-) 0.5-1	0.9-2.1	0.5-1 ¹⁸	[47], [241], [242], [13], [14], [58]
Codeine ⁴⁸	0.03-0.25	0.5-1 ³³⁹	1.8	3-4	[3], [243], [244]
Coffein(e)	see Caffeine				

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Colchicine	0.0003-0.0025	0.005 (0.019 ⁸)	0.009 ⁸ ; 0.024 ⁸	11-32 ¹⁴³	[245], [246], [247], [248], [10]
Colistin	1-5			2-5	
Copper	0.6-1.5	2	5	26 ⁶	[66]
Cotrimoxazole	see Sulfamethoxazole and Trimethoprim				
Coumatetralyl		0.12 ⁸			[249]
Cresol (Methylphenols)		appr. 50	120		[58]
Cromolyn (Cromoglycate)	appr. -0.01			1-1.5	[3]
Cyanide	₁₇₇	0.5	1-3	appr. 19 ¹⁸⁴	[3], [250], [251], [252], [253], [254], [255], [130], [256]
Cyclizine	0.1-0.25	0.75-1	15	24	[11], [58]
Cyclobarbital	2-6	10	20	8-17	
Cyclobenzaprine	appr. 0.003-0.04	0.4		18 (9-40) ²⁵³	[11], [58], [257]
Cyclohexane	-0.4				
Cyclophosphamide	10-25			4-8 (1.3-16)	[3], [8]
Cyclopropane	80-180				[11], [58]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Cyclosporine	see Ciclosporine				
Cyproheptadine	appr. -0.05		0.47 ⁸	8-9	[47], [3]
Cyproterone acetate				30-40	[126]
Cysteamine	appr. > 20 µmol/L ²⁸²			appr. 1	[258], [3]
Cytarabine	0.05-0.5			0.1-0.2 (1.9-2.5)	[209], [9]
2,4-D	see 2,4-Dichloro- phenoxyacetic acid				
Danazol	appr. -0.2			4.5	[3]
Dantrolene	(0.1-) 0.4-1.5 (-3)			4-12	[9], [3], [259]
Dapsone ⁴⁸	0.5-2	10	18 ⁸	25-31	[260], [261]
Darunavir (DRV)	> 3.3 (1.255-7.368) ³⁰¹			appr. 15	[262], [110], [2]
DEET	see N,N-Diethyl-3- methylbenzamide				
Deferoxamine (Desferrioxamine)	3-15			4-6	
Demoxepam	0.5-0.74	1	2.7		[66]
Desipramine ^{48, 69}	0.01-0.5 (0.12-0.25)	0.5-1	3	15-25 ⁷⁰	[74], [263], [78], [79], [80], [264]
Desloratadine ³⁷²	0.002-0.006 ³⁷³			17-27	[47]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Desmethyldiazepam (N-Desmethyldiazepam)	see Nordazepam				[59]
Desvenlafaxine	0.1-0.4	0.6 ³¹¹		11	[4]
Detajmium	0.01-0.7		1.8 ⁸	13-14	[8]
Dexamethasone	appr. 0.05-0.265 ²⁴⁷			2.5-9.5	[3], [265]
Dexfenfluramine ³⁵¹	appr. 0.03-0.06	0.15-0.25		appr. 18	[66], [11], [58]
Dexketoprofen ³⁷⁴	appr. 3.7			0.5-2	[47]
Dexmethylphenidate ³⁴²	0.013-0.023 ³¹⁸	0.044 ^{311; 318}		appr. 2	[4]
Dextromethorphan ⁴⁸	0.01-0.04	0.1	3	2-4	[266], [267], [268], [269] [270]
Dextromoramide ³⁵⁰	0.075-0.15	0.2 ³³⁹	0.9	1.5-4-7	[47], [271], [8], [272], [58]
Dextropropoxyphene ³⁰⁵	0.05-0.3 (-0.5)	0.6-1	1-2	10-30	[30], [48]
Diacetylmorphine or Diamorphine (DAM)	see Heroin (and Morphine)			2-5 min	[273], [274], [275], [276], [277], [278], [279], [280], [281]
3,4-Diaminopyridin (DAP)	< 0.04 ²¹³	0.1 (?)		0.3-2 ²¹⁴	[282]
Diazepam ¹⁹	0.1-2 (-2.5)	3-5		24-48	[241], [283], [284], [3], [285], [59], [224], [13], [14], [286]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Diazinon		0.05-0.1 (-0.5)			[58]
Diazoxide	10-20 (-50)	50 (-100)		20-36 (-48)	[3], [84], [42], [10], [58]
Dibenzepine	0.025-0.15 (0.1-0.5)	3 ³⁵⁹	18 ³⁵⁹	3.5-5	[11], [58]
Dichloromethane		200	280	0.6 (early); 4-8 (late phase)	[47]
2,4-Dichlorophenoxyacetic acid (2,4-D)	-	appr. 100	200; 392 ⁸ ; 720 ⁸	appr. 18 ¹⁸²	[3], [11], [58]
Dichlorvos			29	0.16	[47]
Diciclomine	see Dicyclomine				[8]
Diclofenac	0.5-3	50; 60 ⁸		1-2	[287], [288], [289]
Dicoumarol	8-30	40-50		1-4 ⁶	[8], [11]
Dicyclomine (Dicycloverin)	-0.1	appr. 0.2	0.5	1.8-2	[8]
Didanosine (DDI)	appr. 1-30 µmol/L			appr. 1.4	[290], [291], [38], [2], [3]
Dieldrin	-0.0015	0.15-0.3		2-12 months	[47], [11], [58]
Diethylcarbamazine	> 0.8-1.0			4-15	[292]
Diethylene glycol	-	200-500	2000	3-4	[47]
N,N-Diethyl-3-methylbenzamide (N,N-Diethyl-m-toluamide; DEET)	-	>1 mmol/L		appr. 2.5	
Diethylpentenamide (Valdetamide)	2-10	20	45	6-7	

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Diethylpropion	0.003-0.007 (-0.2)	2	5.4 ⁸	4-8 ²³	[3], [8], [58]
Difenacoum		0.5		11-42 ⁶	[47]
Diflunisal	40-100 (-200)	300-500	600	5-12 ⁸³	[3], [9], [58], [293]
Digitoxin	0.01-0.025	0.03	0.04	140-200	[294], [295]
Digoxin	0.0005-0.0008 (-0.002)	0.0025-0.003	0.005	40-70	[18], [19], [20], [21], [22], [23], [24], [25], [26], [27]
Dihydralazine	see Hydralazine				
Dihydrocodeine	0.03-0.25	0.5-1 ³³⁹	2	3-4	[14], [58]
Dihydroergotamine	0.001-0.01			7-9 (> 30?)	[3], [8]
Diltiazem	0.03-0.13 (-0.25) ¹⁵⁷	0.8-1	2-6; 7 ⁸ ; 8 ⁸	2-6 (4-9)	[3], [84], [58]
Dimenhydrinate	see Diphenhydramine				
Dimethadione ³⁶⁰	(350-) 700-1000	1000		5-10 ⁶	[3], [8], [12], [11]
Dimethindene	0.01-0.05			appr. 6	[3], [15], [8]
Dimethoate			355.5 (160-674) ²⁷⁷		[186]
N,N-Dimethyltryptamine	0.001-0.1				[58]
4,6-Dinitro-2-methylphenol		40			
Dinitro-O-cresol (DNOC)	1-5	30-60	75		[58]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Diphenhydramine	0.05-0.1 (-1)	1-2(-4)	5-10	4-10, 20-60	[296], [297], [114], [58]
Diphenoxylate	appr. 0.01			2-3	
Dipipanone	appr. -0.05	0.2			
Diprophylline	see Dyphylline				
Dipyridamole	0.1-1.5	4		11-13	[9], [13], [14]
Dipyron	see Metamizole				
Diquat		0.1-0.4			[11]
Disopyramide	2-7 ⁷⁸	8		5-8	[70], [11], [58], [64]
Disulfiram	0.05-0.4	0.5 ³¹¹ ; 5	8	appr. 5-7	
Dixyrazine	appr. 0.3 ²⁴⁹		5.5 ⁸ ; 9.4 ⁸		[4], [298]
Domperidone	appr. 0.01-0.1			12-16	[3], [299], [300], [301], [302]
Donepezil ²⁰⁷	appr. 0.03-0.075	0.075 ³¹¹		70-100	[4], [303], [304]
Dothiepin (Dosulepin) ²⁰	0.02-0.1	(0.3-) 0.8	1	11-40	[305], [306]
Doxacurium	0.01-0.3			1-2 ⁸³	
Doxapram	(1.5-) 2-5	9 ²⁶⁸		2.4-9.9	[307], [3], [11], [58]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Doxazosin	0.01-0.15			10-22	[95]
Doxepin ²¹	0.01-0.2 (0.03-0.1)	0.5-1	2-4	8-25	[308], [73], [309], [77], [310], [80], [264]
Doxorubicin (Adriamycin)	0.006-0.02			20-48	[3], [8], [58]
Doxycycline	1-5 (-10)	30		7-20	
Doxylamine ²⁸⁹	0.05-0.2	1-2	5	9-11	[47], [311], [87]
Dronabinol (Delta-9-tetrahydrocannabinol, THC)	0.005-0.01 (-0.05) ¹³⁷			50-100	[241], [312], [313]
Droperidol	appr. -0.05			1.5-2.5 ²³⁷	[3], [314]
Drotrecogin alfa	mean 0.072			1.6	[315]
Duloxetine	0.03-0.12	0.24 ³¹¹		9-19	[4], [223]
Dyphylline	6.5-14 (-20)	40		2	[11], [58]
Edrophonium	0.15-0.2	appr. 0.15		1.3-2.4	[3], [316], [58]
Efavirenz (EFV)	> 1.0 ²⁹⁷			40-55	[110], [2], [111]
Eletriptan	0.06-0.23			3-7	[47]
Enfuvirtide	2.6-3.4			3-4	
Emetine	0.005-0.075	0.5	2.4 ⁸	24-48	[8]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Enalapril ⁵²	0.01-0.05 (-0.1)			8-11	[159], [84]
Encainide ⁴⁸	_175			1.5-3.5 ¹⁷⁶	[3]
Endrin	-0.003	0.01-0.03			[58]
Enoxacin	1-4			3-6	[93]
Enoximone	≥ 0.2 (3-4 ?)			4-7	[3], [95], [8]
Enprofylline	1-5	10		appr. 2	[8]
Entacapone	0.4-1.0 (-7.0)			(0.5-) 1.5-3.5	[3], [15], [8]
Ephedrine	0.02-0.2	1	5 ⁸	3-11	[269], [87], [8], [57], [58]
Epirubicin	0.01-0.05			24-52	
Eprosartan	0.4-1.0 (-1.85)			5-9	[3], [15], [8]
Eptastigmine	0.0002-0.006			appr. 1	[8]
Ergotamine	0.00036-0.00042 ³⁷⁵	0.00082 ³⁷⁶		1.5-2.5	[47]
Erythromycin	0.5-6 (peak 4-12)	12-15		1-3	[11], [58]
Escitalopram ³⁴³	0.015-0.08	0.16 ³¹¹		26.3±10.8	[4], [223]
Esmolol	0.15-2			4-16 min	[7]
Estazolam	0.055-0.2			10-24	[3], [58]
Eszopiclone ³⁴¹	appr. 0.087			4-9	[47]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Et(h)amsylate	15-20			2.5-4	
Ethacrynic acid	0.05-0.1			1-4	[3], [9]
Ethadione	500-1000	1000			[8]
Ethambutol	0.5-6.5	6-10		2.5-3.5	[317], [58]
Ethanol		1000-2000	3500-4000	. ¹³⁹	
Ethchlorvynol	0.5-8	20	50	10-25 (-35)	[3], [58]
Ethinamate	1.5-10	50-100	200 ⁸	appr. 2	
Ethosuximide	30-100 (40-60)	150-200	250	30-60	[161], [164], [12], [64]
Ethyl chloride		200-300			[87]
Ethylene glycol		200-500	2000	11-19 (31 ⁸ ; 27 ⁸)	[318], [319], [320], [321], [322], [323], [324], [325], [66], [326]
Ethylmorphine ⁴⁸	0.3-0.6 ³⁷⁷		0.3-2.9	2-3	[47]
Etidocaine	0.5-1.5	1.6-2		2-3	[327]
Etidronat (Etidronic acid)				. ⁶	[49]
Etilefrine	appr. 0.06			2-3.5	
Etizolam ⁴⁸	appr. 0.008-0.02	0.03 ⁸		7-15	[47]
Etodolac	10-20 (> 14 ²²⁹)			6-8	[328], [3], [15],

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
					[8]
Etomidate	0.1-0.5 (-1)			3.9±1.1 (2-11)	[3], [9]
Etoposide	2-6 (peak 8-14)			4-11	[3], [11]
Etoricoxib	1.3-3.6			20-36	[47]
Etravirine (ETR)	0.275 (0.081-2.98) ³⁰²			appr. 41	[47], [110], [2]
Everolimus	0.003-0.008 (-0.014) ²⁷⁵			28±7	[329], [330], [331], [332]
Ezetimibe	>0.015			appr. 30	[333], [334]
Famotidine	0.02-0.2	0.42 ⁸		2-4.5	[3], [335]. [336]
Fampridine	see 4-Aminopyridine				
Felbamate	(30-) 50-110 ¹⁶⁴	150-200		15-23	[337], [4], [12], [338], [339]
Felbinac	appr. 0.4-1 ³²⁶			10-17	[3], [340]
Felodipine	0.001-0.012	0.01		22-27 ⁸⁸	[341], [84], [8]
Fenbufen	appr. -60			10-12	[3]
Fendiline	0.02-0.15			appr. 20	[47]
Fenfluramine	0.04-0.3	0.5 – 0.7	6	18-25	[47]
Fenitrothion			1.1	33-64	[47]
Fenofibrate	5-30 ²⁴¹			20-22	[3], [342]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Fenoldopam	0.003-0.06			0.1	[15], [8]
Fenoprofen	(25-) 30-60			2-3	[343]
Fenoterol	(0.001-) 0.01-0.04			appr. 7	
Fentanyl	0.003-0.3 ⁴	. ³³⁹	0.003-0.02 ^{8; 103}	1-3.5 (transdermal patch: appr. 17)	[335], [47], [344], [345], [52], [346], [54], [347], [348], [349], [350], [351]
Fenthion			4.9 (0.6-16.6 ²⁷⁹)	12	[47], [186]
Fexofenadine	appr. -0.3 ¹⁹¹			14-18	[8], [352]
Finasteride	0.008-0.01			5-7	[353]
Flecainide ⁴⁸	(0.2-) 0.4-0.8	1-2	2.6 ⁸ ; 13 ⁸	10-20	[354], [70]
Fleroxacin	1-4			8-13	
Flucloxacillin	3-30			1-2	[11], [58]
Fluconazole	appr. 1-5 (-15)	20; 95 ⁸		22-31 ⁸³	[355],[356], [357], [358], [11]
Flucytosine	35-70 (20-50)	100		3-5	[91]
Flumazenil ²²	(0.01-) 0.02-0.1	0.5		1-2	
Flunarizine	0.025-0.2	0.3		. ⁶	[42]
Flunitrazepam ²³	0.005-0.015	0.05		10-20 (-30)	[359], [56],

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
					[59]
Fluoride	0.095-0.190 (-0.285) ³⁹	0.5-2	3	2-9	[47], [123], [360], [361], [130], [10], [58], [362]
5-Fluorouracil	0.05-0.3	0.4-0.6		<0.5	[3], [11], [58]
Fluoxetine	0.12-0.5 ¹³⁰	1	6 ⁸	2-6 ⁶ ; 130	[263], [75], [202], [363], [4], [264], [364]
Flupenthixol	0.001-0.01	0.015 ³¹¹		20-40	[4]
Fluphenazine	0.001-0.01	0.015 ³¹¹		10-18 ⁴⁵	[4]
Flupirtine	0.5-1.5	appr. 3-4		7-11	[365]
Flurazepam ²⁴	0.02-0.1	0.2-0.5	0.8 ; 24 ⁸	appr. 2 ²⁴	
Flurbiprofen	5-15			3-4	[366]
Fluspirilen	0.0001-0.0022	0.0044 ³¹¹		7-14 ⁶	[4]
Flutamide ⁶⁰	0.4-1.5 ⁶⁰			7-20 ⁶⁰	[43], [367]
Fluvastatin	0.05-0.4			1-3	[47]
Fluvoxamine	0.06-0.23	0.5 ³¹¹ -0.65; 1.97 ⁸	2.8 ⁸	(8-) 15-22 (-28)	[47], [368], [202], [4], [369]
Fosamprenavir (FPV)	> 0.4 ²⁹²			7.7 ³¹⁹	[110], [2], [111]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Fosphenytoin ³³⁶	see Phenytoin	30		0.13-0.25	[12]
Frovatriptan	0.004-0.008			20-30	[47]
Furosemide (Frusemide)	2-5 (-10)	25-30		1-3	[3], [58]
Fusidinic acid	30-200			4-6	
Gabapentin	appr. 0.5-6 (-20-30) ¹⁸⁵	25 ³¹¹ ; 45 ⁸ ; 85 ⁸ ; 105 ⁸		5-9	[47], [370], [371], [372], [373], [374], [375], [12], [376], [377], [378], [379], [380], [381], [382], [48]
Galant(h)amine	appr. 0.03-0.06	0.09 ³¹¹		6-8	[383], [4], [384]
Gallopamil	0.02-0.1		8 ⁸	3-8	[385], [84]
Gamma-hydroxybutyricacid (gamma-hydroxybutyrate, gamma-butyrolactone, GHB, liquid ecstasy) ⁴⁸	see 4-Hydroxybutyrate				[386], [387]
Ganciclovir	(0.29-0.51) 0.5-5 ¹⁰⁷	3-5		2-4 ⁸³	[388], [38], [39]
Gemcitabine	15-20 µmol/L ¹⁴⁶	- ¹⁹²		0.05 (0.18-0.43)	[209]
Gemfibrozil	appr. -25			1.5	[3]
Gentamicin	(2-) 4-10 ²³³	12		1.5-6	[389], [67], [390], [20], [391], [392],

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
					[393], [394]
Glibenclamide (Glyburide)	0.05-0.2	0.6		10	[47]
Glicazide	1-3.7			6-14	[47]
Glimepiride	0.09-0.5			4-15	[47]
Glipizide	0.1-1 (-1.5)	2		3-7	[66]
Glutethimide	0.2-5	10-30	20-50	5-20	[30]
Glyburide	see Glibenclamide				
Glyceryl trinitrate (GTN)	see Nitroglycerin				
Gold	3-8	10-15		21-31 ⁶ (oral)	[47], [58], [48]
Granisetron	0.009-0.017 (?)			3-14	[3], [15], [8]
Griseofulvin	0.3-1.3			22	[8]
Guaifenesin	0.3-1.4			appr. 1	[3], [15], [8]
Guanethidine	0.01			5-10 ⁶	[3], [58]
Halazepam ¹⁵	see Nordazepam			30-40	
Haloperidol	0.005-0.017 (0.001-0.02)	0.05-0.5	0.5; 0.18 ^{8, 74}	10-35 ¹⁵³	[43], [395], [185], [396], [193], [397], [398], [240]
Halothan	22-260		3.4 ⁸ ; 8.3 ⁸	43	[87], [48]
Hematin	50-100				

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Hemin	see Hematin				
Heptabarb(ital)	0.5-4	8-15	20	6-11	
Heptaminol	appr. 0.2-1 (-1.5)			2-3	
Heroin (Diacetylmorphine or Diamorphine, [DAM]) ³³⁷	₋₃₃₈	₋₃₃₉		2-5 min	[273], [274], [275], [276], [277], [278], [279], [280], [281]
Hexachlorobenzene (HCB)	-0.0001 ³³²			appr. 2 years	[100]
β-Hexachlorocyclohexane (β-HCH, β-lindane)	-0.0001 ³³²			appr. 7 years	[100]
Hexachlorophene	0.003-0.65 (-1)		35	6-44	[11], [58]
n-Hexane	-0.01			1.5-2	[47]
Hexapropymate	2-5	10-20			[8], [11]
Hexobarbital	1-5	10-20	50	4-6	
Hirudin-rec	₋₁₇₁	₋₁₇₁		(1-) 2.5-3	[399], [43], [3]
Hydralazine ⁵	0.05-0.5 (-1.5)			2-6	[84]
Hydrochlorothiazide	appr. 0.04-2			10-12	[3], [42]
Hydrocodone	0.01-0.05	0.1 ³³⁹	0.2	appr. 4	[8], [244]
Hydromorphone	appr. 0.005-0.015	0.1 ³³⁹	0.2	2-3	[400], [9], [8], [270]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
4-Hydroxybutyrate (GHB) ⁴⁸	appr. 50-120 ⁴	80 (abuse)	250-280 (abuse)	0.3-0.5 (-1)	[47], [3], [8], [244], [401], [402]
Hydroxychloroquine	-0.1 (-0.4)	0.5-0.8	4	dose-dependent ⁶	[3], [403], [13], [14]
4-Hydroxy-3-methoxymethamphetamine (HMMA)	. ³³³			11.5-13.5	[404], [405], [406]
Hydroxyzine	0.05-0.1	0.1	39 ⁸	7-20	[56], [11], [58]
Ibandronat (Ibandronic acid)	. ³²¹				[49]
Ibuprofen	15-30	200	352 ^{8, 346}	2-3	[47], [407], [343], [293], [408]
Idebenone	0.05-0.2			16-22	[3], [409]
Iloperidone	0.005-0.01	0.02 ³¹¹		18-33	[4]
Iloprost	appr. 0.0001			appr. 0.5	
Imatinib	0.72 ²⁵⁸			appr. 18	[410], [411]
Imipenem	0.5-5 (20-75)			1	[8], [412]
Imipramine ^{48, 125}	0.05-0.35	0.5-1	1.5-2	6-20 ²⁶	[308], [74], [309], [76], [77], [413], [78], [79], [80]
Indinavir (IDV)	> 0.1 ²⁶⁰	appr. 0.5		1.5-2	[211], [3], [110], [2], [414], [111]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Indomet(h)acin	0.3-1 (-3)	4-5		3-11	[415]
Indoramin	appr. 0.025-0.1			12 (3.5-15)	[95]
Iproniazid	appr. -5 ?				
Irbesartan	1.9-3.3			11-15	[47]
Iridium	-0.02				
Iron	0.5-2	6	17		[42], [58], [64]
Isoniazid (INH)	5-10	20	(30-) 100	1-3	[3], [317], [8]
Isopropanol ³⁶¹		200-400	1000	2.5-3	[47], [58]
Isosorbid mononitrate (ISMN)	0.1-1			2-5	[95]
Isotretinoin	appr. 0.001-0.002 (topical) ²²⁴			10-20	[3], [416], [417]
Isoxicam	5-15			20-50	
Isradipine	0.0005-0.002 (-0.01)	0.01	0.26 ⁸ , 25 ⁹	5-10	[418], [3], [84], [419], [420]
Itraconazole	appr. 0.4-2 ¹¹¹			24-36	[421], [422], [423], [424]
Ivermectin	appr. 0.05 ⁵¹			16-28	[3], [425]
Kanamycin	1-4 (10-25)	25-30		0.5-3	
Kavain	appr. 0.05			2.8-6.7	[47]
Ketamine	1-6	7 (abuse)	3.8 ⁸ ; 6.9 ⁸	1-3 (-4)	[47], [426],

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
					[56], [427], [428]
Ketanserin	0.05-0.5			10-22	
Ketazolam ¹⁵	0.001-0.02			1-3	[59]
Ketobemidone	0.01-0.05		0.2-3.2	1.8-4.2	[47], [426], [3], [428]
Ketoconazole	1-3 (-6)			6-10	[8]
Ketoprofen	1-6 (-20)		1100 ⁸	1,1-2 (-4.2)	[429], [47], [430], [343], [431], [432], [433]
Ketorolac	0.5-3	5		4-10	[3], [8]
Ketotifen	0.001-0.004	0.02	1.2 ⁸	21	[57]
Labetalol	0.03-0.18 (-0.65) ⁵⁰	1		3-10	[3], [95], [7]
Lacidipine	0.003-0.006			12-19	[8]
Lacosamide	1-10	20 ³¹¹		13	[4]
Lamivudine	~230			5-7	[123], [434],[2]
Lamotrigine	(1-5) 3-14	20-30	35.7 ⁸ ; 347; 50 ⁸	23-37 ¹⁰⁹	[47], [374], [435], [436], [381], [437]
Lead	-0.09 ³²⁴	0.4-0.6	3	~180	[47], [64], [123], [438], [439], [100]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Leflunomide ²⁵⁵	8.8 ± 2.9, 18 ± 9.6, 63 ± 36 ²⁵⁶			11 (4-28) ⁶	[440], [123], [441], [442]
Levacetylmethadol (LAAM)	appr. 0.02-0.06			35-60	[8]
Levamisole	appr. 0.1-0.7			3-6	[8]
Levetiracetam	(3-) 10-40	400 ⁸ ; 264		4-10	[8], [443]
Levocabastine	< 0.001-0.01 ¹⁴⁷			33-40	[444]
Levocetirizine ³⁷⁸	0.3-0.5			6-10	[47]
Levodopa (L-Dopa)	0.3-2	5 ³¹¹	650 ⁸	1-3 ²¹⁵	[445], [446], [447], [448], [4], [449]
Levomepromazine ²⁷	0.005-0.025 (-0.2)	0.4	0.5	15-30 ²⁸	
Levomethadone ³⁵²	0.04-0.4	(0.4-) 1 ³³⁹	0.1-0.2 ³⁶²	10-40	[123], [4], [450]
Levorphanol	0.007-0.02	0.1	2.7 ⁸	11-30	[8]
Levothyroxine	0.045-0.14 ⁴⁷			6-8 ⁶	[451]
Lidocaine (Lignocaine)	(1-) 1.5-5 ¹¹³	6-7	10	1-4 ¹¹³	[452], [453], [391], [70], [327], [454]
Linezolid	appr. 0.5-4			appr. 5	[8]
Lisinopril	(0.005-) 0.02-0.07	0.5		12	[84]
Lithium	4-8 ⁷⁹	13	14	8-50 ²⁸	[455], [456], [457], [80],

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
					[264], [458]
Lofepramine	0.003-0.01			10-20	
Loperamide	.84			7-15	[459]
Lopinavir (LPV)	> 1.0 ²⁹⁴			5-6	[110], [2], [111]
Loprazolam	0.003-0.01			11-20	[59]
Loratadine	0.001-0.02 ¹³⁸			8-14	[460], [461]
Lorazepam	(0.02-) 0.08-0.25	0.3-0.5		10-40	[462], [59], [463], [224]
Lorcainide	0.1-0.4 (-0.9)			5-10	[8], [464], [465], [466]
Lormetazepam	0.002-0.01 (-0.025)	0.1		10-15	[4], [59]
Lornoxicam	0.1-0.8			2-6	[8]
Losartan	< 0.2 (-0.65) ²²⁷			1.5-2	[3], [8]
Loxapine	0.01-0.03 (-0.1)	1	7.7	4 (1-14)	[8], [11]
Lysergide (lysergic acid diethyl amide, LSD)	0.0005-0.005	0.001	0.002-0.005	appr. 2-5	[467], [15], [8], [11]
Magnesium	55-75 ¹²¹	120-140	150-180	2.1-2.9	[47], [3], [468]
Malathione		0.35 ⁸ ; 0.5	1.8 ⁸ ; 175 ⁸ ; 517 ⁸	3-6	[47]
Manganese	0.0005-0.0015			12-36 ⁶	[47]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Maprotiline	0.075-0.13	(0.22-) 0.5-1	1-5	20-60	[4]
Maraviroc (MVC)	> 0.05 ³⁰⁰				[110]
MCPA	see 2-Methyl-4-chlorophenoxyacetic acid				
MCPP	see 2-Methyl-4-chlorophenoxypropionic acid				
MDA	see Methylenedioxyamphetamin e				
MDEA	see Methylenedioxyethylamphet amine				
MDMA	see Methylenedioxymethylamph etamine				
Mebendazole	≥ 0.1 ⁶⁷	appr. 0.6		2.8-9	[43]
Medazepam ³⁰	0.1-0.5 (-1)	0.6		2-5	[59], [8]
Mefenamic acid	2-10 (-20)	25		2-4	[9], [13], [14]
Mefloquine	0.4-1 ¹⁰⁸	1.5-2 ⁸		appr. 21 ⁶	[469], [470]
Melatonin	0.0005-0.1 ³⁷⁹			40-50 min	[47]
Melitracen	0.01-0.1			12-23	[8]
Meloxicam	0.4-2			17-22	[471], [15], [8]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Melperone	0.03-0.1 ²¹⁹	0.2 ³¹¹	17.1 ⁸	4-8	[4], [472], [15], [8], [473]
Melphalan	-1.5			1.5-2	[8]
Memantine	0.09-0.15	0.3 ³¹¹		60-100	[4]
Meperidine	see Pethidine				
Mephenesin	3-10 (?)			appr. 2-4	[15], [8]
Mepindolol	0.007-0.07			3-6	[7]
Mepivacaine	appr. 0.4 (-4)	5-6 (-10)	50	1-3	[15]
Meprobamate	5-10	10-25	30	6-17	[56]
Meptazinol	0.025-0.25			2-3	[8]
Mercaptopurin ³⁶⁴	0.03-0.08	1-2			[8]
Mercury	appr. 0.0015-0.002 (< 0.005) ¹⁷⁸	0.05-0.2	0.5	appr. 3 ⁶	[123], [64], [474], [66], [475], [100], [476], [477], [478]
Mescaline	1.5-3.8			6	[47]
(Mesalazine (Mesalamine))	appr. -1 ¹¹⁹			0.5-2.4 ¹²⁰	[479]
Mesoridazine	0.15-1	3-5	3 ⁸ ; 4 ⁸ ; 16 ⁸	20	[15]
Mesuximide	see Methsuximide				
Metaclazepam	0.05-0.2			7-23	[59]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Metamizole (Dipyrone) ⁵	10 ³²	20 ³²		6-8	[15]
Metformin	0.1-1 (0.6-1.3)	5-10	64 ⁸ ; 85 ⁸ ; 91 ⁸ ; 166 ⁸	2-4 (-10)	[480], [481]
Methadone	(0.05-) 0.1-0.5 (-0.75) ¹³⁵	0.2 ³³⁹	0.4 ³⁶²	23-25 (13-55)	[482], [483], [484], [485], [486], [487], [488], [489]
Methamphetamine (Methylamphetamine)	-0.1	0.15	1-18; 40 ⁸	6-15 ³⁴⁴	[47], [8]
Methanol	appr. -2	200	900	10-12 (-24) ³²⁵	[47], [325], [15], [8], [58], [490]
Methapyrilene	appr. 0.1	4			
Methaqualone	1-3	3-5	5-10	10-40	[8]
Methemoglobin (Met-Hb)	- ¹⁹⁹	25-30 %	60-70 %		[3], [10], [11]
Methimazole	0.5-2.5			2-28	[467], [15], [8]
Methocarbamol	25-40 (-50)	250		0.9-2	[3], [11],[58]
Methohexital	1-6 (-11) ⁵⁵	2-20		1-3	[8]
Methomyl		0.63 ⁸ ; 1.6 ⁸	1.6 ⁸ ; 28 (8-57)		[47]
Methotrexate	0.04-?	0.4		5-9 (low dose); 16-29 (high dose)	[47]
Methotrimeprazine	see Levomepromazine				
Methoxsalen (8-Methoxypsoralene)	0.025-0.1 (-0.2)	1			[3], [10]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Methsuximide (Mesuximide)	10-40 ²²³	40-50		20-40 (-45)	[3], [491], [8], [11], [58]
2-Methyl-4-chlorophenoxyacetic acid (MCPA)	-	appr. 100	appr. 180	- ¹⁸⁷	[3], [492]
2-Methyl-4-chlorophenoxypropionic acid (MCPPE)	-	appr. 100	669 ⁸ ; 715 ^{8,181}	17 ¹⁸³	[3]
Methyl dopa	1-5	9 ⁸		1.5-3	[9], [13], [14]
3,4-Methylenedioxyamphetamine (MDA)	-0.4	1.5	1.8-2; 26 ⁸	10.5-12.5	[15], [8], [58], [467], [404], [405], [406], [493], [494]
3,4-Methylenedioxyethylamphetamine (MDEA, MDE; Eve)	-0.2		1; 4.2 ⁸ ; 12 ⁸	4-8 ³³⁴	[47], [493], [495], [496], [497]
3,4-Methylenedioxymethylamphetamine (MDMA; Ecstasy, XTC; Adam)	0.1-0.35 ²³⁶	0.35-0.5	0.4-0.8	7-8 (-10)	[498], [467], [15], [8], [58], [404], [405], [499], [406], [493], [494]
Methylphenidate	0.01-0.06	0.1-0.5; 1 ⁸	2.3	2-7	[270]
Methylphenobarbital	see Phenobarbital				[12]
4-Methylthioamphetamine (4-MTA, p-MTA)			2 ⁸ ; 4.2 ⁸ ; 7.4 ⁸		[500], [501], [502], [503], [504]
Methyprylon(e)	< 10-20	25-75	50 (-100)	3-6, 9-11	[8]
Metiamide	0.01-0.06				[58]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Metildigoxin ³	0.0005-0.0008	0.0025-0.003	0.005	40-70	[18], [19], [20], [21], [22], [23], [24], [25], [26], [27]
Metipranolol ³³	0.02-0.08			2-3.5	
Metoclopramide	0.05-0.15	0.2	4.4 ⁸	3-6	[66]
Metocurine	appr. -0.4				
Metoprolol ⁴⁸	0.035-0.5	0.65 ⁸ ; 12-18	4.7 ⁸ ; 12 ⁸ ; 18 ⁸ ; 63 ⁸	2.5-7.5	[47], [3], [7]
Metrifonate	appr. 1.4-3.6			2-5	[8]
Metronidazole	3-10 (-20)	200 ⁸		6-10 (-14)	[8]
Mexiletine	0.7-2	2	35 ⁸	5-26	[70], [505]
Mianserin	0.015-0.07	0.14 ³¹¹ ; 0.25-0.5		14-33	[4], [223]
Mibefradil	appr. 0.2-0.3			17-25	[8]
Miconazole	appr. 1			24	[8]
Midazolam	0.04-0.1 (-0.25) ¹³⁴	1-1.5		1.5-3 ⁴⁶	[506], [507], [508], [61], [224]
Mifepristone	216			24-48 (20-54)	[509]
Milnacipran	0.05-0.11	0.22 ³¹¹		5-8	[4]
Milrinone	0.15-0.25	0.3		1-2	[3], [95], [42]
Minaprine	appr. -0.1				

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Minoxidil	appr. 0.02-0.2 ¹⁴⁹	1.4 ⁸ ; 3.1 ⁸	2.7 ⁸	1.3-4.2	[47], [3], [84]
Mirtazapine	0.03-0.08 (-0.3)	1-2; 2.3 ⁸		20-40 ¹⁸⁸	[3], [4], [510]
Misoprostol	~ ²⁸⁶			0.5±0.4	[3], [511], [512]
Mitotane	14-20	20		18-159 ⁶	[513]
Mizolastine	appr. 0.2-0.8			8-17	[3], [8]
Moclobemide ¹⁴¹	0.3-1.0 (-3)	2 ³¹¹ ; 11 ¹⁶² ; 25-60		1-7	[514], [515], [516], [517], [518], [519]
Modafinil	1-1.7 (-3) ²⁵⁷	3.4 ³¹¹		10-15	[89], [4], [8], [520]
Moexiprilat	0.005-0.04			2-10	[8]
Molindone	0.04-0.5	0.15 ⁸	6 ⁸ ; 9.3 ⁸	1.2-2.8	[47]
Molsidomine	0.002-0.01			1-2.5	[95]
Molybdenum	-0.005				
Montelukast	appr. 0.05-0.3			3-6	[3], [15], [8], [521]
Moricicine	0.12-1.27			(3-) 6-13	[467], [15], [8]
Morphine ²⁸⁸	0.01-0.1	0.1 ³³⁹	0.1-4	1-4	[522], [241], [523], [524], [87], [525]
Moxonidine	0.001-0.002 (-0.004)			2-4	[3], [95], [8]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Muromonab-CD3 (OKT 3)	appr. 0.7-1.3			appr. 18	
Mycophenolate mofetil	_211			16-18 ²¹²	[526], [527], [528], [529]
Nabumetone	_206			_206	[3], [530]
Nadolol	0.01-0.25		1.3 ⁸	(14-) 20-24	[8], [7]
Naftidrofuryl (Nafronyl)	<0.5			1-2	
Nalbuphine	0.02-0.2			2.5-7	[8]
Nalidixic acid	10-30	40-50		1-2 (-7)	[3], [9], [15], [8]
Nalmefene	-0.1			8.5-11	[3]
Naloxone	0.01-0.03			1-2	[8]
Naltrexone	0.003-0.05 ⁹⁹			4-10	
Naphyrone (Naphthylpyrovalerone)		0.03 ³³⁴			[531]
Naproxen	20-50 (-100)	200-400; 414 ⁸		10-20	[532], [343], [533], [293]
Naratriptan	appr. 0.01-0.05			5-6	[3], [15], [8]
Nebivolol	< 0.02 (-0.2)	0.48 ⁸		10 (8-27)	[3], [8], [534], [535], [536]
Nedocromil	< 0.025			1.5-3.3	[3]
Nefazodone	appr. 0.01-0.3 (?) ²²⁰	5.5 ^{8, 221}		2-7 ²²²	[8], [3], [537], [538], [539],

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
					[540], [541], [542]
Nefopam	0.01-0.1	4 ⁸	12 ⁸	3-8	[8]
Nelfinavir (NFV)	> 0.8 ²⁹⁵			3.5-5	[110], [87], [2], [111]
Neostigmine	appr. 0.001-0.01 ¹²⁷			0.4-1.3	[316], [543]
Netilmicin	1-12			2-3 ⁸⁰	[8]
Nevirapine (NVP)	> 3.0 ²⁹⁸			25-30	[110], [2], [111]
Nicardipine	0.07-0.1			7-12	[84]
Nickel	-0.003 ³³⁰	0.005			[58], [100]
Nicotine ¹²³	0.005-0.02 (-0.03)	0.4 (-1)	5; 13.6 ⁸	1-4 ¹²⁴	[3], [544], [42], [545]
Nicotinic acid	4-18			0.3-1	[8]
Nifedipine	0.025-0.15	appr. 0.15-0.2	0.15 ⁸ ; 1.2 ⁸ ; 5.4 ⁸	2-5	[47], [84]
Niflumic acid	2-35			2-3	[15]
Nilvadipine	< 0.01			11-20	[84]
Nimesulide ²³⁵	0.1-6.5			2-7 (11-20)	[546], [3], [15], [8]
Nimodipine	0.01-0.05			1-2 (8-9)	[84]
Nimustine	0.0002-0.0005				[58]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Nisoldipine	0.0003-0.001			7-12	[3], [84]
Nitrazepam	0.03-0.1	0.2-3	5	20-30	[8], [59]
Nitrendipine	0.01-0.05			8-12	[84]
p-Nitroaniline			4.2 ⁸		[547]
Nitrofurantoin	(0.5-) 1-3 (-5)	3-4		0.7-1.5	[8]
Nitroglycerin (Glyceryl trinitrate)	appr. -0.015			20-30 min	[548]
Nitroprusside	see Thiocyanate	see also Cyanide			
Nizatidine	0.05-0.5 (-1.0)			0.7-2.1	[8]
Nomifensine	0.01-0.1	8	17 ⁸	2-5	[87], [8]
Nordazepam	(0.02 ²⁷³⁻) 0.2 -0.8	1.5-2		40-80	[284], [285], [467], [8], [15]
Nordiazepam	see Nordazepam				
Norephedrine	see Phenylpropanolamine				
Norfenefrine	-0.4			2-3	[8]
Norfloxacin	0.5-5			3-4	[3], [58]
Normesuximide ³¹	10-30	40		38	
Nortriptyline ⁴⁸	0.02-0.2 (0.05-0.15)	0.3 ³¹¹ ; 0.5	1-3	18-56 ⁶⁸	[76], [80], [81], [82], [223]
Noscapine	0.02-0.4			1.5-4	[47]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Obidoxime	1-10 (appr. 10-15 µmol/L)				[549], [58]
Ofloxacin	appr. 2.5-5.5	(30-) 40 ⁸		(3-) 5-8	[3], [550]
OKT 3	see Muromonab-CD3				
Olanzapine	0.02-0.08	0.15-0.2	0.25 ⁸ ; 1 ⁸ ; 2.5 ⁸ ; 4.9 ⁸	30-60	[47], [551], [101], [552], [553], [4], [72], [554], [15], [555], [58]
Olpadronat (Olpadronic acid)				. ⁶	[49]
Omeprazole ⁴⁸	0.05-4 ⁹⁸			0.5-1 (-1.5)	
Ondansetron	0.03-0.3			3-5.5	[8], [66]
Opi Pramol	0.05-0.5	1 ³¹¹ ; 2-3	7-10	6-12 ²⁶²	[43], [556], [4]
Orphenadrine	0.1-0.2 (-0.6)	1.7	3.6 ⁸ ; 5-7	(10-) 14-18	[296], [56], [9], [557]
Oxatomide	0.02-0.1			14-30	[3]
Oxazepam	0.2-1.5	2	3-5	6-20	[283], [3], [59], [13]
Oxazolam	see Nordazepam				
Oxcarbazepine	10-35 ¹⁷²	45		1-2.5 (-5) ¹⁷²	[3], [558], [12], [559], [560], [381]
Oxibutynin	0.001-0.02				[8]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
N-Desethyloxibutynin	0.01-0.08				[8]
Oxpentifylline	see Pentoxyfylline				
Oxprenolol	0.05-0.3 (-1.0)	2-3	10	1-4	[7], [8]
Oxycodone ⁴⁸	0.005-0.1	0.2 ³³⁹	0.6; 5 ⁸	2-5 ⁵³	[9], [42], [11], [58], [244]
Oxyfedrine	appr. 0.06			4.2	[95]
Oxyphenbutazone	25-100	200		48-72	[47], [8]
Oxypurinol ⁶¹	5-15	20		18-30	[11], [58]
Oxytocin	appr. -0.0002			3-5 min	[3]
Paclitaxel	0.1-1 ¹²²			4-8 (-20)	[8]
Paliperidone	0.02-0.06	0.12 ³¹¹		23	[4]
Pamidronate (Pamidronic acid)	< 0.02 ³²³			. ⁶	[49], [561]
Pancuronium	0.1-0.6	0.4 ⁸ ; 1 ⁹⁸	1.6	1.5-2.5	[562]
Pantoprazole	appr. -4.6 ⁹⁸			1-2	[8], [3]
Papaverine	0.2--2			1-2 (6-7)	[57]
Paracetamol	(5-)10-25	100-150	200-300	2-4	[563], [564], [565], [566], [567], [568], [569], [243], [570], [571]
Paraldehyde	10-100	200	400-500	4-10	[87], [48]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Paraoxon	-	0.005			[11]
Paraquat	-	0.05	0.12 ⁸ ; 348; 1-2 ²⁰¹	8-12 ³⁴⁹	[123], [572], [11], [573], [574], [575], [576], [577], [578], [579], [580]
Parathion	-	0.01-0.05	0.05-0.08		[3], [10], [58]
Paroxetine ⁴⁸	< 0.01-0.05 (-0.12)	0.35-0.4	3.7 ⁸ ; 4 ⁸ ;306	16-24 ⁹³	[263], [368], [202], [581], [582], [583]
Pefloxacin	1-10 (3-6)	25		8-15	[8]
Pemoline	appr. 1-7			7-13	[8]
Penbutolol	0.01-0.3 (-1.0)			20-26	[7]
Penfluridol	0.004-0.025			70	[3], [11]
(D-)Penicillamine	1.7-5.6 (-11)			1-3	[8]
Pentachlorophenol	-0.2	30	45		[11]
Pentamidine	0.3-0.5	appr. 0.8		6-9	[3], [15], [8]
Pentazocine	0.01-0.2	1-2	3	2-5	[8]
Pentobarbital	1-5 (-10)	10-19	15-25	20-40	[87], [48], [8]
Pentoxifylline ⁷²	appr. 0.5-2			0.5-2 (4-6)	[8]
Pentoxyverine	-0.18			2-3	[8]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Perazine	0.02-0.35 (-0.44)	0.5 (6.1 ⁸)		8-16 (-35)	[584], [8]
Perhexiline	0.11-0.6 ³⁰⁹	0.6-1.2		(7-) 12-18 (-23)	[585], [586], [3]
Perici(y)azine	0.005-0.03	0.1			[9]
Perindopril	0.08-0.15			0.8-1.5 ²⁶⁵	[15], [8], [3]
Perphenazine	0.001-0.02 (0.0006-0.0024) ¹⁶¹	0.005 ³¹¹ ; 0.05		8-12 (-21)	[587]
Pethidine	0.1-0.8 ¹¹⁵	1-2	2 (-3)	3-6 (-10)	[588], [589], [590], [591], [592]
Phenacetin ⁶²	5-10 (-20)	50		appr. 1	[9], [13]
Phenazepam	0.02-0.04			60	[47]
Phenazone (Antipyrine)	5-25	50-100		10-12	[8]
Phencyclidine (PCP)	0.01-0.2	0.007-0.24 (-0.8)	(0.3-) 1-5	1-12 (-50)	[467], [15], [8], [11], [58]
Phendimetrazine	0.02-0.1		0.3-0.7	2-4	[8]
Phenelzine	0.001-0.002 (-0.04)	0.5	1.5	6-8	[3], [11], [58]
Pheneturide		5-20		30-90	[12]
Phenformin	0.03-0.1	0.6	3	4-13	[15], [8], [3]
Pheniramine	0.01-0.27		appr. 2	16-19	[15], [8], [3]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Phenmetrazine	0.02-0.25	0.5	4	appr. 8	[8]
Phenobarbital	10-30 (15-40)	30-40	50-60	60-130	[161], [164], [415]
Phenol		50	90		[11]
Phenprocoumon	0.16-3.6 (1-5)	5		100-160 ³⁵	[11], [58]
Phensuximide	4-10 (-20)	80		4-12	[8], [11], [58]
Phentermine	0.03-0.1	0.9	1	appr. 20	[15], [8], [11], [58]
Phenylbutazone ³⁶	50-100	120-200	400	30-175 ³⁷	[9], [13]
Phenylephrine	0.04-0.1			2-3	[8]
Phenylpropanolamine (Norephedrine)	0.1-0.5	2	48	3-7	[3], [9]
Phenytoin	5-15 (10-20) ⁸¹	20-25	43 ⁸ ; 50	10-60 ³⁷	[164], [593], [594], [595], [596],[597], [598], [599], [600]
Pholcodine	appr. 0.07-0.2			35-75	[47]
Physostigmine	< 0.001-0.005			0.4-1	[316], [601], [303]
Pimozide	0.004-0.01 (-0.02)	0.02 ³¹¹		24-55	[4]
Pinazepam ¹⁵	0.01-0.05			16	[59]
Pindolol	0.02-0.15	0.7-1.5		2-5	[7]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Pipamperone	0.1-0.4	0.5-0.6		17-22	[4]
Piperacilline	1-5 (20-70)			1-2	[15], [8], [11], [58]
Piperazine	0.02-0.1	0.5			[42], [66], [58]
Pipotiazine	0.001-0.06	0.1		8-11	[3], [9], [8], [11], [58]
Piracetam	appr. 20-50			4.5-7	[8]
Pirenzepine	0.03-0.45			8-20	[8]
Piritramide	0.0035- 0.014 ¹²⁸	_128		4-10	[602], [8]
Pirmenol	1-4			6-18	[3], [8], [11]
Piroxicam	2-6	14 ⁸		30-70	[8]
Pizotifen	0.007-0.009			26	
Posaconazol	> 0.7 (for invasive aspergillosis)			20-66	[47], [603], [604], [605]
Practolol	1.5-5			appr. 6-8	[8]
Prajmalium ⁴⁸	0.06-0.44			5-7	[8]
Pramipexole	appr. 0.0002-0.007	0.015 ³¹¹		8-14	[4], [467], [15], [8]
Pranlukast	appr. 0.2-1.2			appr. 2-9	[15], [8], [3]
Prazepam ¹⁵	0.2-0.7	1		1-3	[8], [59]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Praziquantel	appr. 0.2			1-2.5	[8]
Prazosin	0.001-0.02	0.9		2.9±0.8	[95], [42]
Prednisolone	0.5-1			2-6	[8]
Pregabalin	2-5 (-8)	10 ³¹¹ ; 13 ⁸ ; 60 ⁸ ; 67 ⁸		appr. 6	[373], [4], [606], [607]
Prilocaine	0.5-1.5 (-2) ¹²⁶	5-6	appr. 20	1-2	[608], [327]
Primaquine	appr. 0.1-0.2			4-7	[8]
Primidone ⁶³	4-12 (8-15)	20-50	65	4-12, 9-22	[161], [164]
Probenecid	100-200 (20-150)			3-17 ³⁷	[8]
Procaine	0.2-2.5 (-15)	15-20	20	-0.5	[15], [11], [58]
Procainamide ⁵	(2.5-) 4-10 (-12)	10-15	20	2-5 (-8)	[70], [609], [8]
N-Acetylprocainamide ³⁸	(5-) 10-35 (-40)			3-7	[8]
Prochlorperazine	0.01-0.05	0.2-0.3	5	7-9 (-18)	[3], [9], [58]
Procyclidine	0.08-0.63	1-2	7.8 ⁸	7-16	[15], [8], [11]
Proguanil ⁴⁸	appr. 0.04-0.15 ¹¹⁴			13-24 ¹¹⁴	[610], [58]
Promazine	0.01-0.05 (-0.4)	1	5	5-41 (8±7)	[8]
Promethazine	0.05-0.2 (-0.4)	1-2	2.4 ⁸ ; 1.8-5.4 ²⁵⁰	8-15 (-20)	[56], [611], [612]
Propafenone ⁴⁸	(0.04-) 0.3-2	(1.1-) 2-3	7.7 ⁸ ; 9 ⁸	5-8, 2-32 ⁴⁸	[613], [70], [42]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Propallylonal	0.3-10	appr. 10		appr. 3	[8]
2-Propanol	see Isopropanol				[64]
Propantheline	appr. -0.02			1-3	[3]
Propiomazine	< 0.3 (?)			8-10	[56], [614]
Propofol ⁴⁸	appr. 2-8			3-8 ⁹¹	[244], [615], [52], [616]
Propoxyphene	see Dextropropoxyphen				
Propoxur			0.3 ⁸		[87]
Propranolol	0.02-0.3	(0.5-) 1-3	4-10	2-6	[7], [112]
Propylene glycol	0.05-0.5	1000; 4700 ⁸		2-5	[47], [11], [58], [617]
Propylhexedrine	0.01	0.5	2-3		[58]
Propyphenazone	3-12			1-1.5 (-3)	[9], [13], [14]
Prothipendyl	0.005-0.01	0.02 ³¹¹ ; 0.1-0.5		2-3	[4]
Protriptyline	0.05-0.3	0.5	1; 20.7 ⁸	50-200	[87], [58]
Pseudoephedrine	(0.05-) 0.5-0.8		19-20 ²⁸⁰	9-16	[618], [266], [267], [269], [15], [11], [58], [619]
Psilocin ³⁸⁰	appr. 0.008	0.018 ⁸		1.8-4.5	[47]
Psilocybin	see Psilocin				

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Pyrazinamide	30-75			9-10(-25)	[620], [3], [9]
Pyridostigmine	< 0.05-0.2			1-2.5	[316], [621], [622]
Pyridoxine	0.003-0.018			3-6	[66]
Pyrilamine			11 ⁸		[87]
Pyrimethamine	appr. -1.5			80-96	[3]
Pyrithyldione	1-10			11-20	[9], [13], [14]
Quazepam	0.01-0.05 (-0.15) ¹³¹			39 (25-41)	[59], [8], [11], [58]
Quetiapine	0.1-0.5 ²³⁹	1 ³¹¹ ; 1.8 ⁸	1.9 ⁸ ; 5.1 ⁸ ; 12.7 ⁸	appr. 5-7 ²⁴⁰	[623], [624], [625], [626], [87], [627], [628]
Quinidine ⁴⁸	1-5	6-10	10-15	4-12	[70], [23]
Quinine	1-7	10		4-15	[629], [630]
Rabeprazole	appr. -0.6			1-2	[15], [8]
Ramipril	appr. 0.001-0.04 ²²⁸			1-5	[3], [8]
Ranitidine	0.05-1			2-4	[631]
Raltegravir (RAL)	0.072 (0.029-0.118) ³⁰³				[110]
Reboxetine	0.06-0.35 ²⁸¹	0.7 ³¹¹		12-14 (-30)	[632], [3], [633], [4]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Recainam	1.3-5.7			5-7	[634]
Remacemide	appr. 0.1-1			4	[8]
Remifentanil	-0.02			0.15	[8]
Remoxipride	2.15±0.59 ¹³²		41-150	5-10	[56], [635], [636]
Retinol (Vitamin A)	0.2-0.8 (0.7-2.8 µmol/L)				[66], [637]
Ricin		0.0005			[638]
Rifabutin	0.05-0.15			24-58	[47], [3]
Rifampicin (Rifampin)	0.1-10 ¹⁰¹	204 ⁸	55 ⁸	1-6 ³⁷	[47], [620], [317], [639]
Rifapentine				13.2	[620]
Riluzole	appr. 0.05-0.5 (-1.5)			9-15	[467], [15], [8]
Risedronat (Risedronic acid)				-.6	[49]
Risperidone ⁴⁸	appr. 0.006 ¹⁵⁸ (0.002-0.02 ²⁷²)	0.12 ³¹¹	1.8 ⁸	2-4 ¹⁵⁹	[47], [457], [4], [640], [641]
Ritonavir	appr. 5-11 (-20)			3-5	[3], [642],[2]
Rivastigmine	0.008-0.02	0.04 ³¹¹		1-2 (oral); appr. 3 (transdermal patch)	[4], [303], [15], [8], [643], [644]
Rizatriptan	appr. -0.1			2-3	[3], [15], [8]
Rocuronium	appr. -17			appr. 1.5	[8]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Ropinirole	0.0004 – 0.006 ²⁵⁴	0.012 ³¹¹		3-10	[4], [8], [645]
Ropivacaine		(1-) 2 ¹⁷³		2 ¹⁶⁸	[646], [647], [648]
Rosiglitazone	appr. 0.1-0.3			4	[8]
Roxatidine	0.1-0.8			5-6	[8]
Roxithromycin	4-12			12	[115], [3]
Rufinamid	5-30	40 ³¹¹		7	[4]
Salbutamol (Albuterol)	0.004-0.02	(0.03-) 0.1-0.15 ¹¹⁶	0.16	3-6	[11], [58], [649]
Salicylamide	5-40			appr. 1	[8]
Salicylic acid	20-200	300-350	(400-) 500	3-20	[28], [3], [29], [30], [31], [32], [33]
Salvinorin A				40-80 min	[47]
Saquinavir (SQV)	> 0.1-0.25 ²⁹⁶			(1-) 3-7 (-12)	[47], [110], [2], [111]
Scopolamine	0.0001-0.0003 (-0.001)			appr. 3	[15], [8], [11]
Secbutabarbital	5-10 (-15)	20	30	34-42	[8]
Secobarbital	1.5-5	7-10	10-15	15-30	[87], [8]
Selegiline	see Amphetamine and Methamphetamine				

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Selenium	0.045-0.13 (-0.19)	0.4-1	2; (2.6 ⁸ ; 2.8 ⁸ ; 304; 18.4 ⁸ ; 38 ⁸)	69-77 ⁶	[47], [3], [650], [87], [651], [652]
Seratrodoast	appr. 3-25				[8]
Sertindole	0.05-0.1	0.2 ³¹¹		55-90	[8], [101], [4]
Sertraline	(0.01-) 0.05-0.25	0.29 ⁸	1.6 ⁸ ; 3 ⁸	24-28 (22-34)	[47], [467], [653], [15], [8], [11], [58], [223]
Sevoflurane	appr. 134 ³⁸¹		8, 26 ⁸	1.8-3.8	[47]
Sibutramine ³⁶⁶	appr. 0.001-0.01			4-8	[47], [8]
Sildenafil	appr. 0.05-0.5			3-5	[3], [15], [8]
Silver	-0.005 ³⁶⁷				[58]
Simvastatin	0.0027-0.0056			appr. 2 ²⁹⁰	[48]
Sirolimus	0.005-0.015 ²⁴⁴	0.015(-0.06)		57-63	[123], [654], [655], [656], [657]
Sisomicin	0.5-10			appr. 1	[8]
Sitagliptin	0.05-0.38			8-14	[47]
Sodium aurothiomalate (gold)	see Gold				
Sodium nitroprusside	see Thiocyanate			0.1	
Sodium oxybate (GHB)	see 4-Hydroxybutyrate				

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Sodium valproate	see Valproic acid				
Sotalol ¹⁶⁷	0.5-3 (-4)	7.5-16 ⁸	40 ⁸ ; 43 ⁸	5-13 (-17)	[658], [70], [7], [659]
Sparteine ⁴⁸	0.5-1			2.5	[8]
Spiramycin	appr. -3			5-8	[3], [660]
Spiraprilate	0.006-0.045			33-41	[8]
Spirolactone	(0.05-) 0.1-0.25 (-0.5) ⁷³			13-24 ⁷³	[8], [11], [58]
Stiripentol	1-10	15(-20)		4-13	[4], [3], [8]
Streptomycin	1-5 (15-40)	40-50		2-4	[467], [8], [11], [58]
Strontium	-0.03			30-60	[47]
Strychnine		0.075-0.1	0.2-2	10-15	[661], [662], [663], [664], [15], [8], [665], [11], [666], [667]
Sufentanil	0.0005-0.01 ⁴	₋₃₃₉	0.001-0.007 ⁸	1.6-5.7 (7-49)	[47], [668], [669], [670], [344], [346], [671], [54]
Sulbactam	-80			1-2 ⁷⁰	[174], [3]
Sulfamethoxazole	30-60 ⁵⁶	200-400		9-12	[3], [672]
Sulfasalazine ³⁴	5-30 (-70)		130 ^{8;304}	4-10	[8]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Sulfisoxazole	90-100				[48]
Sulfinpyrazone	6-17			3-5	[8]
Sulindac	1-5 ¹⁰²			appr. 7	[673], [87]
Sulpiride	0.05-0.4 (-1) ²²⁵	1; 5 ⁸	3.8 ⁸ ; 38 ⁸	4-11 (-14)	[47], [43], [3], [4], [11], [58]
Sultiam (Sulthiame)	0.5-12.5 (2-8)	12-15	20-25	3-30	[491], [8]
Sumatriptan	0.018-0.06			2	[15], [8]
Suramin	> 100 ¹¹⁷	300 ¹¹⁸		44-54	[674]
2,4,5-T	see 2,4,5-Trichloro- phenoxyacetic acid				
Tacrine	appr. 0.01			2-4	[303]
Tacrolimus (FK-506)	0.005-0.015 (-0.02)	(0.015-) 0.02-0.025		9-16	[11], [675], [676], [191], [677], [678], [679], [680], [681], [682], [683], [684]]
Tadalafil	0.09-0.48			16-19	[47]
Talinolol	0.04-0.15		5 ⁸ ; 12 ⁹ ; 20 ⁸	10-14	[7], [685], [686]
Talipexole	appr. 0.0001-0.001			5-9	[15], [8]
Tamoxifen	0.05-0.5			5-7 ⁶	[3]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Tapentadol	0.05-0.13		0.3 ⁸ ; 2 ⁸	3-5	[47]
Taxol	see Paclitaxel				
Teicoplanin	(10-) 15-20 (-40)	200		10-15; 83-168 ⁸³	[687], [688]
Temazepam	0.02-0.15 (-0.9)	1	8.2 ⁸ ; 14 ⁸	6-25	[689], [59], [8], [11], [58]
Tenoxicam ¹⁷⁴	appr. 5-10			(50-) 70-90	[690], [691]
Terazosin	appr. 0.02-0.08			8-12	[15], [8]
Terbinafine	0.01-0.03 ²⁰⁵			22-26	[3], [10], [11], [58]
Terbutaline	0.001-0.006 (-0.01)		0.04	16-20 ⁸⁹	[8], [11], [58]
Terfenadine ³⁶⁸	< 0.01	0.04-0.06 ¹⁴⁸	0.4 ⁸	15-22 ⁶⁴	[47], [3], [692]
Tetrachloroethylene			4-5; 44 ⁸ ; 66 ⁸	33-72	[87], [58]
Tetracycline	1-5 (5-10)	30		6-10	[3], [8], [11]
Tetrazepam ⁴⁰	0.05-0.6 (-1)			(10-) 16-44	[47], [59]
Thalidomide	0.5-1.5 (-8)			5-9	[3], [15], [8]
Thallium	-0.002 (-0.0006 ³³¹)	0.1-0.5 ¹⁷⁹ ; 5.6 ⁸	0.5-11	~6	[693], [3], [11], [694], [100]
Theobromine	10-15	20		6-10	[11], [58]
Theophylline	(5-) 8-15 (-20) ⁸²	20	50	6-9 ⁴¹	[695], [696], [20], [697], [415], [698],

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
					[699], [21], [700], [701], [702], [703], [704], [705]
Thiamphenicol	0.5-3-10 (-15)	20		2-7	[15], [8]
Thiamylal	appr. 5		29 ⁸ ; 30 ⁴	0.6-0.8 (initial); 12-34 (terminal)	[47], [87]
Thiazinamium	0.05-0.15	0.3			[467], [15], [8], [11]
Thiocyanate from Nitroprusside	1-12 ¹⁴⁴ 5-30	35-50 50-100	200	3-4 ⁶	[706], [3], [255], [11]
Thiopental ⁵⁷	1-5	7	10-15 ⁵⁸	3-8	[707], [48]
Thiopropazine	appr. 0.001-0.02	0.1			[15], [8]
Thioridazine	0.1-2 (0.2-0.8-1.25) ¹³³	2.5-5	3-10	7-13 (-36)	[56], [4]
Thiothixene	see Tiotixene				
Thyroxine	see Levothyroxine				
Tiagabine	0.01-0.1 (-0.2)	0.5-0.6; 3.1 ⁸ ; 24 ⁵		7-9 (4-13)	[708], [3], [709], [710], [711], [12], [712], [15], [8], [381], [4]
Tiapride	C _{max} 1-2	4 ³¹¹		appr. 3-4	[4], [8]
Tiaprofenic acid	appr. 15-40 ¹⁹³			1.5-3 (-6)	[3], [713], [714]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Ticlopidine	< 1-2 (?)			70-130 ¹⁰⁰	[47], [8]
Tiletamine			0.85 ⁸ ; 30 ⁴		[87]
Tilidine ²⁵	0.05-0.12	.33 ⁹	1.7 ⁸	appr. 3	[715], [716], [15]
Tiludronate (Tiludronic acid)	0.2-1.5			65-78 (-150)	[49], [717]
Timolol	0.005-0.05 (-0.1)			2-6	[8]
Tin	0.03-0.14				[58]
Tinidazol	max. -60			11-15	[3]
Tiopronin	appr. 2-5			23 ± 11	[718]
Tiotixene	0.001-0.03 (0.002-0.014)	0.1		34-36	[185], [48]
Tiotropium	0.000016 ³⁰⁷			5-6 ⁶	[719]
Tipranavir (TPV)	> 20.5 ²⁹⁹			5.5-6	[110], [2], [111]
Tizanidine	appr. 0.015			appr. 2.5	[3], [8]
Tobramycin	4-10 ¹⁵⁴	12-15		2-3	[67], [3], [198], [41]
Tocainide	4-12 (6-10)	13-15; 20 ⁸	74 ⁸ ; 78 ⁸ ; 140 ⁸	8-25	[47], [3], [720], [721]
Tofenacine	0.025-0.1	0.5-1			[9], [58]
Tolbutamide	45-100	400-500	640 ⁸	4-12	[722], [11], [58]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Tolcapone	C _{max} 3-6	12 ³¹¹		2	[4]
Tolmetin	10-80			2-4	[11], [58]
Tolperisone	0.09-0.3	0.7 ⁸ ; 382	7-14	1.8-2.9	[47]
Toluene			10 (-48 ⁸)	13-68	[47], [58]
Topiramate	2-10 ²¹⁸	16 ³¹¹		20-30	[712], [15], [8], [381]
Topotecan	appr. 0.001-0.01 ¹⁹⁰			2-3	[3], [723], [724]
Tramadol ⁴⁸	0.1-1 (>0.3) ⁸⁷	1	2 ⁸ ; 49; 13 ⁸ ; 38.3 ⁸ ; 252	5-10	[11], [244], [725], [726], [63]
Tranexamic acid	10-50			10	[8]
Tranlycypromine	< 0.05	0.1 ³¹¹ ; 0.5 ⁸ ; 202	0.7 ⁸ ; 5 ⁸	1-3.5	[4], [727]
Trapidil	(4-) 6-10			2-6, 12	[3], [95], [728]
Trazodone ¹⁴⁵	0.7-1	1.2 ³¹¹ ; 3-4	12-15 ⁸	4-11 (-13)	[43], [4], [729], [64]
Triamterene	0.01-0.1			1.5-4	[3], [42]
Triazolam	0.002-0.02	0.04		2-5	[730], [59], [423]
2,2,2-Tribromoethanol		50	90		[58]
1,1,1-Trichloroethane			(15 ⁸); 100-1000	appr. 53	[11], [58]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
2,2,2-Trichloroethanol ³⁶⁹	5-15	40-70	60-100	6-10 ³²⁷	[47], [11], [58]
Trichloroethylene			9.7 ⁸ ; 16 ⁸ ; 21 ⁸	30-38	[87]
2,4,5-Trichlorophenoxyacetic acid (2,4,5-T)	-	appr. 100	200	23-33	[3], [11]
Trifluoperazine	0.001-0.01 (-0.05)	0.1-0.2	0.4 ⁸	7-18	[87], [8]
Triflupromazine	0.03-0.1	0.3-0.5		appr. 6	[8]
Trihexyphenidyl	0.05-0.2 ⁷⁵	0.5		3-5	[9], [114]
Trimeprazine	see Alimemazine				
Trimethadione ²⁷⁴	20-40			16	[11], [58]
Trimethobenzamide	1-2		184 ⁸	7-9	[47], [11], [58]
Trimethoprim	1.5-2.5 ⁵⁶	20		8-11	[3], [672]
Trimipramine	0.01-0.3	0.6 ³¹¹	1.7-8.2 ²⁵¹	10-20 (-40)	[56], [4], [223]
Tripelenamine	0.02-0.06		10 ⁸	5-8	[87], [15], [8], [57], [11]
Tripolidine	0.004-0.045			2-5	[57]
Tropisetron	0.02-0.05			7-9 (-30)	[66], [8]
Tubocurarine	0.04-6			2-4	[48], [8], [58]
Tungsten	-0.035				
Uranium	0.00004 ³³¹				

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
Urapidil	appr. 0.1-0.2			2.7-7	[3], [95]
Valdetamide	see Diethylpentenamide				
Valnoctamide	5-25	40			[58]
Valproic acid	40-100 (50-150)	150-200	556 ⁸ ; 720 ⁸	8-20	[47], [161], [164], [64]
Valsartan	appr. 0.8-6			6-9	[8]
Vanadium	-0.05			4-12 ⁶	[47]
Vancomycin	≤ 5-10 (-12) ¹⁴²	30		2.6-11 ⁸³	[47], [67]. 1994), [390], [731], [732], [733], [734], [735], [736], [64]
Varenicline	0.004-0.005	0.01 ³¹¹		24	[4]
Vecuronium	appr. 0.2-0.37 (-0.5)			1-1.5	[3], [9]
Venlafaxine	0.1-0.4 ¹⁸⁹	1-1.5 ²⁶⁶	6.1-24 ⁸	3-7	[47], [101], [4], [737], [11], [58], [223]
Verapamil ⁹⁰	(0.01-) 0.02-0.25 (-0.4)	1	2.5 ; 3.9 ⁸	6-14 ⁴²	[56], [84], [721], [738], [739], [64]
Vigabatrin	2-10 (-15) ⁹⁴	20 ³¹¹		5-8	[47], [381], [64]
Viloxazine	-6.0-8.0 (?)		45 ⁸	2-5	[43], [3], [15],

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic ("normal")	toxic (from)	comatose-fatal (from)		
					[8]
Vincamine	< 0.25 (?)			1-2 (8-17)	[8]
Vinylbital	1-3	5	8	18-33	[8]
Viquidil	0.15-0.25			6-12	[11], [58]
Vitamin A	see Retinol				
Vitamin C	see Ascorbic acid				
Vitamin D	(0.02-) 0.03-0.09 ²⁶³	0.2		appr. 30 ⁶	[740], [741], [742], [743]
Voriconazole	2-6	3.5 (-6.0) ²⁸⁴		4-10 ³⁷	[47], [603], [744], [745]
Warfarin	1-3 (-7)	10-12	100	37-50 ⁹⁷	[3], [42], [14], [746]
Wismut	see Bismut(h)				
Xamoterol	appr. 0.02-0.04 (-0.1)			7-8	[3]
Xipamide	-20			5-8	[3]
Xylene	1.5 (BAT		3-40	20-30	[47], [11], [58]
Yohimbine	appr. 0.05-0.3			1-3	[64], [15], [8]
Zafirlukast	0.005-0.03			10	[3], [15], [8]
Zalcitabine	appr. 0.1 (0.5 µmol/L)			1-3 ⁸³	[290], [38]
Zaleplon	appr. 0.001-0.1			1	[8]

Substance	Blood-plasma concentration (mg/L)			t _{1/2} (h)	Ref.
	therapeutic (“normal”)	toxic (from)	comatose-fatal (from)		
Zanoterone	0.1-0.5				[747]
Zidovudine	0.1-0.3 (-1) ⁵¹	2-3		1-1.5	[290], [748], [749], [3], [750], [38],[2]
Zinc	0.6-1.3	2	42 ⁸	5-16 months	[47], [66]
Zipeprol	0.1-0.7		5.8 ⁸ ; 10.6 ⁸ ; 31 ⁸	1.2	[47], [57]
Ziprasidone	0.05-0.2	0.4 ³¹¹		2-7	[4], [3], [15], [8]
Zoledronat (Zoledronic acid)				(1-2) 40-385 (-189 ⁶)	[49], [751], [752], [753]
Zolmitriptan	appr. 0.007-0.01			2.5-3	[15], [8]
Zolpidem	0.08-0.15 (-0.2)	0.5	2-4	2-3	[754], ([56], [755], [3], [310], [15], [11]. [756]
Zomepirac	0.1-4		152 ⁸	4-10	[8], [87]
Zonisamide	10--40	40-70	100 ²⁰⁸	50-70 ²⁰⁹	[8], [757], [758],[712], [381]
Zopiclone	0.01-0.05	0.15	0.6-1.8	3.5-8	[56], ([3], [4], [15], [11]
Zotepine	0.01-0.15	0.3 ³¹¹		13-16	[3], [4]
Zuclopenthixol ^{48; 365}	0.004-0.05 (-0.1)	0.1-0.3		15-25	[4], [15], [14]

Clinical categories used for grouping analytical data:

Therapeutic: blood-plasma/serum concentrations (in general, trough at steady state) observed following therapeutically effective doses; no or only minimal side effects (drugs); "normal": concentrations associated with no or only minimal toxic effects (other xenobiotics).

Toxic: blood-plasma/serum concentrations which produce toxicity/clinically relevant side effects/symptoms.

Comatose-fatal: blood-plasma/serum (comatose) concentrations and whole blood (fatal) concentrations reported to have caused coma and death, respectively. Whether published data for deaths refer to levels measured ante-mortem or post-mortem (femoral or heart blood) is often unknown.

In addition to specific references provided in the table, data were compared and contrasted against published review articles and textbooks [3,4,7-15,41-43,47,48,56-59,64,66,74,87,88,259,270,294,467,759-779] but not specifically indicated for every drug/substance, as well as supplemented with our experiences in clinical and forensic toxicology.

Abbreviations: BAT, biological tolerance value (in the work area); rec, recombinant; Ref., references; $t_{1/2}$, in general, terminal elimination half-life (if not stated otherwise, see annotations)

Annotations to Table 1

- 1 active metabolites of acebutolol: N-acetylacebutolol ($t_{1/2}$: 9-14 h): therapeutic concentration 1-2.5 mg/L, comatose-fatal from appr. 90 mg/L, and diacetolol ($t_{1/2}$: 8-13 h): therapeutic 0.65-4.5 mg/L, comatose-fatal from appr. 100 mg/L
- 2 as salicylic acid (for analgesic and antipyretic effect)
- 3 as digoxin
- 4 during mechanical ventilation
- 5 slow (poor) and rapid (extensive) acetylators (metabolisers)
- 6 days
- 7 active metabolites nortriptyline (see Table) and amitriptyline oxide ($t_{1/2}$: 1.5-3 h)
- 8 case report
- 9 in patients with impaired renal function in some cases up to 100 h
- 10 active metabolite 6-mercaptopurine ($t_{1/2}$: 1-1.5 h)
- 11 appr. 0.2 h for azathioprine
- 12 active metabolite carbamazepine-10,11-epoxide ($t_{1/2}$: 5-16 h; usual plasma concentration range 0.2-2 mg/L) should be considered in case of intoxication
- 13 each sum carbromal(um) + carbromide ($t_{1/2}$: 12-15 days)
- 14 each as trichloroethanol
- 15 active metabolite desmethyldiazepam = nordazepam (see Table)
- 16 nephrotoxic
- 17 active metabolite N-desmethyldiazepam (therapeutic reference range: 0.3-3 mg/L; laboratory alert level³¹¹ 5 mg/L)
- 18 duration of pharmacological effects: 0.3-0.4 h; major metabolite: benzoylecgonine ($t_{1/2}$: 5-6 h)
- 19 active metabolites nordazepam and oxazepam (see Table)
- 20 active metabolite nordothiepin ($t_{1/2}$: 20-60 h)
- 21 active metabolite desmethyldoxepin (synonym nordoxepin, $t_{1/2}$: 33-80 h)

- should be considered in case of intoxication
- 22 benzodiazepine antagonist
 - 23 active metabolites
 - 24 active metabolite desalkylflurazepam ($t_{1/2}$: 74 ± 24 h)
 - 25 active metabolite nortilidine ($t_{1/2}$: 6 h), comatose-fatal plasma concentration: 4.4 mg/L⁸
 - 26 in some cases up to 80 h
 - 27 active metabolite levomepromazine sulfoxide ($t_{1/2}$: 5-10 h)
 - 28 $t_{1/2}$ for biological effects; terminal $t_{1/2}$: 16-78 h
 - 29 active metabolite desipramine (see Table)
 - 30 active metabolites diazepam, nordazepam plus oxazepam (see Table)
 - 31 active metabolite of mesuximide
 - 32 sum of active metabolites
 - 33 each as desacetylmepitranolol
 - 34 active metabolite 5-aminosalicylic acid (mesalazine, see Table); rapid/slow acetylators of the primary metabolite sulfapyridine
 - 35 in some cases longer
 - 36 active metabolite oxyphenbutazone ($t_{1/2}$: 27-64 h)
 - 37 dose dependent
 - 38 active metabolite of procainamide
 - 39 for the management of osteoporosis
 - 40 active metabolites diazepam (see Table), nordiazepam (see Table), and nortetrazepam ($t_{1/2}$: 25-51 h)
 - 41 smokers: $t_{1/2}$: 3-6 h
 - 42 during steady state
 - 43 astemizole plus desmethylastemizole
 - 44 blood drug concentrations following therapeutically effective doses below detection limit

- 45 as decanoate ($t_{1/2}$: 5-12 days)
- 46 in intensive care patients in some cases $t_{1/2}$ 8-22 h
- 47 physiologic
- 48 rapid (extensive, EM) and slow (poor) metabolisers (PM; genetic polymorphism)
- 49 6 month-old-child, appr. 15 h after 100 mg tramadol rectally
- 50 total labetalol: 0.7-5.0 mg/L
- 51 C_{max} 0.038 ± 0.006 mg/L after a single oral dose of 150 μ g/kg in nine persons with onchocerciasis ($t_{1/2}$: 56 ± 7 h)
- 52 as enalaprilat
- 53 duration of clinical effect: 3-5 h
- 54 product after hydrolysis
- 55 narcotic; analyzed during distribution phase
- 56 for pneumocystis carinii pneumonia (PcP) treatment: sulfamethoxazole 100-200 mg/L, trimethoprim 5-10 mg/L
- 57 metabolite: pentobarbital (see Table)
- 58 "narcotic"
- 59 higher with meningism (-25 mg/L); decreased protein binding in neonates results in increased unbound drug
- 60 each as 2-hydroxyflutamide (active and major metabolite)
- 61 active metabolite of allopurinol
- 62 active metabolite paracetamol (synonym acetaminophen, see Table)
- 63 active metabolites phenobarbital (see Table) and phenylethylmalonide (7-10 mg/L; $t_{1/2}$: 16-50 h)
- 64 as active carboxylic acid metabolite = fexofenadine ($t_{1/2}$: mean 15 h)
- 65 1 mg oral alprazolam/day equals appr. a plasma concentration of 0.01 mg alprazolam/L during steady state. Usually higher doses/plasma concentrations are recommended for the treatment of phobias when compared to panic disorder/attacks
- 66 highly inter- and intraindividual variable kinetics; for children

- (therapeutically): 0.04-0.1 mg/L; active metabolite desmethylchlorpromazine
- 67 $\geq 0.25 \mu\text{mol/L}$ desirable for echinococcosis
- 68 mean: 27 h; for geriatric patients (> 65 years) in some cases increased to more than 90 h
- 69 active metabolite 2-hydroxydesipramine ($t_{1/2}$: mean 18 h; in patients with impaired renal function several fold increased)
- 70 in patients with impaired renal function several fold increased
- 71 in colon tissue 0.8-1.8 h after 1 x 2 g i.v.: 94.0-7.4 $\mu\text{g/g}$
- 72 active metabolites 1-(5-hydroxyhexyl)-3,7-dimethylxanthine and 1-(3-carboxypropyl)-3,7-dimethylxanthine ($t_{1/2}$: 1-1.6 h), among others, with 5 and 8 times, respectively, higher plasma levels than pentoxifylline
- 73 as canrenone (one of the active metabolites of spironolactone, $t_{1/2}$: 1.3-1.4 h)
- 74 appr. 8 h after ingestion of probably 210 mg haloperidol and 1400 mg orphenadrine-HCl with life-threatening arrhythmias
- 75 data on effective plasma concentrations for Parkinson's disease not proven
- 76 peak: 20-30 mg/L, trough: < 7 mg/L
- 77 for hypertension: 0.2-0.45 mg/L; for angina/coronary heart disease or arrhythmias: 0.3-0.8 mg/L
- 78 therapeutic concentration of the unbound fraction: 0.5-2 mg/L; therapeutic concentration of the metabolite desalkyldisopyramide < 5 mg/L (ratio of metabolite to the parent compound disopyramide guide to duration of therapy and possibly to the likelihood of toxicity)
- 79 in mmol/L (mEq/L, mval/L): 0.4-1.2 (0.6-1.4), toxic from 1.5 mmol/L
- 80 terminal elimination $t_{1/2}$: 37 ± 6 h, increased in case of renal dysfunction
- 81 therapeutic concentration of the unbound fraction: 1-2.2 mg/L
- 82 for (sleep) apnea: 5-10 mg/L
- 83 increased in patients with impaired renal function
- 84 C_{max} 3-5 h after 4 mg loperamide hydrochloride orally: 1-3 ng/mL
- 85 active metabolite N-desmethylclomipramine ($t_{1/2}$: 21-65 h, mean: 40 h)

- 86 12-36 h
- 87 post-operative (on-demand; i.v.): 0.02-1-2 mg/L (median: 0.29-0.92 mg/L)
as minimal (analgesic) effective concentration; O-desmethylnaloxone:
0.03-0.04 mg/L (median: 0.036 mg/L)
- 88 10-36 h
- 89 11-26 h
- 90 stereoselective metabolism (therapeutic concentration after oral
application higher than after intravenous administration)
- 91 $t_{1/2}$ for β -phase of the elimination: 0.5-1 h
- 92 as albandazole sulfoxide (active metabolite)
- 93 $t_{1/2}$ in slow (poor) metabolisers appr. 40 h
- 94 trough plasma concentration at steady state during 2 g twice daily orally
(p.o.) appr. 9 mg/L; C_{max} (0.8 h after 1 g orally): appr. 45 mg/L
- 95 as active metabolite methimazole (thiamazole)
- 96 mean 80 min
- 97 15-85 h
- 98 plasma concentrations do not correspond with pharmacological effects
- 99 naltrexone plus 6- β -naltrexone: 0.025-0.1 mg/L; plasma concentrations of
the less potent major metabolite 6- β -naltrexol ($t_{1/2}$: 11-13 h) are usually
1.5-10 times higher
- 100 at steady state; 4-15 h after a single dose
- 101 sum rifampicin plus metabolites
- 102 sum sulindac plus metabolites (sulindac sulfide, $t_{1/2}$: 15-18 h; $t_{1/2}$ sulindac
sulfone: 17-20 h)
- 103 abuse
- 104 sum carisoprodol plus meprobamate
- 105 12-15 days for the metabolites
- 106 $t_{1/2}$ for total platinum plasma concentrations: 20-40 h (up to 6-7 days)
- 107 2-20 μ mol/L

- 108 carboxylic acid metabolite ($t_{1/2}$: appr. 20 days): 1.5-5.5 mg/L
- 109 during concomitant therapy with carbamazepine or phenytoin 13.5 -15 (8-33) h, during concomitant therapy with valproic acid 48-59 (31-89) h
- 110 in infants and after intoxications in some cases dramatically increased
- 111 during steady state 3-4 h after oral doses of 100-400 mg; prophylaxis of candidiasis: > 0.2 mg/L and of aspergillosis: > 1.0 mg/L in patients with acute myeloid leukemia (AML)
- 112 plasma concentrations of the major metabolite 13-cis-acitretin are usually higher
- 113 higher and increased, respectively, in patients with impaired hepatic function; for tinnitus aurium: therapeutic plasma concentration appr. 1-2 mg/L
- 114 biologically active/major metabolite cycloguanil ($t_{1/2}$: 8-17 h): plasma concentration after daily oral doses of 100-200 mg proguanil appr. 0.02-0.06 mg/L
- 115 active metabolite norpethidine ($t_{1/2}$: 14-24 (-48) h): toxic from appr. 0.5 mg/L
- 116 tremor, hypokalemia
- 117 as cytostatic drug: >200 mg/L
- 118 neurotoxic
- 119 in terminal renal insufficiency appr. 0.5-2 mg/L, cumulation of the inactive metabolite N-acetyl-5-aminosalicylic acid (Ac-5-ASA) up to 20 mg/L without adverse effects
- 120 $t_{1/2}$ of the inactive major metabolite N-acetyl-5-aminosalicylic acid (Ac-5-ASA) appr. 6-9 h
- 121 tocolytic (4.5-6.25 mval(mEq)/L, 2.25-3.125 mmol/L). Approximate normal range: 18-25 $\mu\text{g Mg}^{2+}/\text{mL}$ (0.74-1.03 mmol/L); conversion factor: mg/dL x 0.4113 = mmol/L
- 122 C_{max} appr. 2-8 $\mu\text{mol/L}$ (i.e. 1.7-6.8 mg/L, after 170-275 mg/m² intravenously for 6 h); much lower after intraperitoneal injection
- 123 as transdermal system (patch); plasma concentrations of the major metabolite cotinine ($t_{1/2}$: mean 16-20 h) appr. 10 times higher
- 124 mean 2 h; after application of the transdermal system possibly longer

- 125 active metabolites desipramine (see Table), 2-hydroxyimipramine ($t_{1/2}$: 6-18 h), and 2-hydroxydesipramine⁶⁹
- 126 3-7 min after retrobulbar blockade: 0.5-1.1 mg/L
- 127 for myasthenia gravis
- 128 half maximal effective concentration (EC_{50}) for analgesia: 0.0088 ± 0.0053 mg/L; EC_{50} for respiratory depression: 0.035 ± 0.022 mg/L
- 129 appr. 14 h after oral ingestion of 1.5 g
- 130 fluoxetine plus norfluoxetine; $t_{1/2}$ of the active metabolite norfluoxetine: 4-16, mean 7-9 days
- 131 active metabolites 2-oxoquazepam ($t_{1/2}$: 39 (28-43) h) and N-desalkyl-2-oxoquazepam (N-desalkylflurazepam, $t_{1/2}$: 74 ± 24 h)
- 132 peak plasma concentration during steady state
- 133 range of plasma concentrations after therapeutically effective doses of thioridazine for the active metabolites mesoridazine (thioridazine-2-sulfoxide): 0.2-1.6 mg/L ($t_{1/2}$: 10-14 h) and sulforidazine (thioridazine-2-sulfone): up to 0.6 mg/L ($t_{1/2}$: 10-16 h) and for the inactive metabolite thioridazine-5(ring)-sulfoxide: 0.06-4 mg/L; probably, the best correlation exists between the plasma concentration of mesoridazine and the clinical response
- 134 usually sleep occurred with ≥ 0.1 mg/L; in infants and children (< 13 years): in some cases during mechanical ventilation up to 3 mg/L; α -hydroxymidazolam-glucuronide likely contributes in case of impaired renal function to prolonged sedation
- 135 plasma concentration range of the primary metabolite 1,5-dimethyl-3,3-diphenyl-2-ethylidene-pyrrolidine (EDDP) during steady state: 0.005-0.055 mg/L (daily oral methadone dose: 10-225 mg, mean 60 mg)
- 136 ratio clozapine/active metabolite N-desmethylclozapine (= norclozapine, $t_{1/2}$: 19.2 ± 10.2 h) usually 1.0-2.5
- 137 maximum antiemetic effect at > 0.01 mg/L
- 138 active metabolite descarboethoxyloratadine ($t_{1/2}$: 17-24 h): appr. 0.005-0.02 mg/L
- 139 0.15 ± 0.05 ‰ per h
- 140 during chronic administration appr. 10-20 h (induction of own metabolism)

- 141 caution is warranted in case of concomitant use or intoxication with serotonin reuptake inhibitors (SSRI) such as citalopram, clomipramine (fluoxetine, paroxetine): possible serotonin syndrome
- 142 trough concentration; peak concentration: < 40 mg/L
- 143 distribution half-life: 0.3-0.5 (-1) h
- 144 non-smoker: 1-4 mg/L (17-69 $\mu\text{mol/L}$); smoker: 3-12 mg/L (52-206 $\mu\text{mol/L}$)
- 145 major active metabolite 1-m-chlorophenylpiperazine; plasma concentration appr. 1/10 compared to trazodone
- 146 plasma concentration for maximal cellular accumulation of the active form gemcitabine-5'-triphosphate
- 147 after topical nasal or ocular administration
- 148 Torsade de pointes, usually due to cytochrome P450 3A4 inhibition (e.g., ketoconazole, erythromycin) and/or impaired hepatic function
- 149 after oral administration; after topical application: plasma concentration < 0.03 mg/L and $t_{1/2}$ appr. 22 h
- 150 for each added 1 mg/day dose of clonazepam, there is appr. an increase of 12 ng/mL in the plasma (patients with panic disorder)
- 151 Sum of amoxapine and his major metabolite 8-hydroxyamoxapine ($t_{1/2}$: appr. 30 h; $t_{1/2}$ 7-hydroxyamoxapine: 4-6.5 h)
- 152 sum bupropion (amfebutamone) and morpholinole metabolite ($t_{1/2}$: 19-22 h)
- 153 after i.m.-application as decanoate appr. 3 weeks
- 154 C_{min} < 1-2 mg/L at best (especially in patients with renal dysfunction)
- 155 appr. 0.02 mg/L in organophosphorous ester poisoning depending on clinical symptoms
- 156 in case of organophosphorous ester (e.g. parathione) intoxication; 250 mg intravenously as bolus followed by an infusion of 750 mg/24 h
- 157 if used as an antiarrhythmic appr. 0.1-0.4 mg/L
- 158 using daily oral doses of ≤ 25 mg 0.00046 mg risperidone/L per mg dose and 0.0064 mg/L per mg dose for risperidone plus 9-hydroxyrisperidone (the clinical effects likely results from the combined concentrations)
- 159 extensive metabolisers; $t_{1/2}$ for poor metabolisers: 20 h; $t_{1/2}$ for risperidone plus 9-hydroxyrisperidone: 22-24 h

- 160 6 case reports: post mortem 5.2-49 µg citalopram/g blood and 0.3-1.4 µg desmethylcitalopram/g blood
- 161 concentration/dose-values for extensive metabolisers: 0.025-0.688 (median 0.098) nmol/L per mg oral perphenazine, and 0.096-0.750 (median 0.195) nmol/L per mg oral perphenazine (mol wt 506.07) for poor metabolisers, respectively
- 162 two cases after ingestion of appr. 4 g moclobemide in combination with clomipramine (plasma concentration: 0.3-0.5 mg/L, i.e. toxic)
- 163 as R-enantiomer, mean: 9 mg/L
- 164 dosage: 50-55 mg/kg per day
- 165 appr. 2.5 h after ingestion of 50-100 mg amlodipine besylate with alcohol (263 mmol ethanol/L)
- 166 0.101 mg/L 4 h after ingestion of 70 mg and 0.185 mg/L at 10.5 h, complicated by oxazepam ingestion
- 167 data for d,l-sotalol
- 168 after i.v.-application; $t_{1/2}$: 4-7 h following epidural administration (appr. 4-5 h following intercostal block and appr. 8 h following brachial plexus blockade, respectively)
- 169 mean 19 h; $t_{1/2}$ of oral ciclosporine microemulsion is appr. 8 h
- 170 a longer $t_{1/2}$, up to 3.8 days, has been reported in elderly patients, up to 3.8 days
- 171 target range of activated partial thromboplastin time (aPTT) is prolongation of 50-70 sec; aPTT prolongation of more than 100 seconds has been associated with an increased risk of hemorrhagic events
- 172 as 10-hydroxycarbazepine for seizures (0.4-2 mg/L for oxcarbazepine) ; in patients with trigeminal neuralgia, therapeutic target range of the active metabolite 10-hydroxycarbazepine ($t_{1/2}$: 7-14 (-20) h): 50-110 µmol/L (appr. 13-28 mg/L)
- 173 mild CNS symptoms (limited data)
- 174 pharmacologically inactive metabolites 5' and 6'-hydroxytenoxicam
- 175 effective plasma concentrations for the 2 active metabolites: O-desmethylencaïnide (0.05-0.3; toxic from 0.3 mg/L, $t_{1/2}$: 11 h) and 3-methoxy-o-desmethylencaïnide (0.06-0.28 mg/L; $t_{1/2}$: > 24 h) during long-term therapy

- 176 in poor metabolisers 9-11 h
- 177 "normal": 0.001-0.006; smoker: 0.005-0.012 (-0.15) mg/L; $\mu\text{mol/L} \times 0.026 = \text{mg/L}$
- 178 reference value; 0.001 $\mu\text{g/g}$ creatinine or 0.0014 mg/L urine; < 30 $\mu\text{g}/24 \text{ h}$ urine ("normal"); "toxic" from appr. 0.05-0.3 mg/L urine. Reference value for children in Germany: 0.0008 mg/L blood and 0.0004 mg/L urine
- 179 > 0.04 mg/L urine
- 180 up to years in chronically exposed workers
- 181 combination with 2,4-D and chlorpyrifos
- 182 in case of intoxication/overdose: 70-90 h
- 183 overdose
- 184 one case of toxicokinetic estimation in acute potassium cyanide (KCN) poisoning
- 185 dependent on indication; > 2.0 mg/L for partiell seizures; tentative target range according to Neels HM et al. 2004: 12-20 mg/L; peak concentration at steady state appr. 4.6 mg/L (300 mg three times daily (tid)) and appr. 8.4 mg/L (600 mg tid)
- 186 prolonged in case of impaired renal function to 16-43 h; > 100 h in dialysis dependent patients
- 187 dependent on urine pH, if alkaline appr. 8-10 h
- 188 females showed significantly longer elimination half-lives ($35.4 \pm 13.7 \text{ h}$) than males (mean 21-26 h); the $t_{1/2}$ of the R(-)-enantiomer is twice that of the S(+)-enantiomer
- 189 venlafaxine plus O-desmethylvenlafaxine. After doses of 25, 75, and 150 mg every 8 h for 3 days, mean peak serum levels were 0.053, 0.167, and 0.393 mg/L; corresponding levels of the major active metabolite O-desmethylvenlafaxine ($t_{1/2}$: 10-11 h) were 0.148, 0.397, and 0.686 mg/L
- 190 at least 10 nmol of the lactone (mol wt 421.46)/L; decreases in absolute neutrophil counts of 50-90 % were observed with steady state plasma concentrations of total topotecan (lactone + hydroxy acid) of 20-60 nmol/L, respectively
- 191 a mean steady state peak plasma concentration of 0.286 mg/L was observed in healthy volunteers after 60 mg (oral solution) every 12 hours for 10 doses
- 192 the metabolite 2',2'-difluorodeoxyuridine (dFdU) has minimal antitumor

- activity but may contribute to the toxicity of gemcitabine
- 193 C_{\max} after 200 mg three times daily (tid)
 - 194 serum concentration of benzoic acid following high dose diazepam i.v.-infusion and severe metabolic acidosis (5-year-old girl; urine concentration: 1,200 mg/L)
 - 195 1.5 h in dogs after i.v.-administration
 - 196 for erythropoietic protoporphyria (EPP)
 - 197 trough; peak: 0.1-0.5 mg/L
 - 198 + 0.4 mg of its metabolite 3-deacetylpancuronium/L
 - 199 "normal": $\leq 2-3$ % of total Hb; from 15-20 %: cyanosis, headache, dizziness
 - 200 "normal": ≤ 5 % hemoglobin as carboxyhemoglobin (elderly: -15 %); smoker: 8-10 %
 - 201 2 h after ingestion
 - 202 3 h after ingestion of 400 mg with no severe symptoms
 - 203 mean steady state trough concentration; peak concentration: 5-15 mg/L
 - 204 for Parkinson's disease (appr. 15-50 pmol/mL)
 - 205 peak: 0.5-3 mg/L
 - 206 plasma concentrations below detection limit; plasma concentrations of the active metabolite 6-methoxy-2-naphthylacetic acid ($t_{1/2}$: appr. 24 h), which appears to be responsible for the effects, were 10-37 mg/L 3-6 h after single oral doses of 250, 500, and 1000 mg, respectively
 - 207 active metabolite 6-O-desmethyldonepezil
 - 208 coma in a patient overdosing zonisamide, carbamazepine, and clonazepam
 - 209 25-30 h in patients co-medicated with enzyme-inducing anticonvulsants (e.g. phenobarbital)
 - 210 2-4 h in patients co-medicated with enzyme-inducing anticonvulsants (e.g. phenobarbital)
 - 211 renal-transplant patients treated long-term (2-3 years) with mycophenolate mofetil had significantly lower trough plasma concentrations of the active metabolite mycophenolic acid (1.94 ± 0.24 mg/L) when compared to patients taking mycophenolate mofetil (1 g twice daily) short-term (2-10

- months; 3.53 ± 0.45 mg/L). Proposed mycophenolic acid pre-dose target concentration: 1-3.5 mg/L
- 212 as mycophenolic acid (active metabolite)
- 213 ten men with multiple sclerosis, 10-20 mg p.o. every 6 h and analyzed 30 min before the next dose; peak levels < 0.1 mg/L 30 min after a dose
- 214 nine patients, maximum tolerated oral dose 50-100 mg
- 215 $t_{1/2}$ of the metabolite 3-O-methyldopa: 15 h
- 216 appr. $2.5 \mu\text{mol/l}$ (1 mg/L) 24 h after single doses of 100-800 mg and during daily treatment with 200 mg
- 217 active metabolite 14-hydroxyclearithomycin ($t_{1/2}$: 5-7 h)
- 218 C_{max} following oral administration of 200, 400, 800, and 1200 mg, respectively: 3.7, 8, 18, and 29 mg/L; tentative target range according to Neels et al., 2004: 5-25 mg/L
- 219 at a daily dosage of 60, 120, and 240 mg the mean \pm SD concentration in patients with symptomatic ventricular tachyarrhythmias ($n = 9-18$) was 75 ± 46 , 144 ± 105 , and 324 ± 180 nmol/L, respectively
- 220 nonlinear kinetics
- 221 appr. 5 h after ingestion of 3 g, not associated with severe toxicity to a 27-year-old woman
- 222 slightly increased (8-12 h) in patients with impaired hepatic function; active metabolites hydroxynefazodone ($t_{1/2}$: 2-5 h), m-chlorophenyl-piperazine ($t_{1/2}$: 4-10 h), and triazoledione ($t_{1/2}$: 10-12 h)
- 223 each as N-desmethysuximide; methsuximide ($t_{1/2}$: 1-2 h) steady state concentration: appr. 0.04-0.08 mg/L
- 224 mean steady state trough concentration in 15 young adults receiving a daily dose of 0.47-1.71 mg isotretinoin/kg: 0.05-0.34 mg/L ($t_{1/2}$: 29 ± 40 h), and for the 4-oxo metabolite ($t_{1/2}$: 22 ± 10 h): 0.16-0.68 mg/L
- 225 for depression; higher in case of schizophrenia (0.2-1 mg/L)
- 226 suggested threshold for the sum of clomipramine (0.05-0.06 mg/L) and N-desmethylclomipramine (0.16-0.18 mg/L): 0.2-0.24 mg/L
- 227 for the active metabolite E-3174 ($t_{1/2}$: 4-9 h); plasma concentration of losartan producing 50 % of maximal blood pressure response to exogenous angiotensin-II: 0.032 mg/L
- 228 as ramiprilat ($t_{1/2}$: 13-17 (50-110) h)

- 229 half maximal inhibitory concentration (IC₅₀) for analgesic effect after oral surgery
- 230 the inhibitory concentration to reduce the level of extracellular hepatitis B DNA by 50 % varied from 2.3 µg/L to 1.3 mg/L; C_{max} after 150 – 300 mg *per os* (p.o.): 1.2-2.0 mg/L
- 231 C_{max} at steady state (666 mg three times daily (tid) *per os* (p.o.))
- 232 after oral administration of the enteric-coated tablet
- 233 trough < 2 plus peak 6-10 (5-12) mg/L
- 234 reference value; < 0.015 mg/L urine
- 235 active metabolite 4'-hydroxynimesulide (t_½: 3-9 h)
- 236 mean C_{max} 126.5 and 226.3 ng/mL 2 h after 75 and 125 mg p.o. and 162.9 and 291.8 ng/mL after oral administration of 1.0 and 1.6 mg MDMA/kg body weight, respectively, to young adults; mean C_{max} for the metabolites 4-hydroxy-3-methoxymethamphetamine (HMMA) 171.9 and 173.5 ng/mL, 3,4-methylenedioxymethamphetamine (MDA) 8.4 and 13.8 ng/mL, and 4-hydroxy-3-methoxyamphetamine (HMA) 3.5 and 3.9 ng/mL, respectively
- 237 in patients > 60 years prolonged up to 10 h
- 238 adjuvant in methadone maintenance therapy
- 239 means of the 'average' steady state plasma concentration for the relatively high dose of 250 mg q8h (every 8 hours) appr. 0.4-0.6 mg/L
- 240 combination of distribution and elimination processes
- 241 as active metabolite fenofibric acid
- 242 appr. 37.5 mmol/L (=mval/L, mEq/L)
- 243 steady state concentration 21.6 ± 14.2 mg/L (mean ± SD) during continuous infusion of 3 g (1.1-2.2 mg/kg h) every 24 hours in 44 patients undergoing coronary artery bypass graft surgery
- 244 target trough concentration if ciclosporine is being used at trough concentrations of 0.075-0.15 mg/L; without ciclosporine: appr. 0.03 mg/L (LC/UV assay)
- 245 4 hours after ingestion of 30-40 tiagabine HCl 8 mg tablets (coma)
- 246 bupropion plus 10-hydroxybupropion (t_½: 17-47 h)
- 247 calculated steady state concentration in children (4 months to 16 years) receiving 0.3 mg/kg body weight i.v.

- 248 femoral blood concentration of the metabolite desmethylalimemazine after fatal intoxication: 0.2-1.3 µg/g
- 249 40-50 min after 0.15 mg/kg i.v.
- 250 femoral blood concentration of the metabolite desmethylpromethazine after fatal intoxication (n=3): 0.3-1.8 µg/g
- 251 femoral blood concentration of the metabolite desmethyltrimipramine after fatal intoxication (n=10): 0.3-2.5 µg/g
- 252 fatal overdose with tramadol, alprazolam (0.21 mg/L), and alcohol (1.29 g/kg) in a 30-year-old woman
- 253 enterohepatic circulation; prolonged in elderly subjects to 33.4 hours (range: 20.0-53.4 h)
- 254 C_{min}/D [(ng/mL)/mg], i.e. dose-normalized trough plasma drug concentration, dosage interval 8 h
- 255 all data refer to the active metabolite A771726
- 256 steady state concentrations at 5, 10, and 25 mg/d, respectively
- 257 steady state trough concentrations after 400 mg/d orally; two major metabolites modafinil acid (appr. 0.5-0.8 mg/L, $t_{1/2}$: 7.3 ± 1.1 h) and modafinil sulfone (appr. 4.5-5.3 mg/L), but neither appears to contribute to the wake-promoting properties of modafinil
- 258 mean plasma trough concentration at steady state obtained from 400 mg imatinib/day in 83 adult patients with chronic phase CML; peak: 2.3 mg/L
- 259 in a 5-year-old girl
- 260 suggested minimum target trough concentration in patients with HIV-1 susceptible to the antiretroviral (ARV) drug (dose of 800 mg two times daily (bid))
- 261 active metabolite N-desethylamiodarone ($t_{1/2}$: 57-64 days), which achieves plasma concentrations similar to the parent compound
- 262 inactive metabolites deshydroxyethyl opipramol ($t_{1/2}$: 97 ± 24 h) and opipramol N-oxide ($t_{1/2}$: 10.7 ± 3.2 h)
- 263 as 25-hydroxyvitamin D (25(OH)D, calcidiol); vitamin D deficient: < 0.01 mg/L (< 10 ng/mL = 25 nmol/L); vitamin D insufficient: < 0.02 – 0.03 mg/L (50-75 nmol/L); conversion factor: mg/L x 2,500 = nmol/L (ng/mL x 2.5 = nmol/L)
- 264 6 h after reportedly ingestion of 30 g in a 38-year-old woman
- 265 metabolite perindoprilat, 3 to 10 hours, with a prolonged terminal half-life

- between 25 to 120 h
- 266 sum venlafaxine and O-desmethylvenlafaxine
- 267 for glaucoma 4-5 mg/L
- 268 doxapram + keto-doxapram
- 269 24 h after ingestion of appr. 20 mL
- 270 active metabolite desethylamodiaquine ($t_{1/2}$: 1-10 days)
- 271 smokers: -0.0006 mg/L
- 272 0.01-0.1 mg/L for 9-hydroxyrisperidone
- 273 as active metabolite after administration of therapeutic doses of diazepam
- 274 active metabolite dimethadione (see Table)
- 275 HPLC-MS/MS (or FPIA) blood, in combination with ciclosporine micro-emulsion
- 276 n=439; median in $\mu\text{mol/L}$ (interquartile range)
- 277 n=264; median in $\mu\text{mol/L}$ (interquartile range)
- 278 in the presence of ethanol or during ethanol treatment ; $t_{1/2}$ longer in patients with a serum creatinine concentration $\geq 130 \mu\text{mol/L}$
- 279 n=99; median in $\mu\text{mol/L}$ (interquartile range)
- 280 3 dead infants aged ≤ 6 months with post mortem blood levels of pseudoephedrine ranging from 4.7 to 7.1 mg/L
- 281 daily dose 2-8 mg *per os* (p.o.)
- 282 treatment goal: cystine levels $< 1 \text{ nmol cystine/mg protein}$
- 283 according to other sources: $< 0.005 \text{ mg/L}$; urine: $< 0.05 \text{ mg/L}$; reference value for children in Germany: 0.015 mg/L urine. Case report: $0.13\text{-}0.16 \text{ mg/L}$ (urine: 67.5 mg/L) on the first day after ingestion of appr. 54 g arsenic trioxide
- 284 potentially increased risk for visual adverse effects ($> 3.5 \text{ mg/L}$) and abnormal liver function, respectively
- 285 trough plasma buprenorphine and norbuprenorphine concentrations in excess of 0.0007 mg/L were associated with minimal withdrawal symptoms in 11 heroin-dependent subjects
- 286 serum peak concentration of misoprostol acid (MPA) 574.8 ± 250.7 , 287.6 ± 144.3 , and $125.2 \pm 53.8 \text{ pg/mL}$ after sublingual, oral, and vaginal

- application, respectively, of 0.4 mg misoprostol to 40 women undergoing termination of pregnancy
- 287 on the first day of hospital admission after unintentional ingestion of appr. 400-500 mg carbachol (corresponding urine concentration: 374 mg/L).
- 288 main (probably inactive) metabolite: morphine-3-glucuronide (M3G); active metabolite: morphine-6-glucuronide (M6G)
- 289 metabolite: nordoxylamine
- 290 active β -hydroxy-metabolite
- 291 targeted range between AUC of 9-12 mg/L/h
- 292 as amprenavir; suggested minimum target trough concentration in patients with HIV-1 susceptible to the antiretroviral (ARV) drug (dose of 700 mg bid (twice daily))
- 293 suggested minimum target trough concentration in patients with HIV-1 susceptible to the antiretroviral (ARV) drug (dose of 300 mg qd (once daily))
- 294 suggested minimum target trough concentration in patients with HIV-1 susceptible to the antiretroviral (ARV) drug (dose of 400 mg bid (twice daily))
- 295 suggested minimum target trough concentration in patients with HIV-1 susceptible to the antiretroviral (ARV) drug (dose of 1,250 mg bid (twice daily))
- 296 suggested minimum target trough concentration in patients with HIV-1 susceptible to the antiretroviral (ARV) drug (dose of 1,000 mg bid (twice daily))
- 297 suggested minimum target trough concentration in patients with HIV-1 susceptible to the antiretroviral (ARV) drug (dose of 600 mg qd (once daily))
- 298 suggested minimum target trough concentration in patients with HIV-1 susceptible to the antiretroviral (ARV) drug (dose of 200 mg bid (twice daily))
- 299 suggested minimum target trough concentration for antiretroviral therapy-experienced patients who have resistant HIV-1 strains (dose of 500 mg bid (twice daily))
- 300 suggested minimum target trough concentration for antiretroviral therapy-experienced patients who have resistant HIV-1 strains
- 301 median (range) trough concentration from clinical trials (dose 600 mg bid (twice daily)); suggested threshold: > 0.55 mg/L

- 302 median (range) trough concentration from clinical trials
- 303 median (range) trough concentration from clinical trials
- 304 post-mortem heart blood level (death by hanging?)
- 305 active enantiomer of propoxyphene,; active metabolite norpropoxyphene
- 306 heart blood
- 307 C_{max} at steady state achieved after 2-3 weeks of once-daily inhalation of 18 μ g tiotropium; t_{max} after inhalation of 18 μ g: 5 min
- 308 steady state peak concentration following a 300 mg twice-daily or a 600 mg once-daily regimen
- 309 active metabolite cis-monohydroxyperhexiline ($t_{1/2}$: 10-29 h)
- 310 1-2 h after 50 mg
- 311 “laboratory alert level” according to AGNP Consensus Guidelines for therapeutic drug monitoring (TDM) in psychiatry: update 2011 i.e., drug concentrations above the recommended reference range, based on reports on intolerance or intoxications. In most cases, however, arbitrarily defined as plasma concentration that is 2-fold higher than the upper limit of the therapeutic reference range
- 312 active metabolite 6-hydroxybuspirone
- 313 C_{max} 1-2 h after 4 mg
- 314 at low dose therapy (2.5 mg); at maximum dose (25 mg): 0.001-0.004 mg/L
- 315 C_{max} 0.5-4 h after drug intake for 4 weeks
- 316 C_{max} after 2 h
- 317 60-90 min after intake of 1.2 mg/kg per day
- 318 4 h after 20 mg
- 319 $t_{1/2}$ with ritonavir 15-23 h
- 320 active metabolite 8-hydroxyloxapine ($t_{1/2}$: 20-60 h)
- 321 C_{max} after 2h-infusion of 6 mg: 0.328 mg/L, after infusion of 2 mg: 0.246 mg/L
- 322 mean C_{max} after 2h-infusion of 10 mg: 0.265 mg/L
- 323 mean C_{max} after 4h-infusion of 15 mg: appr. 0.25 mg/L

- 324 male; female: -0.07 mg/L, children: -0.06 mg/L (reference value for children in Germany: 0.035 mg/L (whole) blood)
- 325 shorter in case of hemodialysis or continuous venovenous hemodiafiltration (CVVHDF); in a, fatal, case with 4,400 mg methanol/L blood and in the presence of adequate ethanol level (1,000 mg/L or 1 ‰) appr. 3.5 h
- 326 after topical (dermal) application
- 327 prolonged in newborns (27.8 ± 21.3 h)
- 328 reference value for Germany: 0.014 mg/L urine
- 329 reference value for children in Germany: 0.0003 mg/L urine
- 330 reference value for children in Germany: 0.0045 mg/L urine
- 331 reference value in urine for children in Germany
- 332 reference value in whole blood in Germany
- 333 metabolite of 3,4 methylenedioxy-meth(yl)amphetamine (MDMA)
- 334 $t_{1/2}$ (R)-MDE: 7.9 (6-11) h; $t_{1/2}$ (S)-MDE: 4.0 (3-6) h
- 335 40 h after oral ingestion of appr. 100 mg (0.03 mg/L 60 h after drug intake)
- 336 active metabolite phenytoin
- 337 prodrug; main active metabolites are morphine and morphine-6-glucuronide (M6G); main (probably) inactive metabolite = morphine-3-glucuronide (M3G)
- 338 in maintenance therapy e.g., for heavily dependent opioid addicts. 30 min after i.v.- application of 150-300 mg diacetylmorphine: 0.1-0.24 mg/L morphine ($t_{1/2}$: 1-4 h), 2.6-5.9 mg/L morphine-3-glucuronide (M3G; $t_{1/2}$: (2-) 3-5 h), 0.5-1.0 mg/L morphine-6-glucuronide (M6G; $t_{1/2}$: (1-) 2-3 h), and 0.08-0.29 mg/L 6-monoacetylmorphine (6-MAM; $t_{1/2}$: appr. 2-5 min; N = 4); in another study 30 min after i.v.- application of 260-300 mg diacetylmorphine: 0.39-0.75 mg/L morphine, 3.2-5.2 mg/L M3G, 0.5-0.7 mg/L M6G, and 0.08-0.19 mg/L 6-MAM (N = 4)
- 339 depending on tolerance and state/severity of pain
- 340 metabolites: norbuprenorphine (active; $t_{1/2}$: 35.6 (1.1-66.8) h after i.v., 73.6 (13.4-143) h after buccal, and 83 (10-243) h after sublingual application), buprenorphine-glucuronide, and norbuprenorphine-glucuronide
- 341 active enantiomer of zopiclone
- 342 active enantiomer of methylphenidate

- 343 active enantiomer of citalopram
- 344 strongly dependent on pH of urine
- 345 symptomatic poisoning in adults is more likely with doses above 90 mg
- 346 on hospital day #2
- 347 19 h post-ingestion of appr. 4 g
- 348 5 h post-ingestion; all patients with a plasma paraquat level above 3.44 mg/L died
- 349 prolonged in (paraquat-induced) renal failure to appr. 80-120 (-150) h
- 350 active enantiomer of moramide
- 351 active enantiomer of fenfluramine
- 352 active enantiomer of methadone
- 353 after a bolus dose of 0.25 mg/kg body weight (N=10): 2.3 mg/L at 3 min, 0.84 mg/L at 30 min, 0.61 mg/L at 1 h, and 0.44 mg/L at 2 h
- 354 active metabolite oxypurinol
- 355 11 h after ingestion
- 356 $t_{1/2}$ in poor metabolisers of cytochrome P450 (CYP) 2D6 is appr. 21 h
- 357 metabolite of cocaine
- 358 dependent on pH of urine
- 359 sum of dibenzepine and desmethyldibenzepine
- 360 active metabolite of trimethadione
- 361 metabolite: acetone
- 362 in non-users of opioids/opiates
- 363 active metabolite norlorcainide ($t_{1/2}$: 28-32 h), therapeutic plasma concentration: 0.1-1.5 mg/L
- 364 metabolite of azathioprin
- 365 (cis-) isomer of clopenthixol
- 366 active metabolites norsibutramine ($t_{1/2}$: 12-22 h) and dinorsibutramine ($t_{1/2}$: 14-23 h)
- 367 with silver sulphadiazine ointment for burns: 0.06-0.6 mg/L (non-toxic)

- 368 active metabolite fexofenadine
- 369 as metabolite of chloralhydrate
- 370 peak plasma concentration (C_{max}) after 1 h chewing khat leaves that supplied 32 mg cathine
- 371 higher for poor metabolisers (PM) of cytochrome P450 (CYP) 2C9
- 372 enantiomer of loratadine
- 373 0.001-0.0035 mg/L for the active metabolite 3-hydroxydesloratadine ; $t_{1/2}$: 17-27 h)
- 374 enantiomer of ketoprofen
- 375 after a single oral dose of 2 mg
- 376 average of 12 victims
- 377 serum morphine (active metabolite) levels were appr. 0.013 (extensive metabolisers, EM) and 0.003 (poor metabolisers, PM)
- 378 enantiomer of cetiricine
- 379 endogenous: -0.00001-0.00009 mg/L
- 380 active metabolite of psilocybin
- 381 during anaesthesia
- 382 measured 14 h post-ingestion

List of abbreviations:

appr., approximately; $t_{1/2}$, in general, terminal elimination half-life (if not stated otherwise); C_{min} , minimum (trough) plasma/serum concentration (usually at steady state); C_{max} , maximum (peak) plasma/serum concentration; t_{max} , time to peak concentration (C_{max}); SD, standard deviation; mol wt, molecular weight; AUC, area under the (plasma concentration-time) curve

References

1. Yuen GJ, Weller S, Pakes GE: **A review of the pharmacokinetics of abacavir.** *Clin Pharmacokinet* 2008, **47**: 351-371.
2. University of Liverpool and eMedFusion. University of Liverpool and eMedFusion. <http://www.hiv-druginteractions.org/> (last accessed May 21, 2012)
3. **Micromedex® Healthcare Series.** DRUGDEX® System. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. Updated periodically.

4. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K *et al.*: **AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.** *Pharmacopsychiatry* 2011, **44**: 195-235.
5. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G: **Clinical pharmacokinetics of acamprosate.** *Clin Pharmacokinet* 1998, **35**: 331-345.
6. Rooney M, Massey KL, Jamali F, Rosin M, Thomson D, Johnson DH: **Acebutolol overdose treated with hemodialysis and extracorporeal membrane oxygenation.** *J Clin Pharmacol* 1996, **36**: 760-763.
7. Schulz M, Meyer W, Schmitz W, Scholz J, Schmoldt A: **Beta-Rezeptorenblocker. Grundlagen zur Arzneimittelauswahl für eine rationale Therapie.** *Arzneimitteltherapie* 1989, **7**: 169-176.
8. Regenthal R, Krueger M, Koeppel C, Preiss R: **Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs.** *J Clin Monit Comput* 1999, **15**: 529-544.
9. Meyer FP: **Indicative therapeutic and toxic drug concentrations in plasma: a tabulation.** *Int J Clin Pharmacol Ther* 1994, **32**: 71-81.
10. Uges DRA: **Referentiewaarden van xenobiotica in humaan materiaal.** *Pharm Weekbl* 1995, **130**: 180-204.
11. Uges DRA: *Orientierende Angaben zu therapeutischen und toxischen Konzentrationen von Arzneimitteln und Giften in Blut, Serum oder Urin.* Weinheim: VCH; 1990.
12. Neels HM, Sierens AC, Naelaerts K, Scharpe SL, Hatfield GM, Lambert WE: **Therapeutic drug monitoring of old and newer anti-epileptic drugs.** *Clin Chem Lab Med* 2004, **42**: 1228-1255.
13. Schulz M, Schmoldt A: **Zusammenstellung therapeutischer und toxischer Plasmakonzentrationsbereich von Arzneistoffen.** *Anaesthesist* 1994, **43**: 835-844.
14. Schulz M, Schmoldt A: **Therapeutic and toxic blood concentrations of more than 500 drugs.** *Pharmazie* 1997, **52**: 895-911.
15. Regenthal R, Krüger M, Köppel C, Preiß R: **Zu Möglichkeiten und Grenzen von therapeutischen und klinisch-toxikologischen Referenzwerten für Plasma-/Serum-/Vollblutkonzentrationen von Arzneimitteln bei akuten Vergiftungen - eine Übersicht.** *Anästhesiol Intensivmed* 1999, **40**: 129-144.
16. Wang G, Maranelli G, Perbellini L, Raineri E, Brugnone F: **Blood acetone concentration in "normal people" and in exposed workers 16 h after the end of the workshift.** *Int Arch Occup Environ Health* 1994, **65**: 285-289.
17. Zettinig G, Watzinger N, Eber B, Henning G, Klein W: **Überlebte Vergiftung nach Einnahme der zehnfachen Letaldosis von Aceton.** *Dtsch Med Wochenschr* 1997, **122**: 1489-1492.

18. Adams KF, Jr., Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA *et al.*: **Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis.** *J Am Coll Cardiol* 2005, **46**: 497-504.
19. Dobbs RJ, O'Neill CJ, Deshmukh AA, Nicholson PW, Dobbs SM: **Serum concentration monitoring of cardiac glycosides. How helpful is it for adjusting dosage regimens?** *Clin Pharmacokinet* 1991, **20**: 175-193.
20. El Desoky E, Meinshausen J, Buhl K, Engel G, Harings-Kaim A, Drewelow B *et al.*: **Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies.** *Ther Drug Monit* 1993, **15**: 281-288.
21. Hoppe MM, Iafrate RP, Hendeles L, Neims A: **A pediatric drug dosing and monitoring guide.** *Fl J Hosp Pharm* 1988, **8**: 259-269.
22. Josune I, Victoria CM, Mar AM, Dominguez-Gil HA: **Impact of written guidelines on the appropriateness of serum digoxin concentrations.** *Ann Pharmacother* 1993, **27**: 791-792.
23. Mordel A, Halkin H, Zulty L, Almog S, Ezra D: **Quinidine enhances digitalis toxicity at therapeutic serum digoxin levels.** *Clin Pharmacol Ther* 1993, **53**: 457-462.
24. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM: **Association of serum digoxin concentration and outcomes in patients with heart failure.** *JAMA* 2003, **289**: 871-878.
25. Terra SG, Washam JB, Dunham GD, Gattis WA: **Therapeutic range of digoxin's efficacy in heart failure: what is the evidence?** *Pharmacotherapy* 1999, **19**: 1123-1126.
26. Ujhelyi MR, Colucci RD, Cummings DM, Green PJ, Robert S, Vlasses PH *et al.*: **Monitoring serum digoxin concentrations during digoxin immune Fab therapy.** *DICP* 1991, **25**: 1047-1049.
27. Wells TG, Young RA, Kearns GL: **Age-related differences in digoxin toxicity and its treatment.** *Drug Saf* 1992, **7**: 135-151.
28. Cham BE, Johns D, Bochner F, Imhoff DM, Rowland M: **Simultaneous liquid-chromatographic quantitation of salicylic acid, salicyluric acid, and gentisic acid in plasma.** *Clin Chem* 1979, **25**: 1420-1425.
29. Herren T, Como F, Krahenbuhl S, Wyss PA: **Die Therapie der akuten Salizylatintoxikation.** *Schweiz Med Wochenschr* 1993, **123**: 1775-1783.
30. Irey NS, Froede RC: **Evaluation of deaths from drug overdose. A clinicopathologic study.** *Am J Clin Pathol* 1974, **61**: 778-784.
31. Mandelli M, Tognoni G: **Monitoring plasma concentrations of salicylate.** *Clin Pharmacokinet* 1980, **5**: 424-440.

32. Martens J, Meyer FP: **Besondere Eignung eines photometrischen Verfahrens zur Bestimmung von Salicylsäure im Therapeutischen Drug Monitoring.** *Pharmazie* 1995, **50**: 41-43.
33. Pond SM, Armstrong JG, Henderson A: **Late diagnosis of chronic salicylate intoxication.** *Lancet* 1993, **342**: 687.
34. Watson JE, Tagupa ET: **Suicide attempt by means of aspirin enema.** *Ann Pharmacother* 1994, **28**: 467-469.
35. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F: **Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol.** *J Invest Dermatol* 1993, **100**: 623-627.
36. Sommerburg C, Bauer R, Orfanos CE, Petres J, Thiele B, Ulrich REH: **Therapeutische Wirksamkeit und neue Daten zur Pharmakokinetik von Acitretin.** *Dt Dermatol* 1994, **42**: 1316-1327.
37. Friedman D, Weller S, Dix L: **Acyclovir plasma concentrations and duration of herpes zoster pain: higher levels associated with the greater efficacy achieved with Valtrex (valacyclovir HCl).** In: *34. Int. Conf. AAC*; 1993:A72.
38. Morse GD, Shelton MJ, O'Donnell AM: **Comparative pharmacokinetics of antiviral nucleoside analogues.** *Clin Pharmacokinet* 1993, **24**: 101-123.
39. Shibata N, Kitamura A, Yoshikawa Y, Inoue T, Bamba T, Takada K: **Simultaneous determination of aciclovir and ganciclovir in plasma by HPLC and pharmacokinetic interactions.** *Pharm Pharmacol Commun* 2000, **6**: 501-506.
40. Committee for Medicinal Products for Human Use (CHMP). **Humira (adalimumab) EPAR - Product information.** [European Medicines Agency] (last accessed November 17, 2011)
41. Sonntag O: *Arzneimittel-Interferenzen.* Stuttgart - New York: Thieme; 1985.
42. Repetto MR, Repetto M: **Therapeutic, toxic, and lethal concentrations in human fluids of 90 drugs affecting the cardiovascular and hematopoietic systems.** *J Toxicol Clin Toxicol* 1997, **35**: 345-351.
43. Dinnendahl V, Fricke U: *Arzneistoff-Profile. Basisinformation über arzneiliche Wirkstoffe.* Eschborn: Govi; 2006.
44. Marriner SE, Morris DL, Dickson B, Bogan JA: **Pharmacokinetics of albendazole in man.** *Eur J Clin Pharmacol* 1986, **30**: 705-708.
45. Mirfazaelian A, Dadashzadeh S, Rouini MR: **An HPLC method for determination of albendazole main metabolites.** *Pharm Pharmacol Commun* 2000, **6**: 563-566.
46. Zeugin T, Zysset T, Cotting J: **Therapeutic monitoring of albendazole: a high-performance liquid chromatography method for determination of its**

- active metabolite al bendazole sulfoxide.** *Ther Drug Monit* 1990, **12**: 187-190.
47. Baselt RC: *Disposition of toxic drugs and chemicals in man*, 9 edn. Seal Beach: Biomedical Publications; 2011.
 48. Winek CL, Wahba WW, Winek CL, Jr., Balzer TW: **Drug and chemical blood-level data 2001.** *Forensic Sci Int* 2001, **122**: 107-123.
 49. Cremers SC, Pillai G, Papapoulos SE: **Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.** *Clin Pharmacokinet* 2005, **44**: 551-570.
 50. Porras AG, Holland SD, Gertz BJ: **Pharmacokinetics of alendronate.** *Clin Pharmacokinet* 1999, **36**: 315-328.
 51. Cocquyt V, Kline WF, Gertz BJ, Van Belle SJ, Holland SD, DeSmet M *et al.*: **Pharmacokinetics of intravenous alendronate¹.** *J Clin Pharmacol* 1999, **39**: 385-393.
 52. Lemmens HJ: **Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia.** *Clin Pharmacokinet* 1995, **29**: 231-242.
 53. Maitre PO, Vozech S, Heykants J, Thomson DA, Stanski DR: **Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients.** *Anesthesiology* 1987, **66**: 3-12.
 54. Scholz J, Steinfath M, Schulz M: **Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.** *Clin Pharmacokinet* 1996, **31**: 275-292.
 55. Wada DR, Mandema JW: **Context sensitive pharmacokinetics in anesthesia: application to alfentanil [abstract].** *Pharm Res* 1994, **11**: S-424.
 56. Druid H, Holmgren P: **A compilation of fatal and control concentrations of drugs in postmortem femoral blood.** *J Forensic Sci* 1997, **42**: 79-87.
 57. Repetto MR, Repetto M: **Therapeutic, toxic, and lethal concentrations of 73 drugs affecting respiratory system in human fluids.** *J Toxicol Clin Toxicol* 1998, **36**: 287-293.
 58. Uges DRA: TIAFT reference blood level list of therapeutic and toxic substances.
[http://www.gtfch.org/cms/images/stories/Updated_TIAFT_list_202005.pdf]
 59. Klotz U, Laux G: *Tranquillantien*. Stuttgart: WVG; 1996.
 60. Labbate LA, Pollack MH, Otto MW, Tesar GM, Rosenbaum JF: **The relationship of alprazolam and clonazepam dose to steady-state concentration in plasma.** *J Clin Psychopharmacol* 1994, **14**: 274-276.

61. Laurijssens BE, Greenblatt DJ: **Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.** *Clin Pharmacokinet* 1996, **30**: 52-76.
62. Lesser IM, Lydiard RB, Antal E, Rubin RT, Ballenger JC, DuPont R: **Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.** *Am J Psychiatry* 1992, **149**: 1556-1562.
63. Michaud K, Augsburger M, Romain N, Giroud C, Mangin P: **Fatal overdose of tramadol and alprazolam.** *Forensic Sci Int* 1999, **105**: 185-189.
64. Flanagan RJ: **Guidelines for the interpretation of analytical toxicology results and unit of measurement conversion factors.** *Ann Clin Biochem* 1998, **35**: 261-267.
65. N.N.: **Aluminium.** *Bundesgesundhbl* 1998, **41**: 271.
66. Repetto MR, Repetto M: **Concentrations in human fluids: 101 drugs affecting the digestive system and metabolism.** *J Toxicol Clin Toxicol* 1999, **37**: 1-9.
67. Butler DR, Kuhn RJ, Chandler MH: **Pharmacokinetics of anti-infective agents in paediatric patients.** *Clin Pharmacokinet* 1994, **26**: 374-395.
68. Stork CM, Hoffman RS: **Characterization of 4-aminopyridine in overdose.** *J Toxicol Clin Toxicol* 1994, **32**: 583-587.
69. Bouillon T, Bartmus D, Schiffmann H, Gundert-Remy U: **Amiodaron zur Therapie ventrikulärer Arrhythmien bei einem Neugeborenen. Computergestützte pharmakokinetische Analyse zur Dosisfindung.** *Arzneimitteltherapie* 1994, **12**: 151-154.
70. Jürgens G, Graudal NA, Kampmann JP: **Therapeutic drug monitoring of antiarrhythmic drugs.** *Clin Pharmacokinet* 2003, **42**: 647-663.
71. Sauro SC, DeCarolis DD, Pierpont GL, Gornick CC: **Comparison of plasma concentrations for two amiodarone products.** *Ann Pharmacother* 2002, **36**: 1682-1685.
72. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR: **Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.** *Clin Pharmacokinet* 2007, **46**: 359-388.
73. Boehnert MT, Lovejoy FH, Jr.: **Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants.** *N Engl J Med* 1985, **313**: 474-479.
74. Breyer-Pfaff U, Gaertner HJ: *Antidepressiva. Pharmakologie, therapeutischer Einsatz und Klinik der Depression.* Stuttgart: WVG; 1987.

75. el-Yazigi A, Chaleby K, Gad A, Raines DA: **Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone.** *J Clin Pharmacol* 1995, **35**: 17-21.
76. Furlanut M, Benetello P, Spina E: **Pharmacokinetic optimisation of tricyclic antidepressant therapy.** *Clin Pharmacokinet* 1993, **24**: 301-318.
77. Hanzlick RL: **Postmortem blood concentrations of parent tricyclic antidepressant (TCA) drugs in 11 cases of suicide.** *Am J Forensic Med Pathol* 1984, **5**: 11-13.
78. Lieberman JA, Cooper TB, Suckow RF, Steinberg H, Borenstein M, Brenner R *et al.*: **Tricyclic antidepressant and metabolite levels in chronic renal failure.** *Clin Pharmacol Ther* 1985, **37**: 301-307.
79. Lieberman JA, Cooper TB, Suckow RF, Steinberg H, Borenstein M, Brenner R *et al.*: **Tricyclic antidepressant drug and metabolite levels in chronic renal failure.** *Ann N Y Acad Sci* 1986, **463**: 304-306.
80. Linder MW, Keck PE, Jr.: **Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry.** *Clin Chem* 1998, **44**: 1073-1084.
81. Miljkovic B, Pokrajac M, Timotijevic I, Varagic V: **Clinical response and plasma concentrations of amitriptyline and its metabolite-nortriptyline in depressive patients.** *Eur J Drug Metab Pharmacokinet* 1996, **21**: 251-255.
82. Preskorn SH, Fast GA: **Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness.** *J Clin Psychiatry* 1991, **52 Suppl:23-33**: 23-33.
83. Ulrich S, Läuter J: **Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression.** *Clin Pharmacokinet* 2002, **41**: 853-876.
84. Kirsten R, Nelson K, Kirsten D, Heintz B: **Clinical pharmacokinetics of vasodilators. Part I.** *Clin Pharmacokinet* 1998, **34**: 457-482.
85. Koch AR, Vogelaers DP, Decruyenaere JM, Callens B, Verstraete A, Buylaert WA: **Fatal intoxication with amlodipine.** *J Toxicol Clin Toxicol* 1995, **33**: 253-256.
86. Stanek EJ, Nelson CE, DeNofrio D: **Amlodipine overdose.** *Ann Pharmacother* 1997, **31**: 853-856.
87. Musshoff F, Padosch S, Steinborn S, Madea B: **Fatal blood and tissue concentrations of more than 200 drugs.** *Forensic Sci Int* 2004, **142**: 161-210.
88. Sweetman SC: *Martindale. The complete drug reference*, 33 edn. London: Pharmaceutical Press; 2002.

89. Hellriegel ET, Arora S, Nelson M, Robertson P, Jr.: **Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers.** *J Clin Pharmacol* 2002, **42**: 450-460.
90. Cleary JD, Hayman J, Sherwood J, Lasala GP, Piazza-Hepp T: **Amphotericin B overdose in pediatric patients with associated cardiac arrest.** *Ann Pharmacother* 1993, **27**: 715-719.
91. Hay RJ: **Recent advances in the management of fungal infections.** *Q J Med* 1987, **64**: 631-639.
92. Lipp H-P: **Amphotericin B und seine Lipidcarrier. Eine kritische Übersicht.** *Krankenhauspharmazie* 1997, **18**: 104-113.
93. Mohr JF, Hall AC, Ericsson CD, Ostrosky-Zeichner L: **Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation.** *Pharmacotherapy* 2005, **25**: 426-428.
94. Hellinger A, Wolter K, Marggraf G, Pentz R, Fritschka E: **Elimination of amrinone during continuous veno-venous haemofiltration after cardiac surgery.** *Eur J Clin Pharmacol* 1995, **48**: 57-59.
95. Kirsten R, Nelson K, Kirsten D, Heintz B: **Clinical pharmacokinetics of vasodilators. Part II.** *Clin Pharmacokinet* 1998, **35**: 9-36.
96. Paxton JW, Kim SN, Whitfield LR: **Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.** *Cancer Res* 1990, **50**: 2692-2697.
97. N.N.: **Stoffmonographie und Referenzwerte für monocyclische Aminoaromaten im Urin. Stellungnahme der Kommission Human-Biomonitoring des Umweltbundesamtes.** *Bundesgesundhbl* 2011, **54**: 650-663.
98. Iwersen-Bergmann S, Schmoldt A: **Acute intoxication with aniline: detection of acetaminophen as aniline metabolite.** *Int J Legal Med* 2000, **113**: 171-174.
99. Kütting B, Goen T, Schwegler U, Fromme H, Uter W, Angerer J *et al.*: **Monoarylamines in the general population--a cross-sectional population-based study including 1004 Bavarian subjects.** *Int J Hyg Environ Health* 2009, **212**: 298-309.
100. Schulz C, Angerer J, Ewers U, Heudorf U, Wilhelm M: **Revised and new reference values for environmental pollutants in urine or blood of children in Germany derived from the German environmental survey on children 2003-2006 (GerES IV).** *Int J Hyg Environ Health* 2009, **212**: 637-647.
101. Choong E, Rudaz S, Kottelat A, Guillarme D, Veuthey JL, Eap CB: **Therapeutic drug monitoring of seven psychotropic drugs and four**

- metabolites in human plasma by HPLC-MS.** *J Pharm Biomed Anal* 2009, **50**: 1000-1008.
102. Young MC, Shah N, Cantrell FL, Clark RF: **Risk assessment of isolated aripiprazole exposures and toxicities: a retrospective study.** *Clin Toxicol (Phila)* 2009, **47**: 580-583.
 103. Duenas-Laita A, Perez-Miranda M, Gonzalez-Lopez MA, Martin-Escudero JC, Ruiz-Mambrilla M, Blanco-Varela J: **Acute arsenic poisoning.** *Lancet* 2005, **365**: 1982.
 104. Oertel R, Rahn R, Kirch W: **Clinical pharmacokinetics of articaine.** *Clin Pharmacokinet* 1997, **33**: 417-425.
 105. Biesalski HK: **Antioxidative Vitamine in der Prävention.** *Dt Ärztebl* 1995, **92**: A-1316.
 106. Jacob RA: **Assessment of human vitamin C status.** *J Nutr* 1990, **120 Suppl 11:1480-5**: 1480-1485.
 107. Lykkesfeldt J, Prieme H, Loft S, Poulsen HE: **Effect of smoking cessation on plasma ascorbic acid concentration.** *BMJ* 1996, **313**: 91.
 108. Wang S, Schram IM, Sund RB: **Determination of plasma ascorbic acid by HPLC: method and stability studies.** *Eur J Pharm Sci* 1995, **3**: 231-239.
 109. Snook J, Boothman-Burrell D, Watkins J, Colin-Jones D: **Torsade de pointes ventricular tachycardia associated with astemizole overdose.** *Br J Clin Pract* 1988, **42**: 257-259.
 110. **HHS Panel on Antiretroviral Guidelines for Adults and Adolescents [Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents].** [Department of Health & Human Services, USA] (last accessed October 14, 2011)
 111. von Hentig N: **Messung von Plasmakonzentrationen antiretroviraler Arzneimittel in der HIV-Therapie.** *Dtsch Med Wochenschr* 2008, **133**: 191-195.
 112. Stoschitzky K, Kahr S, Donnerer J, Schumacher M, Luha O, Maier R *et al.*: **Stereoselective increase of plasma concentrations of the enantiomers of propranolol and atenolol during exercise.** *Clin Pharmacol Ther* 1995, **57**: 543-551.
 113. Spencer CM, Goa KL: **Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.** *Drugs* 1995, **50**: 176-196.
 114. Tune L, Coyle JT: **Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects.** *Arch Gen Psychiatry* 1980, **37**: 293-297.

115. Bahal N, Nahata MC: **The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.** *Ann Pharmacother* 1992, **26**: 46-55.
116. Lode H: **The pharmacokinetics of azithromycin and their clinical significance.** *Eur J Clin Microbiol Infect Dis* 1991, **10**: 807-812.
117. Peters DH, Friedel HA, McTavish D: **Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.** *Drugs* 1992, **44**: 750-799.
118. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ: **Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.** *Antimicrob Agents Chemother* 1997, **41**: 1399-1402.
119. Schulz M, Peruche B: **Azithromycin, ein neues Makrolid-Antibiotikum.** *Pharm Ztg* 1994, **139**: 3346-3352.
120. Hiller JL, Benda GI, Rahatzad M, Allen JR, Culver DH, Carlson CV *et al.*: **Benzyl alcohol toxicity: impact on mortality and intraventricular hemorrhage among very low birth weight infants.** *Pediatrics* 1986, **77**: 500-506.
121. Lopez-Herce J, Bonet C, Meana A, Albajara L: **Benzyl alcohol poisoning following diazepam intravenous infusion.** *Ann Pharmacother* 1995, **29**: 632.
122. Hakamäki T, Apoil E, Arstila M, Timmer CJ, Lehtonen A: **Bepidil in the elderly. A pharmacokinetic and clinical monitoring study.** *Curr Ther Res* 1988, **44**: 752-758.
123. DRUGDEX® System. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. Updated periodically.
124. Greenberg ER, Baron JA, Karagas MR, Stukel TA, Nierenberg DW, Stevens MM *et al.*: **Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation.** *JAMA* 1996, **275**: 699-703.
125. Berthault F, Kintz P, Tracqui A, Mangin P: **A fatal case of betaxolol poisoning.** *J Anal Toxicol* 1997, **21**: 228-231.
126. Mahler C, Verhelst J, Denis L: **Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.** *Clin Pharmacokinet* 1998, **34**: 405-417.
127. Palmer RB, Alakija P, de Baca JE, Nolte KB: **Fatal brodifacoum rodenticide poisoning: autopsy and toxicologic findings.** *J Forensic Sci* 1999, **44**: 851-855.
128. Danel VC, Saviuc PF, Hardy GA, Lafond JL, Mallaret MP: **Bromide intoxication and pseudohyperchloremia.** *Ann Pharmacother* 2001, **35**: 386-387.

129. Hoizey G, Souchon PF, Trenque T, Frances C, Lamiable D, Nicolas A *et al.*: **An unusual case of methyl bromide poisoning.** *J Toxicol Clin Toxicol* 2002, **40**: 817-821.
130. Stein U, Steinecke H, Pragst F, Prügel M, Ulrich P, Gondro T: **Ionenselektive Elektroden und Mikrodestillation.** *Toxichem Krimtech* 1999, **66**: 129-141.
131. Saito T, Takeichi S, Nakajima Y, Yukawa N, Osawa M: **A case of homicidal poisoning involving several drugs.** *J Anal Toxicol* 1997, **21**: 584-586.
132. Hempel V, Lenz G: **Lokalanästhetika - Wirkungsweise, Eigenschaften, Pharmakokinetik und Toxizität.** *Anästh Intensivmed* 1982, **23**: 337-345.
133. Kastrissios H, Triggs EJ, Sinclair F, Moran P, Smithers M: **Plasma concentrations of bupivacaine after wound infiltration of an 0.5% solution after inguinal herniorrhaphy: a preliminary study.** *Eur J Clin Pharmacol* 1993, **44**: 555-557.
134. Lenderink AW, Langen MCJ, Schippers D: **Bupivacain serum levels after intra-abdominal instillation [abstract].** *Pharm World Sci* 1994, **16**: D8.
135. Elkader A, Sproule B: **Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.** *Clin Pharmacokinet* 2005, **44**: 661-680.
136. Kuhlman JJ, Jr., Levine B, Johnson RE, Fudala PJ, Cone EJ: **Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.** *Addiction* 1998, **93**: 549-559.
137. Tracqui A, Kintz P, Ludes B: **Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities.** *J Anal Toxicol* 1998, **22**: 430-434.
138. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE: **Clinical pharmacology of buprenorphine: ceiling effects at high doses.** *Clin Pharmacol Ther* 1994, **55**: 569-580.
139. Kintz P: **Deaths involving buprenorphine: a compendium of French cases.** *Forensic Sci Int* 2001, **121**: 65-69.
140. Kuhlman JJ, Jr., Lalani S, Magluilo J, Jr., Levine B, Darwin WD: **Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.** *J Anal Toxicol* 1996, **20**: 369-378.
141. Lai SH, Yao YJ, Lo DS: **A survey of buprenorphine related deaths in Singapore.** *Forensic Sci Int* 2006, **162**: 80-86.
142. Findlay JWA, Van Wyck FJ, Smith PG, Butz RF, Hinton ML, Blum MR *et al.*: **Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects.** *Eur J Clin Pharmacol* 1981, **21**: 127-135.

143. Friel PN, Logan BK, Fligner CL: **Three fatal drug overdoses involving bupropion.** *J Anal Toxicol* 1993, **17**: 436-438.
144. Holm KJ, Spencer CM: **Bupropion: a review of its use in the management of smoking cessation.** *Drugs* 2000, **59**: 1007-1024.
145. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA: **Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers.** *J Clin Pharmacol* 1997, **37**: 737-743.
146. Lai AA, Schroeder DH: **Clinical pharmacokinetics of bupropion: a review.** *J Clin Psychiatry* 1983, **44**: 82-84.
147. Posner J, Bye A, Dean K, Peck AW, Whiteman PD: **The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses.** *Eur J Clin Pharmacol* 1985, **29**: 97-103.
148. Sweet RA, Pollock BG, Kirshner M, Wright B, Altieri LP, DeVane CL: **Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression.** *J Clin Pharmacol* 1995, **35**: 876-884.
149. Cull G, O'Halloran S, Ilett KF: **Therapeutic drug monitoring for busulfan in plasma during conditioning chemotherapy for autologous stem cell transplantation in relapsed primary cerebral lymphoma.** *Ther Drug Monit* 2010, **32**: 333-337.
150. Juenke JM, Miller KA, McMillin GA, Johnson-Davis KL: **An automated method for supporting busulfan therapeutic drug monitoring.** *Ther Drug Monit* 2011, **33**: 315-320.
151. Malar R, Sjoo F, Rentsch K, Hassan M, Gungor T: **Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.** *Pediatr Transplant* 2011, **15**: 580-588.
152. Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M *et al.*: **HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen.** *Blood* 2003, **102**: 31-35.
153. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI *et al.*: **Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.** *Blood* 1997, **89**: 3055-3060.
154. Yeh RF, Pawlikowski MA, Blough DK, McDonald GB, O'Donnell PV, Rezvani A *et al.*: **Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients.** *Biol Blood Marrow Transplant* 2011.
155. Cook DG, Peacock JL, Feyerabend C, Carey IM, Jarvis MJ, Anderson HR *et al.*: **Relation of caffeine intake and blood caffeine concentrations during**

- pregnancy to fetal growth: prospective population based study.** *BMJ* 1996, **313**: 1358-1362.
156. Mizuno A, Uematsu T, Gotoh S, Katoh E, Nakashima M: **The measurement of caffeine concentration in scalp hair as an indicator of liver function.** *J Pharm Pharmacol* 1996, **48**: 660-664.
157. Risselmann B, Rosenbaum F, Roscher S, Schneider V: **Fatal caffeine intoxication.** *Forensic Sci Int* 1999, **103**: S49-S52.
158. Köppel C, Martens F, Schirop T, Ibe K: **Hemoperfusion in acute camphor poisoning.** *Intensive Care Med* 1988, **14**: 431-433.
159. Alderman CP: **Adverse effects of the angiotensin-converting enzyme inhibitors.** *Ann Pharmacother* 1996, **30**: 55-61.
160. Schulz M, Graefe T, Stuby K, Andresen H, Kupfermann N, Schmoltdt A: **Case report: acute unintentional carbachol intoxication.** *Crit Care* 2006, **10**: R84.
161. Brodie MJ, Dichter MA: **Antiepileptic drugs.** *N Engl J Med* 1996, **334**: 168-175.
162. Collins DM, Gidal BE, Pitterle ME: **Potential interaction between carbamazepine and loxapine: case report and retrospective review.** *Ann Pharmacother* 1993, **27**: 1180-1187.
163. Elmquist WF, Riad LE, Leppik IE, Sawchuk RJ: **The relationship between urine and plasma concentrations of carbamazepine: implications for therapeutic drug monitoring.** *Pharm Res* 1991, **8**: 282-284.
164. French J: **The long-term therapeutic management of epilepsy.** *Ann Intern Med* 1994, **120**: 411-422.
165. Kale PB, Thomson PA, Provenzano R, Higgins MJ: **Evaluation of plasmapheresis in the treatment of an acute overdose of carbamazepine.** *Ann Pharmacother* 1993, **27**: 866-870.
166. Liu H, Delgado MR: **Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.** *Clin Pharmacokinet* 1999, **36**: 453-470.
167. Duck BJ, Woolias M: **Reversed-phase high performance liquid chromatographic determination of carbaryl in postmortem specimens.** *J Anal Toxicol* 1985, **9**: 177-179.
168. Stockis A, Deroubaix X, Jeanbaptiste B, Lins R, Allemon AM, Laufen H: **Relative bioavailability of carbinoxamine and phenylephrine from a retard capsule after single and repeated dose administration in healthy subjects.** *Arzneimittelforschung* 1995, **45**: 1009-1012.

169. Schmoldt A, Schulz M, Frese JH: **Klinik und Therapie einer Intoxikation mit Tetrachlorkohlenstoff.** In *Gerichtsmedizin. Festschrift für Wilhelm Holczabek.* Edited by Bauer G. Wien: Franz Deuticke; 1988:529-531.
170. Goldermann L, Gellert J, Teschke R: **Quantitative assessment of carbon tetrachloride levels in human blood by head-space gas chromatography: application in a case of suicidal carbon tetrachloride intoxication.** *Intensive Care Med* 1983, **9**: 131-135.
171. Mathieson PW, Williams G, MacSweeney JE: **Survival after massive ingestion of carbon tetrachloride treated by intravenous infusion of acetylcysteine.** *Hum Toxicol* 1985, **4**: 627-631.
172. Ruprah M, Mant TG, Flanagan RJ: **Acute carbon tetrachloride poisoning in 19 patients: implications for diagnosis and treatment.** *Lancet* 1985, **1**: 1027-1029.
173. Tombolini A, Cingolani M: **Fatal accidental ingestion of carbon tetrachloride: a postmortem distribution study.** *J Forensic Sci* 1996, **41**: 166-168.
174. Danziger LH, Piscitelli SC, Occhipinti DJ, Resnick DJ, Rodvold KA: **Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis.** *Ann Pharmacother* 1994, **28**: 703-707.
175. Schulz M, Schmoldt A: **Konzentrationen von Cefotiam im Kolongewebe und Plasma nach Applikation zur perioperativen Antibiotikaprophylaxe.** *ZAC Zeitschr antimikr antineopl Chemother* 1992, **10**: 33-37.
176. Lorenz R, Lehn N, Born P, Herrmann M, Neuhaus H: **Antibiotische Prophylaxe mit Cefuroxim bei endoskopischen Eingriffen an den Gallenwegen.** *Dtsch Med Wochenschr* 1996, **121**: 223-230.
177. Pass SE, Miyagawa CI, Healy DP, Ivey TD: **Serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients.** *Ann Pharmacother* 2001, **35**: 409-413.
178. Koren G: **Therapeutic drug monitoring principles in the neonate.** National Academy of CLinical Biochemistry. *Clin Chem* 1997, **43**: 222-227.
179. Bailey DN: **Blood concentrations and clinical findings following overdose of chlordiazepoxide alone and chlordiazepoxide plus ethanol.** *J Toxicol Clin Toxicol* 1984, **22**: 433-446.
180. Maxa JL, Ogu CC, Adeeko MA, Swaner TG: **Continuous-infusion flumazenil in the management of chlordiazepoxide toxicity.** *Pharmacotherapy* 2003, **23**: 1513-1516.
181. Köppel C, Kristinsson J, Wagemann A, Tenczer J, Martens F: **Chlormezanone plasma and blood levels in patients after single and repeated oral doses and after suicidal drug overdose.** *Eur J Drug Metab Pharmacokinet* 1991, **16**: 43-47.

182. Dell'Aglio DM, Sutter ME, Schwartz MD, Koch DD, Algren DA, Morgan BW: **Acute chloroform ingestion successfully treated with intravenously administered N-acetylcysteine.** *J Med Toxicol* 2010, **6**: 143-146.
183. Croes K, Augstijns P, Sabbe M, Desmet K, Verbeke N: **Diazepam treatment in chloroquine intoxication: a case report [abstract].** *Pharm Weekbl Sci* 1992, **14**: D9.
184. Javaid JI: **Clinical pharmacokinetics of antipsychotics.** *J Clin Pharmacol* 1994, **34**: 286-295.
185. Milton GV, Jann MW: **Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs.** *Clin Pharmacokinet* 1995, **28**: 494-504.
186. Eddleston M, Eyer P, Worek F, Mohamed F, Senarathna L, von ML *et al.*: **Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study.** *Lancet* 2005, **366**: 1452-1459.
187. Vaughan Williams EM: **Classifying antiarrhythmic actions: by facts or speculation.** *J Clin Pharmacol* 1992, **32**: 964-977.
188. Dumont RJ, Ensom MH: **Methods for clinical monitoring of cyclosporin in transplant patients.** *Clin Pharmacokinet* 2000, **38**: 427-447.
189. Horton RC, Bonser RS: **Interaction between cyclosporin and fluoxetine.** *BMJ* 1995, **311**: 422.
190. Lindholm A: **Cyclosporine A: clinical experience and therapeutic drug monitoring.** *Ther Drug Monit* 1995, **17**: 631-637.
191. Lindholm A, Sawe J: **Pharmacokinetics and therapeutic drug monitoring of immunosuppressants.** *Ther Drug Monit* 1995, **17**: 570-573.
192. Oellerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R *et al.*: **Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel.** *Ther Drug Monit* 1995, **17**: 642-654.
193. Tonkin AL, Bochner F: **Therapeutic drug monitoring and patient outcome. A review of the issues.** *Clin Pharmacokinet* 1994, **27**: 169-174.
194. Gugler R, Fuchs G, Dieckmann M, Somogyi AA: **Cimetidine plasma concentration-response relationships.** *Clin Pharmacol Ther* 1981, **29**: 744-748.
195. Shinn AF: **Clinical relevance of cimetidine drug interactions.** *Drug Saf* 1992, **7**: 245-267.
196. Cohen H, Francisco DH: **Twelve-gram overdose of ciprofloxacin with mild symptomatology.** *Ann Pharmacother* 1994, **28**: 805-806.

197. Davis JD, Aarons L, Houston JB: **Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition.** *Pharm Res* 1994, **11**: 1424-1428.
198. Schentag JJ, Nix DE, Adelman MH: **Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.** *DICP* 1991, **25**: 1050-1057.
199. Staß H, Peltola H, Kuhlmann J, Rahm V: **Single dose and steady state pharmacokinetics of ciprofloxacin (CIP) in pediatric patients following administration of a new oral suspension (10 mg/kg tid) [abstract].** *Naunyn-Schmiedeberg's Arch Pharmacol* 1996, **353**: R153.
200. Friberg LE, Isbister GK, Hackett LP, Duffull SB: **The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach.** *J Pharmacokinet Pharmacodyn* 2005, **32**: 571-605.
201. Gutierrez M, Abramowitz W: **Steady-state pharmacokinetics of citalopram in young and elderly subjects.** *Pharmacotherapy* 2000, **20**: 1441-1447.
202. van Harten J: **Clinical pharmacokinetics of selective serotonin reuptake inhibitors.** *Clin Pharmacokinet* 1993, **24**: 203-220.
203. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W: **Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.** *Clin Pharmacol Ther* 1995, **58**: 532-541.
204. Öström M, Eriksson A, Thorson J, Spigset O: **Fatal overdose with citalopram.** *Lancet* 1996, **348**: 339-340.
205. Overo KF: **Preliminary studies of the kinetics of citalopram in man.** *Eur J Clin Pharmacol* 1978, **14**: 69-73.
206. Overo KF: **Kinetics of citalopram in man; plasma levels in patients.** *Prog Neuropsychopharmacol Biol Psychiatry* 1982, **6**: 311-318.
207. Overo KF, Toft B, Christophersen L, Gylding-Sabroe JP: **Kinetics of citalopram in elderly patients.** *Psychopharmacology (Berl)* 1985, **86**: 253-257.
208. Beutler E: **Cladribine (2-chlorodeoxyadenosine).** *Lancet* 1992, **340**: 952-956.
209. Johnson SA: **Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.** *Clin Pharmacokinet* 2000, **39**: 5-26.
210. Kath R, Knauf WU, Mitrou PS, Rummel M, Höffken K, Peters HD: **Cladribin (2-CdA). Pharmakologisches Profil und klinische Anwendung.** *Onkologe* 1995, **1**: 626.
211. Boruchoff SE, Sturgill MG, Grasing KW, Seibold JR, McCrea J, Winchell GA *et al.*: **The steady-state disposition of indinavir is not altered by the**

- concomitant administration of clarithromycin.** *Clin Pharmacol Ther* 2000, **67**: 351-359.
212. Rodvold KA: **Clinical pharmacokinetics of clarithromycin.** *Clin Pharmacokinet* 1999, **37**: 385-398.
213. Schulz J: **Clarithromycin - ein neues Makrolid-Antibiotikum.** *Pharm Ztg* 1992, **137**: 1626-1631.
214. Breccia A, Ferri E, Girotti S, Bignanmini AA, Budini RA: **High performance liquid chromatography and capillary gas chromatography-mass spectrometry determination of clemastine in serum: plasma kinetics after dermatologic application.** *Curr Ther Res* 1991, **49**: 622-626.
215. Knapp J, Boknik P, Gumbinger HG, Linck B, Luss H, Muller FU *et al.*: **Quantitation of clobazam in human plasma using high-performance liquid chromatography.** *J Chromatogr Sci* 1999, **37**: 145-149.
216. Klug E, Schneider V: **Vergiftungen durch Clomethiazol.** *Z Rechtsmed* 1984, **93**: 89-94.
217. Ulrich S, Danos P, Baumann B, Muller D, Lehmann D, Treuheit TO *et al.*: **Serum concentration of chlormethiazole and therapeutic effect in acute alcohol withdrawal syndrome: an open clinical trial.** *Ther Drug Monit* 2002, **24**: 446-454.
218. Balant-Gorgia AE, Gex-Fabry M, Balant LP: **Clinical pharmacokinetics of clomipramine.** *Clin Pharmacokinet* 1991, **20**: 447-462.
219. Dale O, Hole A: **Biphasic time-course of serum concentrations of clomipramine and desmethylclomipramine after a near-fatal overdose.** *Vet Hum Toxicol* 1994, **36**: 309-310.
220. Faravelli C, Ballerini A, Ambonetti A, Broadhurst AD, Das M: **Plasma levels and clinical response during treatment with clomipramine.** *J Affect Disord* 1984, **6**: 95-107.
221. Gex-Fabry M, Balant-Gorgia AE, Balant LP: **Clomipramine concentration as a predictor of delayed response: a naturalistic study.** *Eur J Clin Pharmacol* 1999, **54**: 895-902.
222. Kuss HJ, Jungkunz G: **Nonlinear pharmacokinetics of chlorimipramine after infusion and oral administration in patients.** *Prog Neuropsychopharmacol Biol Psychiatry* 1986, **10**: 739-748.
223. Waade RB, Molden E, Refsum H, Hermann M: **Serum concentrations of antidepressants in the elderly.** *Ther Drug Monit* 2012, **34**: 25-30.
224. Rey E, Treluyer JM, Pons G: **Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes.** *Clin Pharmacokinet* 1999, **36**: 409-424.

225. Erickson SJ, Duncan A: **Clonidine poisoning--an emerging problem: epidemiology, clinical features, management and preventative strategies.** *J Paediatr Child Health* 1998, **34**: 280-282.
226. Nichols MH, King WD, James LP: **Clonidine poisoning in Jefferson County, Alabama.** *Ann Emerg Med* 1997, **29**: 511-517.
227. Raber JH, Shinar C, Finkelstein S: **Clonidine patch ingestion in an adult.** *Ann Pharmacother* 1993, **27**: 719-722.
228. Couchman L, Morgan PE, Spencer EP, Flanagan RJ: **Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.** *Ther Drug Monit* 2010, **32**: 438-447.
229. Dahl SG: **Pharmacokinetics of antipsychotic drugs in man.** *Acta Psychiatr Scand Suppl* 1990, **358:37-40.**: 37-40.
230. Dettling M, Sachse C, Brockmoller J, Schley J, Muller-Oerlinghausen B, Pickersgill I *et al.*: **Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients.** *Psychopharmacology (Berl)* 2000, **152**: 80-86.
231. Fleischhaker C, Schulz E, Clement H-W, Krieg C, Remschmidt H: **Therapeutisches Drug-Monitoring von Clozapin bei Kindern, Jugendlichen und Erwachsenen mit einer schizophrenen Psychose.** *Psychopharmakotherapie* 1999, **6**: 102-105.
232. Guitton C, Kinowski JM, Abbar M, Chabrand P, Bressolle F: **Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia.** *J Clin Pharmacol* 1999, **39**: 721-728.
233. Ismail Z, Wessels AM, Uchida H, Ng W, Mamo DC, Rajji TK *et al.*: **Age and Sex Impact Clozapine Plasma Concentrations in Inpatients and Outpatients With Schizophrenia.** *Am J Geriatr Psychiatry* 2011.
234. Mahoney MC, Connolly BF, Smith CM: **A clozapine overdose with markedly elevated serum levels.** *J Clin Pharmacol* 1999, **39**: 97-100.
235. Schulte P: **What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.** *Clin Pharmacokinet* 2003, **42**: 607-618.
236. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia AG *et al.*: **Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.** *Psychopharmacology (Berl)* 2000, **148**: 83-89.
237. Ulrich S, Wolf R, Staedt J: **Serum level of clozapine and relapse.** *Ther Drug Monit* 2003, **25**: 252-255.

238. Van der Zwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB: **Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.** *Am J Psychiatry* 1996, **153**: 1579-1584.
239. Wohlfarth A, Toepfner N, Hermanns-Clausen M, Auwarter V: **Sensitive quantification of clozapine and its main metabolites norclozapine and clozapine-N-oxide in serum and urine using LC-MS/MS after simple liquid-liquid extraction work-up.** *Anal Bioanal Chem* 2011, **400**: 737-746.
240. Zaleon CR, Guthrie SK: **Antipsychotic drug use in older adults.** *Am J Hosp Pharm* 1994, **51**: 2917-2943.
241. Buechler KF, Moi S, Noar B, McGrath D, Villela J, Clancy M *et al.*: **Simultaneous detection of seven drugs of abuse by the Triage panel for drugs of abuse.** *Clin Chem* 1992, **38**: 1678-1684.
242. Perez-Reyes M, Jeffcoat AR: **Ethanol/cocaine interaction: cocaine and cocaethylene plasma concentrations and their relationship to subjective and cardiovascular effects.** *Life Sci* 1992, **51**: 553-563.
243. Skeith KJ, Brocks DR: **Pharmacokinetic optimisation of the treatment of osteoarthritis.** *Clin Pharmacokinet* 1994, **26**: 233-242.
244. Meyer MR, Maurer HH: **Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.** *Pharmacogenomics* 2011, **12**: 215-233.
245. Baud FJ, Sabouraud A, Vicaut E, Taboulet P, Lang J, Bismuth C *et al.*: **Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments.** *N Engl J Med* 1995, **332**: 642-645.
246. Brvar M, Ploj T, Kozelj G, Mozina M, Noc M, Bunc M: **Case report: fatal poisoning with *Colchicum autumnale*.** *Crit Care* 2004, **8**: R56-R59.
247. Peters FT, Beyer J, Ewald AH: **Colchicine poisoning after mix-up of Ramsons (*Allium ursinum* L.) and meadow saffron (*Colchicum autumnale* L.).** *Toxichem Krimtech* 2004, **71**: 156-160.
248. Rochdi M, Sabouraud A, Baud FJ, Bismuth C, Scherrmann JM: **Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases.** *Hum Exp Toxicol* 1992, **11**: 510-516.
249. Grobosch T, Angelow B, Lampe D: **Akute Intoxikation mit Coumatetralyl. Simultane Bestimmung von 5 Superwarfarinen und 5 weiteren Vitamin K-Antagonisten in Humanserum mittels LC-ESI-MS.** *Toxichem Krimtech* 2005, **72**: 46-55.
250. Baud FJ, Borron SW, Bavoux E, Astier A, Hoffman JR: **Relation between plasma lactate and blood cyanide concentrations in acute cyanide poisoning.** *BMJ* 1996, **312**: 26-27.

251. Gracia R, Shepherd G: **Cyanide poisoning and its treatment.** *Pharmacotherapy* 2004, **24**: 1358-1365.
252. Hall AH, Rumack BH: **Clinical toxicology of cyanide.** *Ann Emerg Med* 1986, **15**: 1067-1074.
253. Houeto P, Hoffman JR, Imbert M, Levillain P, Baud FJ: **Relation of blood cyanide to plasma cyanocobalamin concentration after a fixed dose of hydroxocobalamin in cyanide poisoning.** *Lancet* 1995, **346**: 605-608.
254. Rindone JP, Sloane EP: **Cyanide toxicity from sodium nitroprusside: risks and management.** *Ann Pharmacother* 1992, **26**: 515-519.
255. Salkowski AA, Penney DG: **Cyanide poisoning in animals and humans: a review.** *Vet Hum Toxicol* 1994, **36**: 455-466.
256. Strehl E: **Cyanid-Intoxikationen. Hydroxycobalamin bereichert das Antidotarium.** *Krankenhauspharmazie* 2000, **21**: 293-297.
257. Winchell GA, King JD, Chavez-Eng CM, Constanzer ML, Korn SH: **Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency.** *J Clin Pharmacol* 2002, **42**: 61-69.
258. Belldina EB, Huang MY, Schneider JA, Brundage RC, Tracy TS: **Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.** *Br J Clin Pharmacol* 2003, **56**: 520-525.
259. USP DI® Volume I: *Drug Information for the Health Care Professional.* 26th edition. Greenwood Village, CO, USA: Thomson Reuters (Healthcare) Inc.; 2006.
260. Kraemer T, Paul LD, Jochum C, Maurer HH: **Acute poisoning with dapsone - a case report.** *Toxichem Krimtech* 2002, **69**: 80-85.
261. Piscitelli SC, Occhipinti DJ, Danziger LH, Hill C, West DP, Fischer JH: **Therapeutic monitoring and pharmacist intervention in a Hansen's disease clinic.** *Ann Pharmacother* 1993, **27**: 1526-1531.
262. Fabbiani M, Bracciale L, Ragazzoni E, Santangelo R, Cattani P, Di GS *et al.*: **Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure.** *Infection* 2011, **39**: 563-569.
263. Burke MJ, Harvey AT, Preskorn SH: **Pharmacokinetics of the newer antidepressants.** *Am J Med* 1996, **100**: 119-121.
264. von Moltke LL, Greenblatt DJ, Shader RI: **Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications.** *Clin Pharmacokinet* 1993, **24**: 141-160.

265. Richter O, Ern B, Reinhardt D, Becker B: **Pharmacokinetics of dexamethasone in children.** *Pediatr Pharmacol (New York)* 1983, **3**: 329-337.
266. Gunn VL, Taha SH, Liebelt EL, Serwint JR: **Toxicity of over-the-counter cough and cold medications.** *Pediatrics* 2001, **108**: E52.
267. Hanzlick R: **National Association of Medical Examiners Pediatric Toxicology (PedTox) Registry Report 3. Case submission summary and data for acetaminophen, benzene, carboxyhemoglobin, dextromethorphan, ethanol, phenobarbital, and pseudoephedrine.** *Am J Forensic Med Pathol* 1995, **16**: 270-277.
268. Härtter S, Baier D, Dingemans J, Ziegler G, Hiemke C: **Steady state pharmacokinetics of dextromethorphan [abstract].** *Naunyn-Schmiedeberg's Arch Pharmacol (Suppl)* 1996, **353**: R154.
269. Marinetti L, Lehman L, Casto B, Harshbarger K, Kubiczek P, Davis J: **Over-the-counter cold medications-postmortem findings in infants and the relationship to cause of death.** *J Anal Toxicol* 2005, **29**: 738-743.
270. Repetto MR, Repetto M: **Habitual, toxic, and lethal concentrations of 103 drugs of abuse in humans.** *J Toxicol Clin Toxicol* 1997, **35**: 1-9.
271. Kintz P, Tracqui A, Mangin P, Lugnier AA, Chaumont AJ: **Fatal intoxication by dextromoramide: a report on two cases.** *J Anal Toxicol* 1989, **13**: 238-239.
272. Ufkes JG, de Vos JW, van Brussel GH: **Determination and pharmacokinetics of dextromoramide in methadone maintenance therapy.** *Pharm World Sci* 1998, **20**: 83-87.
273. Iwersen-Bergmann S, Toennes SW, Schmidt K, Köhler W, Zokai A, Kauert GF: **Bewertung von Morphinspiegeln bei fraglich Herointoten - immer noch eine Herausforderung [abstract].** *Rechtsmedizin* 2007, **17**: 259.
274. Teske J, Weller JP, Tröger HD, Koal T, Kaefer V, Breyer R *et al.*: **Blutspiegel von Heroinfolgeprodukten bei hochdosierter Heroinapplikation [abstract].** *Rechtsmedizin* 2004, **14**: 315.
275. Halbsguth U, Rentsch KM, Eich-Hochli D, Diterich I, Fattinger K: **Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure.** *Br J Clin Pharmacol* 2008, **66**: 781-791.
276. Perger L, Rentsch KM, Kullak-Ublick GA, Verotta D, Fattinger K: **Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets.** *Eur J Pharm Sci* 2009, **36**: 421-432.
277. Girardin F, Rentsch KM, Schwab MA, Maggiorini M, Pauli-Magnus C, Kullak-Ublick GA *et al.*: **Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts.** *Clin Pharmacol Ther* 2003, **74**: 341-352.

278. Kidd S, Brennan S, Stephen R, Minns R, Beattie T: **Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children.** *Arch Dis Child* 2009, **94**: 974-978.
279. Rentsch KM, Kullak-Ublick GA, Reichel C, Meier PJ, Fattinger K: **Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics.** *Clin Pharmacol Ther* 2001, **70**: 237-246.
280. Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH: **Population pharmacokinetics of heroin and its major metabolites.** *Clin Pharmacokinet* 2006, **45**: 401-417.
281. Rook EJ, van Ree JM, van den Brink W, Hillebrand MJ, Huitema AD, Hendriks VM *et al.*: **Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients.** *Basic Clin Pharmacol Toxicol* 2006, **98**: 86-96.
282. Bever CT, Jr., Leslie J, Camenga DL, Panitch HS, Johnson KP: **Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.** *Ann Neurol* 1990, **27**: 421-427.
283. Divoll M, Greenblatt DJ, Lacasse Y, Shader RI: **Benzodiazepine overdose: plasma concentrations and clinical outcome.** *Psychopharmacology (Berl)* 1981, **73**: 381-383.
284. Friedman H, Greenblatt DJ, Peters GR, Metzler CM, Charlton MD, Harmatz JS *et al.*: **Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time.** *Clin Pharmacol Ther* 1992, **52**: 139-150.
285. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR: **The effects of age and liver disease on the disposition and elimination of diazepam in adult man.** *J Clin Invest* 1975, **55**: 347-359.
286. Traeger SM, Haug MT, III: **Reduction of diazepam serum half life and reversal of coma by activated charcoal in a patient with severe liver disease.** *J Toxicol Clin Toxicol* 1986, **24**: 329-337.
287. Davies NM, Anderson KE: **Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.** *Clin Pharmacokinet* 1997, **33**: 184-213.
288. Fowler PD, Dawes PT, John VA, Shotton PA: **Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation.** *Eur J Clin Pharmacol* 1986, **31**: 469-472.
289. Fowler PD, Shadforth MF, Crook PR, John VA: **Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis.** *Eur J Clin Pharmacol* 1983, **25**: 389-394.

290. Burger DM, Meenhorst PL, Beijnen JH: **Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.** *Pharm World Sci* 1995, **17**: 25-30.
291. Burger DM, Meenhorst PL, ten Napel CHH, Mulder JW, Henrichs JH, Frissen PHJ *et al.*: **Limited sampling models for the antiretroviral agent didanosine.** *J Pharm Sci* 1995, **3**: 7-13.
292. Bolla S, Boinpally RR, Poondru S, Devaraj R, Jasti BR: **Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects.** *J Clin Pharmacol* 2002, **42**: 327-331.
293. White S, Wong SH: **Standards of laboratory practice: analgesic drug monitoring. National Academy of Clinical Biochemistry.** *Clin Chem* 1998, **44**: 1110-1123.
294. Dollery C: *Therapeutic Drugs.* Edinburgh: Churchill Livingstone; 1991.
295. Gschwantler M, Gulz W, Brownstone E, Feichtenschlager T, Pulgram T, Schrutka-Kolbl C *et al.*: **Digitoxin-induzierte Thrombozytopenie.** *Wien Klin Wochenschr* 1993, **105**: 500-502.
296. Daldrup T, Pier S: **Tödliche Vergiftung durch Orphenadrin/Diphenhydramin.** *Toxichem Krimtech* 1994, **61**: 9.
297. Isabelle C, Warner A: **Long-term heavy use of diphenhydramine without anticholinergic delirium.** *Am J Health Syst Pharm* 1999, **56**: 555-557.
298. Oikkonen M, Karkela J, Seppala T: **CSF concentrations and clinical effects following intravenous dixyrazine premedication.** *Eur J Clin Pharmacol* 1995, **47**: 445-447.
299. Barone JA: **Domperidone: a peripherally acting dopamine₂-receptor antagonist.** *Ann Pharmacother* 1999, **33**: 429-440.
300. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H: **On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.** *Eur J Drug Metab Pharmacokinet* 1981, **6**: 61-70.
301. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJ: **Pharmacokinetics and dose proportionality of domperidone in healthy volunteers.** *J Clin Pharmacol* 1986, **26**: 628-632.
302. Michiels M, Hendriks R, Heykants J: **On the pharmacokinetics of domperidone in animals and man II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat.** *Eur J Drug Metab Pharmacokinet* 1981, **6**: 37-48.

303. Imbimbo BP: **Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.** *CNS Drugs* 2001, **15**: 375-390.
304. Rogers SL, Friedhoff LT: **The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.** The Donepezil Study Group. *Dementia* 1996, **7**: 293-303.
305. Keller T, Schneider A, Tutsch-Bauer E: **Fatal intoxication due to dothiepin.** *Forensic Sci Int* 2000, **109**: 159-166.
306. Schulz M, Schmoldt A: **Successful physostigmine treatment of acute dothiepin intoxication.** *Pharmazie* 1994, **49**: 614.
307. Barbe F, Hansen C, Badonnel Y, Legagneur H, Vert P, Boutroy MJ: **Severe side effects and drug plasma concentrations in preterm infants treated with doxapram.** *Ther Drug Monit* 1999, **21**: 547-552.
308. Apple FS: **Postmortem tricyclic antidepressant concentrations: assessing cause of death using parent drug to metabolite ratio.** *J Anal Toxicol* 1989, **13**: 197-198.
309. Ereshefsky L, Tran-Johnson T, Davis CM, LeRoy A: **Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine--new data and review.** *Clin Chem* 1988, **34**: 863-880.
310. Kretzschmar M: **Intoxikationen mit schlaffördernden Mitteln.** *Z Arztl Fortbild Qual sich* 2001, **95**: 45-49.
311. Bockholdt B, Klug E, Schneider V: **Suicide through doxylamine poisoning.** *Forensic Sci Int* 2001, **119**: 138-140.
312. Johansson E, Agurell S, Hollister LE, Halldin MM: **Prolonged apparent half-life of delta 1-tetrahydrocannabinol in plasma of chronic marijuana users.** *J Pharm Pharmacol* 1988, **40**: 374-375.
313. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK: **Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.** *Clin Pharmacol Ther* 1980, **28**: 409-416.
314. Sawyer CA, Baker AB, Ramzan I, Regaglia F: **Droperidol elimination after cardiopulmonary bypass surgery.** *J Clin Pharmacol* 1998, **38**: 160-165.
315. Committee for Medicinal Products for Human Use (CHMP). **Xigris (drotrecogin alfa) EPAR - Product information.** [European Medicines Agency] (last accessed April 22, 2010)
316. Aquilonius SM, Hartvig P: **Clinical pharmacokinetics of cholinesterase inhibitors.** *Clin Pharmacokinet* 1986, **11**: 236-249.

317. Iseman MD: **Treatment of multidrug-resistant tuberculosis.** *N Engl J Med* 1993, **329**: 784-791.
318. Brent J, McMartin K, Phillips S, Burkhart KK, Donovan JW, Wells M *et al.*: **Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group.** *N Engl J Med* 1999, **340**: 832-838.
319. Fraser AD: **Clinical toxicologic implications of ethylene glycol and glycolic acid poisoning.** *Ther Drug Monit* 2002, **24**: 232-238.
320. Divanon F, Leroyer R, Leprince MC, Riby JP, Collet C: **A propos d'une intoxication par l'éthylène glycol.** *J Pharm Clin* 1997, **16**: 177-182.
321. Hantson P, Vanbinst R, Mahieu P: **Determination of ethylene glycol tissue content after fatal oral poisoning and pathologic findings.** *Am J Forensic Med Pathol* 2002, **23**: 159-161.
322. Hoffmann U, Abel P, Neurath H: **Acute ethylene glycol poisoning after intentional ingestion.** *Toxichem Krimtech* 2008, **75**: 130-133.
323. Leikin JB, Toerne T, Burda A, McAllister K, Erickson T: **Summertime cluster of intentional ethylene glycol ingestions.** *JAMA* 1997, **278**: 1406.
324. Porter WH, Rutter PW, Bush BA, Pappas AA, Dunnington JE: **Ethylene glycol toxicity: the role of serum glycolic acid in hemodialysis.** *J Toxicol Clin Toxicol* 2001, **39**: 607-615.
325. Reddy NJ, Lewis LD, Gardner TB, Osterling W, Eskey CJ, Nierenberg DW: **Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol.** *Clin Pharmacol Ther* 2007, **81**: 114-121.
326. Sivilotti ML, Burns MJ, McMartin KE, Brent J: **Toxicokinetics of ethylene glycol during fomepizole therapy: implications for management. For the Methylpyrazole for Toxic Alcohols Study Group.** *Ann Emerg Med* 2000, **36**: 114-125.
327. Wildsmith JA, Tucker GT, Cooper S, Scott DB, Covino BG: **Plasma concentrations of local anaesthetics after interscalene brachial plexus block.** *Br J Anaesth* 1977, **49**: 461-466.
328. Boni J, Korth-Bradley J, McGoldrick K, Appel A, Cooper S: **Pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery.** *J Clin Pharmacol* 1999, **39**: 729-737.
329. Kirchner GI, Meier-Wiedenbach I, Manns MP: **Clinical pharmacokinetics of everolimus.** *Clin Pharmacokinet* 2004, **43**: 83-95.
330. Kovarik JM, Kaplan B, Tedesco SH, Kahan BD, Dantal J, Vitko S *et al.*: **Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.** *Transplantation* 2002, **73**: 920-925.

331. Kovarik JM, Eisen H, Dorent R, Mancini D, Vigano M, Rouilly M *et al.*: **Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.** *J Heart Lung Transplant* 2003, **22**: 1117-1125.
332. Starling RC, Hare JM, Hauptman P, McCurry KR, Mayer HW, Kovarik JM *et al.*: **Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling.** *Am J Transplant* 2004, **4**: 2126-2131.
333. Ezzet F, Krishna G, Wexler DB, Statkevich P, Kosoglou T, Batra VK: **A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe.** *Clin Ther* 2001, **23**: 871-885.
334. Ezzet F, Wexler D, Statkevich P, Kosoglou T, Patrick J, Lipka L *et al.*: **The plasma concentration and LDL-C relationship in patients receiving ezetimibe.** *J Clin Pharmacol* 2001, **41**: 943-949.
335. AHFS: *AHFS Drug Information*. Bethesda: American Society of Health-System Pharmacists; 2002.
336. Yoshimoto K, Saima S, Echizen H, Nakamura Y, Kondo T, Yagishita Y *et al.*: **Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure.** *Clin Pharmacol Ther* 1994, **55**: 693-700.
337. Graves NM: **Felbamate.** *Ann Pharmacother* 1993, **27**: 1073-1081.
338. Troupin AS, Montouris G, Hussein G: **Felbamate: Therapeutic range and other kinetic information.** *Epilepsy* 1997, **10**: 26-31.
339. Wagner ML: **Felbamate: a new antiepileptic drug.** *Am J Hosp Pharm* 1994, **51**: 1657-1666.
340. Bolten W, Salzmann G, Goldmann R, Miehle K: **Plasma- und Gewebekonzentrationen von Biphenyllessigsäure nach einwöchiger oraler Fenbufenmedikation bzw. topischer Anwendung von Felbinac-Gel am Kniegelenk.** *Z Rheumatol* 1989, **48**: 317-322.
341. Blychert E, Edgar B, Elmfeldt D, Hedner T: **Plasma concentration--effect relationships for felodipine: a meta analysis.** *Clin Pharmacol Ther* 1992, **52**: 80-89.
342. Lössner A, Banditt P, Troger U: **Rapid and simple method for detection of fenofibric acid in human serum by high-performance liquid chromatography.** *Pharmazie* 2001, **56**: 50-51.
343. Hercegova A, Polonsky J: **Determination of non-steroidal anti-inflammatory drugs in biological fluids.** *Pharmazie* 1999, **54**: 479-486.
344. Hug CC: **Fentanyl and sufentanil anesthesia revisited: establish an effective plasma concentration and achieve it at the right time.** *Anesthesiology* 1991, **74**: 390.

345. Lehmann KA, Freier J, Daub D: **Fentanyl-Pharmakokinetik und postoperative Atemdepression.** *Anaesthesist* 1982, **31**: 111-118.
346. Philbin DM, Rosow CE, Schneider RC, Koski G, D'Ambra MN: **Fentanyl and sufentanil anesthesia revisited: establish an effective plasma concentration and achieve it at the right time.** *Anesthesiology* 1991, **74**: 389-390.
347. Singleton MA, Rosen JI, Fisher DM: **Plasma concentrations of fentanyl in infants, children and adults.** *Can J Anaesth* 1987, **34**: 152-155.
348. Smialek JE, Levine B, Chin L, Wu SC, Jenkins AJ: **A fentanyl epidemic in Maryland 1992.** *J Forensic Sci* 1994, **39**: 159-164.
349. Stanley TH, Bailey PL: **Fentanyl and sufentanil anesthesia revisited: establish an effective plasma concentration and achieve it at the right time.** *Anesthesiology* 1991, **74**: 388-390.
350. Yerasi AB, Butts JD, Butts JD: **Disposal of used fentanyl patches.** *Am J Health Syst Pharm* 1997, **54**: 85-86.
351. Andresen H, Gullans A, Veselinovic M, Anders S, Schmoltdt A, Iwersen-Bergmann S *et al.*: **Fentanyl: toxic or therapeutic? Postmortem and antemortem blood concentrations after transdermal fentanyl application.** *J Anal Toxicol* 2012, **36**: 182-194.
352. Simons FE, Bergman JN, Watson WT, Simons KJ: **The clinical pharmacology of fexofenadine in children.** *J Allergy Clin Immunol* 1996, **98**: 1062-1064.
353. Steiner JF: **Clinical pharmacokinetics and pharmacodynamics of finasteride.** *Clin Pharmacokinet* 1996, **30**: 16-27.
354. Evers J, Eichelbaum M, Kroemer HK: **Unpredictability of flecainide plasma concentrations in patients with renal failure: relationship to side effects and sudden death?** *Ther Drug Monit* 1994, **16**: 349-351.
355. Debruyne D, Ryckelynck JP: **Clinical pharmacokinetics of fluconazole.** *Clin Pharmacokinet* 1993, **24**: 10-27.
356. Debruyne D: **Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.** *Clin Pharmacokinet* 1997, **33**: 52-77.
357. Reuman PD, Neiberger R, Kondor DA: **Intraperitoneal and intravenous fluconazole pharmacokinetics in a pediatric patient with end stage renal disease.** *Pediatr Infect Dis J* 1992, **11**: 132-133.
358. Scholz J, Schulz M, Steinfath M, Hover S, Bause H: **Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient.** *J Mol Med* 1995, **73**: 145-147.

359. Bond A, Seijas D, Dawling S, Lader M: **Systemic absorption and abuse liability of snorted flunitrazepam.** *Addiction* 1994, **89**: 821-830.
360. Pak CY, Sakhaee K, Rubin CD, Zerwekh JE: **Sustained-release sodium fluoride in the management of established postmenopausal osteoporosis.** *Am J Med Sci* 1997, **313**: 23-32.
361. Pitt P, Berry H: **Fluoride treatment in osteoporosis.** *Postgrad Med J* 1991, **67**: 323-326.
362. von Werder K, Schulz M: *Prophylaxe und Therapie der Osteoporose.* Stuttgart: WVG; 1991.
363. Henry JA: **Toxicity of antidepressants: comparisons with fluoxetine.** *Int Clin Psychopharmacol* 1992, **6 Suppl 6:22-7**: 22-27.
364. Renshaw PF, Guimaraes AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG *et al.*: **Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration.** *Am J Psychiatry* 1992, **149**: 1592-1594.
365. Niebch G, Borbe HO, Hummel T, Kobal G: **Dose-proportional plasma levels of the analgesic flupirtine maleate in man. Application of a new HPLC assay.** *Arzneimittelforschung* 1992, **42**: 1343-1345.
366. Forland SC, Wechter WJ, Witchwoot S, Clifford KH, Arnett RL, Cutler RE: **Human plasma concentrations of R, S, and racemic flurbiprofen given as a toothpaste.** *J Clin Pharmacol* 1996, **36**: 546-553.
367. Schulz M, Schmoldt A, Donn F, Becker H: **The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment.** *Eur J Clin Pharmacol* 1988, **34**: 633-636.
368. Grimsley SR, Jann MW: **Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.** *Clin Pharm* 1992, **11**: 930-957.
369. Wood DM, Rajalingam Y, Greene SL, Morgan PE, Gerrie D, Jones AL *et al.*: **Status epilepticus following intentional overdose of fluvoxamine: a case report with serum fluvoxamine concentration.** *Clin Toxicol (Phila)* 2007, **45**: 791-793.
370. Andrews CO, Fischer JH: **Gabapentin: a new agent for the management of epilepsy.** *Ann Pharmacother* 1994, **28**: 1188-1196.
371. Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P *et al.*: **Pharmacokinetics of gabapentin in subjects with various degrees of renal function.** *Clin Pharmacol Ther* 1994, **56**: 154-159.
372. Bockbrader HN: **Clinical pharmacokinetics of gabapentin.** *Drugs Today* 1995, **31**: 613-619.

373. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P: **A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.** *Clin Pharmacokinet* 2010, **49**: 661-669.
374. Btaiche IF, Woster PS: **Gabapentin and lamotrigine: novel antiepileptic drugs.** *Am J Health Syst Pharm* 1995, **52**: 61-69.
375. Knörle R, Feuerstein TJ, Schulze-Bonhage A: **Determination of gabapentin-lactam in serum of patients under gabapentin therapy.** *Arzneimittelforschung* 2004, **54**: 139-142.
376. Peruche B, Schulz M: **Gabapentin, ein neues Antiepileptikum.** *Pharm Ztg* 1996, **141**: 1396-1404.
377. Radulovic LL, Taylor CP, Walker RM: **The preclinical pharmacology, pharmacokinetics and toxicology of gabapentin.** *Drugs Today* 1995, **31**: 597-611.
378. Sivenius J, Kalviainen R, Ylinen A, Riekkinen P: **Double-blind study of Gabapentin in the treatment of partial seizures.** *Epilepsia* 1991, **32**: 539-542.
379. Spiller HA, Dunaway MD, Cutino L: **Massive gabapentin and presumptive quetiapine overdose.** *Vet Hum Toxicol* 2002, **44**: 243-244.
380. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN: **A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma.** *Pharm Res* 1993, **10**: 276-281.
381. Tomson T, Johannessen SI: **Therapeutic monitoring of the new antiepileptic drugs.** *Eur J Clin Pharmacol* 2000, **55**: 697-705.
382. Wilson EA, Sills GJ, Forrest G, Brodie MJ: **High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients.** *Epilepsy Res* 1998, **29**: 161-166.
383. Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz M *et al.*: **Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.** *Clin Pharmacol Ther* 1991, **50**: 420-428.
384. Scott LJ, Goa KL: **Galantamine: a review of its use in Alzheimer's disease.** *Drugs* 2000, **60**: 1095-1122.
385. Frese JH, Rohland L, Schulz M, Schmoldt A: **Intoxikation mit Gallopamil. Verlauf und Therapie.** *Dtsch Med Wochenschr* 1988, **113**: 770-772.
386. Andresen H, Sprys N, Schmoldt A, Mueller A, Iwersen-Bergmann S: **Gamma-hydroxybutyrate in urine and serum: additional data supporting current cut-off recommendations.** *Forensic Sci Int* 2010, **200**: 93-99.

387. Andresen H, Aydin BE, Mueller A, Iwersen-Bergmann S: **An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results.** *Drug Test Anal* 2011, **3**: 560-568.
388. Jung D, Griffy K, Wong R, Colburn W, Hulse J: **Steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus.** *J Clin Pharmacol* 1998, **38**: 1021-1024.
389. Brier ME, Zurada JM, Aronoff GR: **Neural network predicted peak and trough gentamicin concentrations.** *Pharm Res* 1995, **12**: 406-412.
390. Edwards DJ: **Therapeutic drug monitoring of aminoglycosides and vancomycin: guidelines and controversies.** *J Pharm Pract* 1991, **IV**: 211-224.
391. Inciardi JF, Willits NH: **Setting confidence intervals for drug concentrations from pharmacokinetic parameters.** *Ann Pharmacother* 1992, **26**: 1070-1074.
392. Kozyrskyj A, Masih M, Hahn J, Ho C, Wong M, Sirdevan M: **New neonatal gentamicin dosing guidelines: results of an evaluation of serum concentrations.** *Can J Hosp Pharm* 1994, **47**: 262-267.
393. Modi N, Maggs AF, Clarke C, Chapman C, Swann RA: **Gentamicin concentration and toxicity.** *Lancet* 1998, **352**: 70.
394. Watling SM, Kisor DF: **Population pharmacokinetics: development of a medical intensive care unit-specific gentamicin dosing nomogram.** *Ann Pharmacother* 1993, **27**: 151-154.
395. Lam YW, Jann MW, Chang WH, Yu HS, Lin SK, Chen H *et al.*: **Intra- and interethnic variability in reduced haloperidol to haloperidol ratios.** *J Clin Pharmacol* 1995, **35**: 128-136.
396. Potkin SG, Shen Y, Pardes H, Phelps BH, Zhou D, Shu L *et al.*: **Haloperidol concentrations elevated in Chinese patients.** *Psychiatry Res* 1984, **12**: 167-172.
397. Ulrich S, Wurthmann C, Brosz M, Meyer FP: **The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.** *Clin Pharmacokinet* 1998, **34**: 227-263.
398. Ulrich S, Meyer FP: **Reduzierte Haloperidol und Haloperidolpyridinium-Metaboliten bei schizophrenen Patienten.** *Psychopharmakotherapie* 1999, **6**: 100-102.
399. Challapalli R, Lefkovits J, Topol EJ: **Clinical trials of recombinant hirudin in acute coronary syndromes.** *Coron Artery Dis* 1996, **7**: 429-437.
400. Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC: **Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-**

- glucuronide in cancer patients after immediate and controlled-release hydromorphone.** *J Clin Pharmacol* 1995, **35**: 37-44.
401. Mason PE, Kerns WP: **Gamma hydroxybutyric acid (GHB) intoxication.** *Acad Emerg Med* 2002, **9**: 730-739.
402. Steinecke H: **Beitrag zur Bewertung von Gamma-Hydroxybuttersäure (GBH) - Konzentrationen im Blut lebender Personen sowie in postmortalem Blut.** *Toxichem Krimtech* 2007, **74**: 150-154.
403. Kunze K, Kauert U, Schmoldt A: **Drug induced myopathy by hydroxychloroquine.** *Vet Hum Toxicol* 1987, **29**: 59-60.
404. Abraham TT, Barnes AJ, Lowe RH, Kolbrich Spargo EA, Milman G, Pirnay SO *et al.*: **Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.** *J Anal Toxicol* 2009, **33**: 439-446.
405. Barnes AJ, Scheidweiler KB, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA: **MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration.** *Ther Drug Monit* 2011, **33**: 602-608.
406. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA: **Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.** *Ther Drug Monit* 2008, **30**: 320-332.
407. Forsyth DR, Jayasinghe KS, Roberts CJ: **Do nizatidine and cimetidine interact with ibuprofen?** *Eur J Clin Pharmacol* 1988, **35**: 85-88.
408. Holubek WJ, Wetter A, Howland MA, Hoffman RS, Nelson LS: **Death from a massive ibuprofen overdose [abstract].** *Clin Toxicol* 2006, **44**: 488.
409. Pisano P, Durand A, Autret E, Desnuelle C, Pinsard N, Serratrice G *et al.*: **Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy.** *Eur J Clin Pharmacol* 1996, **51**: 167-169.
410. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM *et al.*: **Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.** *N Engl J Med* 2001, **344**: 1031-1037.
411. Lyseng-Williamson K, Jarvis B: **Imatinib.** *Drugs* 2001, **61**: 1765-1774.
412. Tegeder I, Bremer F, Oelkers R, Schüttler J, Brune K, Geisslinger G: **Therapeutic drug monitoring of imipenem during continuous veno-venous hemofiltration [abstract].** *Naunyn-Schmiedeberg's Arch Pharmacol* 1996, **355**: R129.

413. Jorgensen OS, Lober M, Christiansen J, Gram LF: **Plasma concentration and clinical effect in imipramine treatment of childhood enuresis.** *Clin Pharmacokinet* 1980, **5**: 386-393.
414. Rayner CR, Galbraith KJ, Marriott JL, Duncan GJ: **A critical evaluation of the therapeutic range of indinavir.** *Ann Pharmacother* 2002, **36**: 1230-1237.
415. Gilman JT, Gal P: **Pharmacokinetic and pharmacodynamic data collection in children and neonates. A quiet frontier.** *Clin Pharmacokinet* 1992, **23**: 1-9.
416. Mistry GC, Jensen BK, Rakhit A, Huselton CA, Patel IH: **Systemic availability of retinoids following excessive topical application of isotrex to patients with acne vulgaris [abstract].** *Pharm Res* 1995, **12**: S-414.
417. Nulman I, Berkovitch M, Klein J, Pastuszak A, Lester RS, Shear N *et al.*: **Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety.** *J Clin Pharmacol* 1998, **38**: 926-930.
418. Chellingsworth MD, Willis JV, Jack DB, Kendall MJ: **Pharmacokinetics and pharmacodynamics of isradipine (PN200-110) in young and elderly patients.** *Am J Med* 1988, **72**: 72-79.
419. Romano MJ, Gaylor A, Sang CJ, Jr.: **Life-threatening isradipine poisoning in a child.** *Pharmacotherapy* 2002, **22**: 766-770.
420. Tse FL, Jaffe JM: **Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man.** *Eur J Clin Pharmacol* 1987, **32**: 361-365.
421. Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH *et al.*: **Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.** *Pharmacotherapy* 1998, **18**: 295-301.
422. Lipp H-P: **Klinische Pharmakokinetik von Itraconazol.** *Krankenhauspharmazie* 1996, **17**: 388-395.
423. Neuvonen PJ, Varhe A, Olkkola KT: **The effect of ingestion time interval on the interaction between itraconazole and triazolam.** *Clin Pharmacol Ther* 1996, **60**: 326-331.
424. Slain D, Rogers PD, Cleary JD, Chapman SW: **Intravenous itraconazole.** *Ann Pharmacother* 2001, **35**: 720-729.
425. Okonkwo PO, Ogbuokiri JE, Ofoegbu E, Klotz U: **Protein binding and ivermectin estimations in patients with onchocerciasis.** *Clin Pharmacol Ther* 1993, **53**: 426-430.
426. Bondesson U, Hartvig P, Danielsson B: **Quantitative determination of the urinary excretion of ketobemidone and four of its metabolites after intravenous and oral administration in man.** *Drug Metab Dispos* 1981, **9**: 376-380.

427. Hartvig P, Valtysson J, Lindner KJ, Kristensen J, Karlsten R, Gustafsson LL *et al.*: **Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers.** *Clin Pharmacol Ther* 1995, **58**: 165-173.
428. Steentoft A, Worm K: **Cases of fatal intoxication with Ketogan.** *J Forensic Sci Soc* 1994, **34**: 181-185.
429. Ballerini R, Casini A, Chinol M, Mannucci C, Giaccari L, Salvi M: **Study on the absorption of ketoprofen topically administered in man: comparison between tissue and plasma levels.** *Int J Clin Pharmacol Res* 1986, **6**: 69-72.
430. Dionne RA, Gordon SM, Tahara M, Rowan J, Troullos E: **Analgesic efficacy and pharmacokinetics of ketoprofen administered into a surgical site.** *J Clin Pharmacol* 1999, **39**: 131-138.
431. Ishizaki T, Sasaki T, Suganuma T, Horai Y, Chiba K, Watanabe M *et al.*: **Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration.** *Eur J Clin Pharmacol* 1980, **18**: 407-414.
432. Lewellen ORW, Templeton RT: **The pharmacokinetics of ketoprofen in man during and after repeated oral dosing (50 mg q.i.d.) with Orudis(R) [abstract].** *Scand J Rheumatol* 1976, **14**: 53-62.
433. Netter P, Bannwarth B, Lopicque F, Harrewyn JM, Frydman A, Tamisier JN *et al.*: **Total and free ketoprofen in serum and synovial fluid after intramuscular injection.** *Clin Pharmacol Ther* 1987, **42**: 555-561.
434. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE: **Clinical pharmacokinetics of lamivudine.** *Clin Pharmacokinet* 1999, **36**: 41-66.
435. Rambeck B, Wolf P: **Lamotrigine clinical pharmacokinetics.** *Clin Pharmacokinet* 1993, **25**: 433-443.
436. Schapel GJ, Beran RG, Vajda FJ, Berkovic SF, Mashford ML, Dunagan FM *et al.*: **Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures.** *J Neurol Neurosurg Psychiatry* 1993, **56**: 448-453.
437. French LK, McKeown NJ, Hendrickson RG: **Complete heart block and death following lamotrigine overdose.** *Clin Toxicol (Phila)* 2011, **49**: 330-333.
438. Schaller K-H, Angerer H, Lehnert G: **Bio-Monitoring in der Arbeits- und Umweltmedizin.** *Dt Arztebl* 1993, **90**: C-1430-C-1435.
439. Schmid I, Paulweber B, Pechböck W, Oberkofler H, Patsch W: **Eine spät erkannte Bleiintoxikation.** *Toxichem Krimtech* 2000, **67**: 96-97.
440. Beaman JM, Hackett LP, Luxton G, Illett KF: **Effect of hemodialysis on leflunomide plasma concentrations.** *Ann Pharmacother* 2002, **36**: 75-77.

441. Goldenberg MM: **Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.** *Clin Ther* 1999, **21**: 1837-1852.
442. Lucien J, Dias VC, LeGatt DF, Yatscoff RW: **Blood distribution and single-dose pharmacokinetics of leflunomide.** *Ther Drug Monit* 1995, **17**: 454-459.
443. Barrueto F, Jr., Williams K, Howland MA, Hoffman RS, Nelson LS: **A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data.** *J Toxicol Clin Toxicol* 2002, **40**: 881-884.
444. Heykants J, Van PA, Van dV, V, Snoeck E, Meuldermans W, Woestenborghs R: **The pharmacokinetic properties of topical levocabastine. A review.** *Clin Pharmacokinet* 1995, **29**: 221-230.
445. Baas H, Harder S, Burklin F, Demisch L, Fischer PA: **Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.** *Clin Neuropharmacol* 1998, **21**: 86-92.
446. Harder S, Baas H, Rietbrock S: **Concentration-effect relationship of levodopa in patients with Parkinson's disease.** *Clin Pharmacokinet* 1995, **29**: 243-256.
447. Harder S, Baas H, Bergemann N, Demisch L, Rietbrock S: **Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation.** *Br J Clin Pharmacol* 1995, **39**: 39-44.
448. Harder S, Baas H: **Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.** *Clin Pharmacol Ther* 1998, **64**: 183-191.
449. Sturner WQ, Garriott JC: **L-dopa poisoning.** *J Forensic Sci* 1972, **17**: 440-443.
450. Schall U, Katta T, Pries E, Klöppel A, Gastpar M: **Dosierung von Levomethadon in der Substitutionsbehandlung i.v.-Opiatabhängiger.** *Dt Arztebl* 1994, **91**: C-556-C-557.
451. Foy JL, Eastman RC, Nealon RC, Bowen PM, Pengelly ML, Drass JA *et al.*: **Automated therapeutic drug monitoring in an ambulatory care endocrine clinic.** *Ann Pharmacother* 1992, **26**: 675-678.
452. Dawling S, Flanagan RJ, Widdop B: **Fatal lignocaine poisoning: report of two cases and review of the literature.** *Hum Toxicol* 1989, **8**: 389-392.
453. den Hartigh J, Hilders CG, Schoemaker RC, Hulshof JH, Cohen AF, Vermeij P: **Tinnitus suppression by intravenous lidocaine in relation to its plasma concentration.** *Clin Pharmacol Ther* 1993, **54**: 415-420.
454. Wu FL, Razzaghi A, Souney PF: **Seizure after lidocaine for bronchoscopy: case report and review of the use of lidocaine in airway anesthesia.** *Pharmacotherapy* 1993, **13**: 72-78.

455. Alderman CP, Lindsay KS: **Increased serum lithium concentration secondary to treatment with tiaprofenic acid and fosinopril.** *Ann Pharmacother* 1996, **30**: 1411-1413.
456. Goff DC, Baldessarini RJ: **Drug interactions with antipsychotic agents.** *J Clin Psychopharmacol* 1993, **13**: 57-67.
457. Grobosch T, Schönberg L, Lampe D: **Toxikologisches Monitoring von Risperidon und Lithium bei einer akuten Intoxikation.** *Toxichem Krimtech* 2004, **71**: 10-16.
458. Müller N, Kapfhammer HP, Spatz R, Hippus H: **Die Lithium-Prophylaxe: hohe Effizienz und geringes Risiko bei regelmäßiger Überwachung.** *Dt Ärztebl* 1995, **92**: C-236-C-239.
459. Killinger JM, Weintraub HS, Fuller BL: **Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride.** *J Clin Pharmacol* 1979, **19**: 211-218.
460. Radwanski E, Hilbert J, Symchowicz S, Zampaglione N: **Loratadine: multiple-dose pharmacokinetics.** *J Clin Pharmacol* 1987, **27**: 530-533.
461. Zhong D, Blume H: **HPLC-Bestimmung von Loratadin und seinem aktiven Metaboliten Descarboethoxyloratadin in Humanplasma.** *Pharmazie* 1994, **49**: 736-739.
462. Henry DW, Burwinkle JW, Klutman NE: **Determination of sedative and amnestic doses of lorazepam in children.** *Clin Pharm* 1991, **10**: 625-629.
463. Reiter PD, Stiles AD: **Lorazepam toxicity in a premature infant.** *Ann Pharmacother* 1993, **27**: 727-729.
464. Gillis AM, Kates RE: **Clinical pharmacokinetics of the newer antiarrhythmic agents.** *Clin Pharmacokinet* 1984, **9**: 375-403.
465. Mead RH, Keefe DL, Kates RE, Winkle RA: **Chronic lorcaïnide therapy for symptomatic premature ventricular complexes: efficacy, pharmacokinetics and evidence for norlorcaïnide antiarrhythmic effect.** *Am J Cardiol* 1985, **55**: 72-78.
466. Somani P, Simon V, Gupta RK, King P, Shapiro RS, Stockard H: **Lorcaïnide kinetics and protein binding in patients with end-stage renal disease.** *Int J Clin Pharmacol Ther Toxicol* 1984, **22**: 121-125.
467. Ludewig R: *Akute Vergiftungen.* Stuttgart: WVG; 1999.
468. Wilimzig C, Latz R, Vierling W, Mutschler E, Trnovec T, Nyulassy S: **Increase in magnesium plasma level after orally administered trimagnesium dicitrate.** *Eur J Clin Pharmacol* 1996, **49**: 317-323.

469. Burgmann H, Winkler S, Uhl F, Feucht M, Hellgren U, Bergqvist Y *et al.*: **Mefloquin und Sulfadoxin/Pyrimethamin-Überdosierung bei Malaria tropica.** *Wien Klin Wochenschr* 1993, **105**: 61-63.
470. Hellgren U, Jastrebova J, Jerling M, Krysen B, Bergqvist Y: **Comparison between concentrations of racemic mefloquine, its separate enantiomers and the carboxylic acid metabolite in whole blood serum and plasma.** *Eur J Clin Pharmacol* 1996, **51**: 171-173.
471. Noble S, Balfour JA: **Meloxicam.** *Drugs* 1996, **51**: 424-430.
472. Hui WK, Mitchell LB, Kavanagh KM, Gillis AM, Wyse DG, Manyari DE *et al.*: **Melperone: electrophysiologic and antiarrhythmic activity in humans.** *J Cardiovasc Pharmacol* 1990, **15**: 144-149.
473. Stein S, Schmoldt A, Schulz M: **Fatal intoxication with melperone.** *Forensic Sci Int* 2000, **113**: 409-413.
474. N.N.: **Quecksilber-Referenzwerte.** *Bundesgesundhbl* 1998, **41**: 270.
475. Singer AJ, Mofenson HC, Caraccio TR, Ilasi J: **Mercuric chloride poisoning due to ingestion of a stool fixative.** *Clin Toxicol* 1994, **32**: 577-582.
476. Bernhoft RA: **Mercury toxicity and treatment: a review of the literature.** *J Environ Public Health* 2012, **2012**: 460508.
477. Akyildiz BN, Kondolot M, Kurtoglu S, Konuskan B: **Case series of mercury toxicity among children in a hot, closed environment.** *Pediatr Emerg Care* 2012, **28**: 254-258.
478. Dargan PI, Giles LJ, Wallace CI, House IM, Thomson AH, Beale RJ *et al.*: **Case report: severe mercuric sulphate poisoning treated with 2,3-dimercaptopropane-1-sulphonate and haemodiafiltration.** *Crit Care* 2003, **7**: R1-R6.
479. Klotz U, Stracciari GL: **Steady state disposition of 5-aminosalicylic acid following oral dosing.** *Arzneim -Forsch /Drug Res* 1993, **43**: 1357-1359.
480. Desel H, Stedtler U, Behrens A, Neuratz H: **Mischintoxikation mit Metformin.** *Toxichem Krimtech* 2000, **67**: 4-8.
481. Reeker W, Schneider G, Felgenhauer N, Tempel G, Kochs E: **Metformin-induzierte Laktazidose.** *Dtsch Med Wochenschr* 2000, **125**: 249-251.
482. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K: **A community-based evaluation of sudden death associated with therapeutic levels of methadone.** *Am J Med* 2008, **121**: 66-71.
483. Horns WH, Rado M, Goldstein A: **Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride.** *Clin Pharmacol Ther* 1975, **17**: 636-649.

484. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM: **Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain.** *Clin Pharmacol Ther* 1987, **41**: 392-401.
485. Inturrisi CE, Verebely K: **The levels of methadone in the plasma in methadone maintenance.** *Clin Pharmacol Ther* 1972, **13**: 633-637.
486. Schmidt N, Sittl R, Brune K, Geisslinger G: **Rapid determination of methadone in plasma, cerebrospinal fluid, and urine by gas chromatography and its application to routine drug monitoring.** *Pharm Res* 1993, **10**: 441-444.
487. Ufkes JG, de Vos JW, Geerlings PJ, van Wilgenburg H: **Determination of methadone and its primary metabolite in twenty opiate addicts [abstract].** *Pharm World Sci* 1994, **16**: D6.
488. Heinemann A, Iwersen-Bergmann S, Stein S, Schmoldt A, Puschel K: **Methadone-related fatalities in Hamburg 1990-1999: implications for quality standards in maintenance treatment?** *Forensic Sci Int* 2000, **113**: 449-455.
489. Karch SB: **Is it time to reformulate racemic methadone?** *J Addict Med* 2011, **5**: 229-231.
490. Epker JL, Bakker J: **Accidental methanol ingestion: case report.** *BMC Emerg Med* 2010, **10**: 3.
491. Stefan H: **Epilepsitherapie. Teil 1: Konservative Behandlung.** *Dt Arztebl* 1998, **95**: C-2204-C-2210.
492. Schmoldt A, Iwersen S, Schluter W: **Massive ingestion of the herbicide 2-methyl-4-chlorophenoxyacetic acid (MCPA).** *J Toxicol Clin Toxicol* 1997, **35**: 405-408.
493. Kraemer T, Maurer HH: **Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.** *Ther Drug Monit* 2002, **24**: 277-289.
494. Moore KA, Mozayani A, Fierro MF, Poklis A: **Distribution of 3,4-methylenedioxyamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning.** *Forensic Sci Int* 1996, **83**: 111-119.
495. Buechler J, Schwab M, Mikus G, Fischer B, Hermle L, Marx C *et al.*: **Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine.** *J Chromatogr B Analyt Technol Biomed Life Sci* 2003, **793**: 207-222.
496. Freudenmann RW, Spitzer M: **The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA).** *CNS Drug Rev* 2004, **10**: 89-116.

497. Meyer MR, Peters FT, Maurer HH: **The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxyethylamphetamine and its single enantiomers.** *Drug Metab Dispos* 2009, **37**: 1152-1156.
498. Cami J, de la Torre R, Ortuno J, Farre M, Mas M, Roset PN *et al.*: **Pharmacokinetics of ecstasy (MDMA) in healthy subjects [abstract].** *Eur J Clin Pharmacol* 1997, **52**: A168.
499. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ: **Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans.** *Clin Chem* 1999, **45**: 1058-1069.
500. de Boer D., Egberts T, Maes RA: **Para-methylthioamphetamine, a new amphetamine designer drug of abuse.** *Pharm World Sci* 1999, **21**: 47-48.
501. Elliott SP: **Fatal poisoning with a new phenylethylamine: 4-methylthioamphetamine (4-MTA).** *J Anal Toxicol* 2000, **24**: 85-89.
502. Poortman AJ, Lock E: **Analytical profile of 4-methylthioamphetamine (4-MTA), a new street drug.** *Forensic Sci Int* 1999, **100**: 221-233.
503. Tarbah FA, Zweipfennig P, Pier S, Temme O, Daldrup T: **Tödliche Vergiftung mit dem Amphetaminderivat 4-MTA.** *Toxichem Krimtech* 2001, **68**: 21.
504. Weise M: **Das traurige Ende einer "Geburtstagsfeier" - Fatale Intoxikation mit 4-Methylthioamphetamin.** *Toxichem Krimtech* 2001, **68**: 38-42.
505. Meibohm B, Wegener S: **Mexiletin-Theophyllin-Interaktion. Pharmakokinetische Auswirkungen und klinische Relevanz.** *Krankenhauspharmazie* 1992, **13**: 331-333.
506. Backman JT, Olkkola KT, Neuvonen PJ: **Rifampin drastically reduces plasma concentrations and effects of oral midazolam.** *Clin Pharmacol Ther* 1996, **59**: 7-13.
507. Blumer JL: **Clinical pharmacology of midazolam in infants and children.** *Clin Pharmacokinet* 1998, **35**: 37-47.
508. Hughes J, Gill AM, Mulhearn H, Powell E, Choonara I: **Steady-state plasma concentrations of midazolam in critically ill infants and children.** *Ann Pharmacother* 1996, **30**: 27-30.
509. Heikinheimo O: **Clinical pharmacokinetics of mifepristone.** *Clin Pharmacokinet* 1997, **33**: 7-17.
510. Stimmel GL, Dopheide JA, Stahl SM: **Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects.** *Pharmacotherapy* 1997, **17**: 10-21.

511. Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC: **Pharmacokinetics of different routes of administration of misoprostol.** *Hum Reprod* 2002, **17**: 332-336.
512. Tang OS, Schweer H, Lee SW, Ho PC: **Pharmacokinetics of repeated doses of misoprostol.** *Hum Reprod* 2009, **24**: 1862-1869.
513. Committee for Medicinal Products for Human Use (CHMP). **Lysodren (mitotane) EPAR - Product information.** [European Medicines Agency] (last accessed May 6, 2011)
514. Fulton B, Benfield P: **Moclobemide. An update of its pharmacological properties and therapeutic use.** *Drugs* 1996, **52**: 450-474.
515. Hackett LP, Joyce DA, Hall RW, Dusci LJ, Ilett KF: **Disposition and clinical effects of moclobemide and three of its metabolites following overdose.** *Drug Invest* 1993, **5**: 281-284.
516. Iwersen S, Schmoldt A: **Three suicide attempts with moclobemide.** *J Toxicol Clin Toxicol* 1996, **34**: 223-225.
517. Mayersohn M, Guentert TW: **Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.** *Clin Pharmacokinet* 1995, **29**: 292-332.
518. Myrenfors PG, Eriksson T, Sandsted CS, Sjoberg G: **Moclobemide overdose.** *J Intern Med* 1993, **233**: 113-115.
519. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E: **Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses.** *Lancet* 1993, **342**: 1419.
520. Moachon G, Kanmacher I, Clenet M, Matinier D: **Pharmacokinetic profile of modafinil.** *Drugs Today* 1996, **32**: 327-337.
521. Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R *et al.*: **Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.** *Biopharm Drug Dispos* 1997, **18**: 769-777.
522. Aderjan R, Schmitt G, Hofmann S: **Morphin und dessen Glucuronide im Serum von Heroinabhängigen.** *Toxichem Krimtech* 1994, **61**: 24-29.
523. Glare PA, Walsh TD: **Clinical pharmacokinetics of morphine.** *Ther Drug Monit* 1991, **13**: 1-23.
524. June HL, Stitzer ML, Cone E: **Acute physical dependence: time course and relation to human plasma morphine concentrations.** *Clin Pharmacol Ther* 1995, **57**: 270-280.
525. Lugo RA, Kern SE: **Clinical pharmacokinetics of morphine.** *J Pain Palliat Care Pharmacother* 2002, **16**: 5-18.

526. Behrend M: **Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.** *BioDrugs* 2001, **15**: 37-53.
527. Fulton B, Markham A: **Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.** *Drugs* 1996, **51**: 278-298.
528. Hübner GI, Eismann R, Sziegleit W: **Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients.** *Arzneim -Forsch /Drug Res* 2000, **50**: 936-940.
529. Sanquer S, Breil M, Baron C, Dahmane D, Astier A, Lang P: **Trough blood concentrations in long-term treatment with mycophenolate mofetil.** *Lancet* 1998, **351**: 1557.
530. Willkens RF: **An overview of the long-term safety experience of nabumetone.** *Drugs* 1990, **40**: 34-37.
531. Derungs A, Schietzel S, Meyer MR, Maurer HH, Krahenbuhl S, Liechti ME: **Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone).** *Clin Toxicol (Phila)* 2011, **49**: 691-693.
532. Davies NM, Anderson KE: **Clinical pharmacokinetics of naproxen.** *Clin Pharmacokinet* 1997, **32**: 268-293.
533. Marzo A, Dal BL, Wool C, Cerutti R: **Bioavailability, food effect and tolerability of S-naproxen betainate sodium salt monohydrate in steady state.** *Arzneimittelforschung* 1998, **48**: 935-940.
534. Heinroth KM, Kuhn C, Walper R, Busch I, Winkler M, Prondzinsky R: **Akute Intoxikation mit dem β 1-selektiven β -Rezeptorenblocker Nebivolol in suizidaler Absicht.** *Dtsch Med Wochenschr* 1999, **124**: 1230-1234.
535. Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J: **Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients.** *Eur J Clin Pharmacol* 1996, **51**: 259-264.
536. McNeely W, Goa KL: **Nebivolol in the management of essential hypertension: a review.** *Drugs* 1999, **57**: 633-651.
537. Barbhaiya RH, Shukla UA, Chaikin P, Greene DS, Marathe PH: **Nefazodone pharmacokinetics: assessment of nonlinearity, intra-subject variability and time to attain steady-state plasma concentrations after dose escalation and de-escalation.** *Eur J Clin Pharmacol* 1996, **50**: 101-107.
538. Davis R, Whittington R, Bryson HM: **Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.** *Drugs* 1997, **53**: 608-636.
539. Gaffney PN, Schuckman HA, Beeson MS: **Nefazodone overdose.** *Ann Pharmacother* 1998, **32**: 1249-1250.

540. Greene DS, Barbhैया RH: **Clinical pharmacokinetics of nefazodone.** *Clin Pharmacokinet* 1997, **33**: 260-275.
541. Kaul S, Shukla UA, Barbhैया RH: **Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses.** *J Clin Pharmacol* 1995, **35**: 830-839.
542. Salazar DE, Marathe PH, Fulmor IE, Lee JS, Raymond RH, Uderman HD: **Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men.** *J Clin Pharmacol* 1995, **35**: 1109-1118.
543. Calvey TN, Wareing M, Williams NE, Chan K: **Pharmacokinetics and pharmacological effects of neostigmine in man.** *Br J Clin Pharmacol* 1979, **7**: 149-155.
544. Kadoya C, Domino EF, Matsuoka S: **Relationship of electroencephalographic and cardiovascular changes to plasma nicotine levels in tobacco smokers.** *Clin Pharmacol Ther* 1994, **55**: 370-377.
545. Schneider S, Diederich N, Appenzeller B, Schartz A, Lorang C, Wennig R: **Internet suicide guidelines: Report of a life threatening poisoning using tobacco extract.** *Toxichem Krimtech* 2008, **75**: 134-136.
546. Bernareggi A: **Clinical pharmacokinetics of nimesulide.** *Clin Pharmacokinet* 1998, **35**: 247-274.
547. Bakdash A, Ganswindt M, Herre S, Nakulski T, Pragst F: **Lethal poisoning with p-nitroaniline.** *Toxichem Krimtech* 2006, **73**: 61-65.
548. Moller Jensen K, Berg Dahl J: **Plasma concentrations of glyceryl trinitrate and its dinitrate metabolites after sublingual administration to volunteers. Simultaneous determination of glyceryl trinitrate and its dinitrate metabolites.** *Arzneim Forsch /Drug Res* 1994, **44**: 951-953.
549. Thiermann H, Mast U, Eyer P, Hilber A, Pfab R, Felgenhauer J *et al.*: **Parathion poisoning: pharmacokinetics and laboratory findings during continuous infusion of obidoime and atropine [abstract].** *Naunyn-Schmiedeberg's Arch Pharmacol* 1996, **353**: R146.
550. Lamp KC, Bailey EM, Rybak MJ: **Ofloxacin clinical pharmacokinetics.** *Clin Pharmacokinet* 1992, **22**: 32-46.
551. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: **Olanzapine. Pharmacokinetic and pharmacodynamic profile.** *Clin Pharmacokinet* 1999, **37**: 177-193.
552. Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG *et al.*: **Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.** *J Clin Psychopharmacol* 2009, **29**: 278-283.

553. Elian AA: **Fatal overdose of olanzepine.** *Forensic Sci Int* 1998, **91**: 231-235.
554. Perry PJ, Lund BC, Sanger T, Beasley C: **Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.** *J Clin Psychopharmacol* 2001, **21**: 14-20.
555. Shrestha M, Hendrickson RG, Henretig FM: **Striking extrapyramidal movements seen in large olanzapine overdose.** *Clin Toxicol* 2001, **39**: 282.
556. Kees F, Jehkul A, Bucher M, Mair G, Kiermaier J, Grobecker H: **Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers.** *Arzneimittelforschung* 2003, **53**: 87-92.
557. Van Herreweghe I, Mertens K, Maes V, Ramet J: **Orphenadrine poisoning in a child: clinical and analytical data.** *Intensive Care Med* 1999, **25**: 1134-1136.
558. Gonzalez-Esquivel DF, Ortega-Gavilan M, Alcantara-Lopez G, Jung-Cook H: **Plasma level monitoring of oxcarbazepine in epileptic patients.** *Arch Med Res* 2000, **31**: 202-205.
559. May TW, Korn-Merker E, Rambeck B: **Clinical pharmacokinetics of oxcarbazepine.** *Clin Pharmacokinet* 2003, **42**: 1023-1042.
560. Theisohn M, Heimann G: **Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers.** *Eur J Clin Pharmacol* 1982, **22**: 545-551.
561. Cremers S, Sparidans R, den HJ, Hamdy N, Vermeij P, Papapoulos S: **A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis.** *Eur J Clin Pharmacol* 2002, **57**: 883-890.
562. Vandebrom RH, Wierda JM: **Pancuronium bromide in the intensive care unit: a case of overdose.** *Anesthesiology* 1988, **69**: 996-997.
563. Bond GR, Krenzelok EP, Normann SA, Tendler JD, Morris-Kukoski CL, McCoy DJ *et al.*: **Acetaminophen ingestion in childhood--cost and relative risk of alternative referral strategies.** *J Toxicol Clin Toxicol* 1994, **32**: 513-525.
564. Graudins A, Aaron CK, Linden CH: **Overdose of extended-release acetaminophen.** *N Engl J Med* 1995, **333**: 196.
565. Kamali F, Edwards C, Rawlins MD: **The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics.** *Br J Clin Pharmacol* 1992, **33**: 309-312.
566. van der Marel CD, van Lingen RA, Pluim MA, Scoones G, van DM, Vaandrager JM *et al.*: **Analgesic efficacy of rectal versus oral acetaminophen in**

- children after major craniofacial surgery.** *Clin Pharmacol Ther* 2001, **70**: 82-90.
567. Nielsen JC, Bjerring P, rendt-Nielsen L: **A comparison of the hypoalgesic effect of paracetamol in slow-release and plain tablets on laser-induced pain.** *Br J Clin Pharmacol* 1991, **31**: 267-270.
568. Rose SR: **Subtleties of managing acetaminophen poisoning.** *Am J Hosp Pharm* 1994, **51**: 3065-3068.
569. Schiodt FV, Ott P, Christensen E, Bondesen S: **The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdose.** *Clin Pharmacol Ther* 2002, **71**: 221-225.
570. Smilkstein MJ, Douglas DR, Daya MR: **Acetaminophen poisoning and liver function.** *N Engl J Med* 1994, **331**: 1310-1311.
571. Vale JA, Proudfoot AT: **Paracetamol (acetaminophen) poisoning.** *Lancet* 1995, **346**: 547-552.
572. Hart TB, Nevitt A, Whitehead A: **A new statistical approach to the prognostic significance of plasma paraquat concentrations.** *Lancet* 1984, **2**: 1222-1223.
573. Bismuth C, Garnier R, Baud FJ, Muszynski J, Keyes C: **Paraquat poisoning. An overview of the current status.** *Drug Saf* 1990, **5**: 243-251.
574. Dinis-Oliveira RJ, Duarte JA, Sanchez-Navarro A, Remiao F, Bastos ML, Carvalho F: **Paraquat poisonings: mechanisms of lung toxicity, clinical features, and treatment.** *Crit Rev Toxicol* 2008, **38**: 13-71.
575. Fairshter RD, Dabir-Vaziri N, Smith WR, Glauser FL, Wilson AF: **Paraquat poisoning: an analytical toxicologic study of three cases.** *Toxicology* 1979, **12**: 259-266.
576. Gil HW, Kang MS, Yang JO, Lee EY, Hong SY: **Association between plasma paraquat level and outcome of paraquat poisoning in 375 paraquat poisoning patients.** *Clin Toxicol (Phila)* 2008, **46**: 515-518.
577. Gawarammana IB, Buckley NA: **Medical management of paraquat ingestion.** *Br J Clin Pharmacol* 2011, **72**: 745-757.
578. Houze P, Baud FJ, Mouy R, Bismuth C, Bourdon R, Scherrmann JM: **Toxicokinetics of paraquat in humans.** *Hum Exp Toxicol* 1990, **9**: 5-12.
579. Kang MS, Gil HW, Yang JO, Lee EY, Hong SY: **Comparison between kidney and hemoperfusion for paraquat elimination.** *J Korean Med Sci* 2009, **24 Suppl**: S156-S160.
580. Lheureux P, Leduc D, Vanbinst R, Askenasi R: **Survival in a case of massive paraquat ingestion.** *Chest* 1995, **107**: 285-289.

581. Kuhs H, Rudolf GA: **Cardiovascular effects of paroxetine.** *Psychopharmacology (Berl)* 1990, **102**: 379-382.
582. Sindrup SH, Gram LF, Broesen K, Eshoj O, Mogensen EF: **The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms.** *Pain* 1990, **42**: 135-144.
583. Sindrup SH, Grodum E, Gram LF, Beck-Nielsen H: **Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study.** *Ther Drug Monit* 1991, **13**: 408-414.
584. Gosciniak H-T: **Suizid mit Perazin.** *Psychopharmakotherapie* 1997, **4**: 105.
585. Amoah AG, Gould BJ, Parke DV, Lockhart JD: **Further studies on the pharmacokinetics of perhexiline maleate in humans.** *Xenobiotica* 1986, **16**: 63-68.
586. Jones TE, Morris RG, Horowitz JD: **Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state.** *Br J Clin Pharmacol* 2004, **57**: 263-269.
587. Linnet K, Wiborg O: **Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism.** *Clin Pharmacol Ther* 1996, **60**: 41-47.
588. Armstrong PJ, Bersten A: **Normeperidine toxicity.** *Anesth Analg* 1986, **65**: 536-538.
589. Baumann TJ, Smythe MA, Marikis B, Bivins BA: **Meperidine serum concentrations and analgesic response in postsurgical patients.** *DICP* 1991, **25**: 724-727.
590. Hagemeyer KO, Mauro LS, Mauro VF: **Meperidine-related seizures associated with patient-controlled analgesia pumps.** *Ann Pharmacother* 1993, **27**: 29-32.
591. Holmberg L, Odar-Cederlof I, Boreus LO, Heyner L, Ehrnebo M: **Comparative disposition of pethidine and norpethidine in old and young patients.** *Eur J Clin Pharmacol* 1982, **22**: 175-179.
592. Kaiko RF, Foley KM, Grabinski PY, Heidrich G, Rogers AG, Inturrisi CE *et al.*: **Central nervous system excitatory effects of meperidine in cancer patients.** *Ann Neurol* 1983, **13**: 180-185.
593. Anderson GD, Pak C, Doane KW, Griffy KG, Temkin NR, Wilensky AJ *et al.*: **Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia.** *Ann Pharmacother* 1997, **31**: 279-284.
594. Brandolese R, Scordo MG, Spina E, Gusella M, Padriani R: **Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.** *Clin Pharmacol Ther* 2001, **70**: 391-394.

595. Frey OR, von Brenndorff AI, Probst W: **Comparison of phenytoin serum concentrations in premature neonates following intravenous and oral administration.** *Ann Pharmacother* 1998, **32**: 300-303.
596. Hayes G, Kootsikis ME: **Reassessing the lower end of the phenytoin therapeutic range: a review of the literature.** *Ann Pharmacother* 1993, **27**: 1389-1392.
597. Howard CE, Roberts RS, Ely DS, Moyer RA: **Use of multiple-dose activated charcoal in phenytoin toxicity.** *Ann Pharmacother* 1994, **28**: 201-203.
598. Mlynarek ME, Peterson EL, Zarowitz BJ: **Predicting unbound phenytoin concentrations in the critically ill neurosurgical patient.** *Ann Pharmacother* 1996, **30**: 219-223.
599. Murphy JM, Motiwala R, Devinsky O: **Phenytoin intoxication.** *South Med J* 1991, **84**: 1199-1204.
600. Privitera MD: **Clinical rules for phenytoin dosing.** *Ann Pharmacother* 1993, **27**: 1169-1173.
601. Asthana S, Greig NH, Hegedus L, Holloway HH, Raffaele KC, Schapiro MB *et al.*: **Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.** *Clin Pharmacol Ther* 1995, **58**: 299-309.
602. Kietzmann D, Hamm C, Bouillon T, Kettler D, Gundert-Remy U: **Concentration-effect relationship of piritramid (Dipidolor(R)) in a postoperative pain model [abstract].** *Naunyn-Schmiedeberg's Arch Pharmacol* 1994, **349**: R139.
603. Heinz W, Trebesch I, Ulrich A, Klöser C, Kl: **Ist ein therapeutisches Drug-Monitoring bei Azolen sinnvoll? [abstract].** *Med Klin* 2008, **103**: 63.
604. Hohmann C, Kang EM, Jancel T: **Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations.** *Clin Infect Dis* 2010, **50**: 939-940.
605. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R *et al.*: **Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.** *Clin Infect Dis* 2007, **44**: 2-12.
606. Shoji S, Suzuki M, Tomono Y, Bockbrader HN, Matsui S: **Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy.** *Br J Clin Pharmacol* 2011, **72**: 63-76.
607. Wood DM, Berry DJ, Glover G, Eastwood J, Dargan PI: **Significant pregabalin toxicity managed with supportive care alone.** *J Med Toxicol* 2010, **6**: 435-437.

608. Goggin M, Crowley K, O'Malley K, Barry P, Kelly G, Blake J: **Serum concentrations of prilocaine following retrobulbar block.** *Br J Anaesth* 1990, **64**: 107-109.
609. Moffett BS, Cannon BC, Friedman RA, Kertesz NJ: **Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment.** *Pharmacotherapy* 2006, **26**: 1687-1693.
610. Edstein MD, Veenendaal JR, Scott HV, Rieckmann KH: **Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man.** *Chemotherapy* 1988, **34**: 385-392.
611. Gandia P, Saivin S, Le-Traon AP, Guell A, Houin G: **Influence of simulated weightlessness on the intramuscular and oral pharmacokinetics of promethazine in 12 human volunteers.** *J Clin Pharmacol* 2006, **46**: 1008-1016.
612. Strenkoski-Nix LC, Ermer J, DeCleene S, Cevallos W, Mayer PR: **Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects.** *Am J Health Syst Pharm* 2000, **57**: 1499-1505.
613. Janousek J, Paul T, Reimer A, Kallfelz HC: **Usefulness of propafenone for supraventricular arrhythmias in infants and children.** *Am J Cardiol* 1993, **72**: 294-300.
614. Hartvig P, Roos BE, Ahs U, Ryde M: **Pharmacokinetics of propiomazine following intravenous, intramuscular and oral administration with special reference to the elimination phase.** *Curr Ther Res* 1981, **29**: 351-362.
615. Arndt GA, Reiss WG, Bathke KA, Springman SR, Kenny G: **The estimated plasma concentration (EPC) at which patients are induced and awake from general anesthesia with propofol.** *Clin Pharmacol Ther* 1993, **53**: 224.
616. Iwersen-Bergmann S, Rosner P, Kuhnau HC, Junge M, Schmoldt A: **Death after excessive propofol abuse.** *Int J Legal Med* 2001, **114**: 248-251.
617. Brooks DE, Wallace KL: **Acute propylene glycol ingestion.** *J Toxicol Clin Toxicol* 2002, **40**: 513-516.
618. Centers for Disease Control and Prevention (CDC): **Infant deaths associated with cough and cold medications--two states, 2005.** *MMWR Morb Mortal Wkly Rep* 2007, **56**: 1-4.
619. Wingert WE, Mundy LA, Collins GL, Chmara ES: **Possible role of pseudoephedrine and other over-the-counter cold medications in the deaths of very young children.** *J Forensic Sci* 2007, **52**: 487-490.
620. Douglas JG, McLeod MJ: **Pharmacokinetic factors in the modern drug treatment of tuberculosis.** *Clin Pharmacokinet* 1999, **37**: 127-146.

621. White MC, De SP, Havard CW: **Plasma pyridostigmine levels in myasthenia gravis.** *Neurology* 1981, **31**: 145-150.
622. Williams NE, Calvey TN, Chan K: **Plasma concentration of pyridostigmine during the antagonism of neuromuscular block.** *Br J Anaesth* 1983, **55**: 27-31.
623. Arvanitis LA, Miller BG: **Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.** *Biol Psychiatry* 1997, **42**: 233-246.
624. DeVane CL, Nemeroff CB: **Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.** *Clin Pharmacokinet* 2001, **40**: 509-522.
625. Harmon TJ, Benitez JG, Krenzelok EP, Cortes-Belen E: **Loss of consciousness from acute quetiapine overdose.** *J Toxicol Clin Toxicol* 1998, **36**: 599-602.
626. Isbister GK, Friberg LE, Hackett LP, Duffull SB: **Pharmacokinetics of quetiapine in overdose and the effect of activated charcoal.** *Clin Pharmacol Ther* 2007, **81**: 821-827.
627. Nudelman E, Vinuela LM, Cohen CI: **Safety in overdose of quetiapine: a case report.** *J Clin Psychiatry* 1998, **59**: 433.
628. Pollak PT, Zbuk K: **Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions.** *Clin Pharmacol Ther* 2000, **68**: 92-97.
629. von Dusterlho J, Homann J: **Lebensbedrohliche Herzrhythmusstörungen unter Chinin-Medikation.** *Dtsch Med Wochenschr* 1995, **120**: 542-543.
630. Paintaud G, Alvan G, Berninger E, Gustafsson LL, Idrizbegovic E, Karlsson KK *et al.*: **The concentration-effect relationship of quinine-induced hearing impairment.** *Clin Pharmacol Ther* 1994, **55**: 317-323.
631. Mignon M, Chau NP, Nguyen-Phuoc BK, Sauvage M, Leguy F, Bonfils S: **Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships.** *Br J Clin Pharmacol* 1982, **14**: 187-193.
632. Fleishaker JC: **Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.** *Clin Pharmacokinet* 2000, **39**: 413-427.
633. Härtter S: **Moderne Antidepressiva: Pharmakokinetik, Interaktionspotenzial und TDM.** *Pharm Unserer Zeit* 2004, **33**: 296-303.
634. Anderson JL, Reddy CP, Myerburg RJ, Waxman HL, de Vane PJ: **Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam**

- in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia.** *Am J Cardiol* 1993, **71**: 686-694.
635. Jostell KG, Lapierre YD: **Plasma concentration of remoxipride in relation to antipsychotic effect and adverse symptoms. The Canadian Remoxipride Study Group.** *Acta Psychiatr Scand Suppl* 1990, **358:48-50.**: 48-50.
636. Lappenberg-Pelzer M, Baudisch H: **Ein Todesfall nach Remoxiprideinnahme.** *Toxichem Krimtech* 1994, **61**: 10.
637. Michaelsson K, Lithell H, Vessby B, Melhus H: **Serum retinol levels and the risk of fracture.** *N Engl J Med* 2003, **348**: 287-294.
638. Kopferschmitt J, Flesch F, Lugnier A, Sauder P, Jaeger A, Mantz JM: **Acute voluntary intoxication by ricin.** *Hum Toxicol* 1983, **2**: 239-242.
639. Plomp TA, Battista HJ, Unterdorfer H, van Ditmarsch WC, Maes RA: **A case of fatal poisoning by rifampicin.** *Arch Toxicol* 1981, **48**: 245-252.
640. Peruche B, Schulz M: **Risperidon, ein neues atypisches Neuroleptikum.** *Pharm Ztg* 1996, **141**: 2920-2924.
641. Seto K, Dumontet J, Ensom MH: **Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?** *Ther Drug Monit* 2011, **33**: 275-283.
642. Hsu A, Granneman GR, Bertz RJ: **Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.** *Clin Pharmacokinet* 1998, **35**: 275-291.
643. Darreh-Shori T, Jelic V: **Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.** *Expert Opin Drug Saf* 2010, **9**: 167-176.
644. Dhillon S: **Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.** *Drugs* 2011, **71**: 1209-1231.
645. Kaye CM, Nicholls B: **Clinical pharmacokinetics of ropinirole.** *Clin Pharmacokinet* 2000, **39**: 243-254.
646. Emanuelsson B-M, Norsten-Höög C, Sandberg R, Sjövall J: **Ropivacaine and its 2H3-labelled analogue - bioanalysis and disposition in healthy volunteers.** *Eur J Pharm Sci* 1997, **5**: 171-177.
647. Markham A, Faulds D: **Ropivacaine. A review of its pharmacology and therapeutic use in regional anaesthesia.** *Drugs* 1996, **52**: 429-449.
648. Scott DB, Lee A, Fagan D, Bowler GM, Bloomfield P, Lundh R: **Acute toxicity of ropivacaine compared with that of bupivacaine.** *Anesth Analg* 1989, **69**: 563-569.

649. Lewis LD, Essex E, Volans GN, Cochrane GM: **A study of self poisoning with oral salbutamol--laboratory and clinical features.** *Hum Exp Toxicol* 1993, **12**: 397-401.
650. Moser M, Buchberger W: **Selenium status of elderly Austrians suffering from circulation disorders.** *Wien Klin Wochenschr* 1993, **105**: 497-499.
651. Müller D, Desel H: **Problematik, Klinik und Beispiele der Spurenelementvergiftung - Selen.** *Toxichem Krimtech* 2012, **79**: 5-16.
652. Aldosary BM, Sutter ME, Schwartz M, Morgan BW: **Case series of selenium toxicity from a nutritional supplement.** *Clin Toxicol (Phila)* 2012, **50**: 57-64.
653. Milner DA, Hall M, Davis GG, Brissie RM, Robinson CA: **Fatal multiple drug intoxication following acute sertraline use.** *J Anal Toxicol* 1998, **22**: 545-548.
654. Kahan BD, Napoli KL: **Role of therapeutic drug monitoring of rapamycin.** *Transplant Proc* 1998, **30**: 2189-2191.
655. MacDonald A, Scarola J, Burke JT, Zimmerman JJ: **Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.** *Clin Ther* 2000, **22 Suppl B**: B101-B121.
656. Mahalati K, Kahan BD: **Clinical pharmacokinetics of sirolimus.** *Clin Pharmacokinet* 2001, **40**: 573-585.
657. Zimmerman JJ, Kahan BD: **Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration.** *J Clin Pharmacol* 1997, **37**: 405-415.
658. Edvardsson N, Varnauskas E: **Clinical course serum concentrations and elimination rate in a case of massive sotalol intoxication.** *Pharmacokinetics* 1989, **6**: 558.
659. Steinecke H, Stein U, Lang J, Kluge S, Hentschel H, Muth G: **Intoxikation mit Sotalol.** *Toxichem Krimtech* 1999, **66**: 100-102.
660. Brook I: **Pharmacodynamics and pharmacokinetics of spiramycin and their clinical significance.** *Clin Pharmacokinet* 1998, **34**: 303-310.
661. Edmunds M, Sheehan TM, Van't Hoff W: **Strychnine poisoning: clinical and toxicological observations on a non-fatal case.** *J Toxicol Clin Toxicol* 1986, **24**: 245-255.
662. Heiser JM, Daya MR, Magnussen AR, Norton RL, Spyker DA, Allen DW *et al.*: **Massive strychnine intoxication: serial blood levels in a fatal case.** *J Toxicol Clin Toxicol* 1992, **30**: 269-283.
663. Oberpaur B, Donoso A, Claveria C, Valverde C, Azocar M: **Strychnine poisoning: an uncommon intoxication in children.** *Pediatr Emerg Care* 1999, **15**: 264-265.

664. Palatnick W, Meatherall R, Sitar D, Tenenbein M: **Toxicokinetics of acute strychnine poisoning.** *J Toxicol Clin Toxicol* 1997, **35**: 617-620.
665. Rosano TG, Hubbard JD, Meola JM, Swift TA: **Fatal strychnine poisoning: application of gas chromatography and tandem mass spectrometry.** *J Anal Toxicol* 2000, **24**: 642-647.
666. Winek CL, Wahba WW, Esposito FM, Collom WD: **Fatal strychnine ingestion.** *J Anal Toxicol* 1986, **10**: 120-121.
667. Wood DM, Webster E, Martinez D, Dargan PI, Jones AL: **Case report: Survival after deliberate strychnine self-poisoning, with toxicokinetic data.** *Critical Care* 2002, **6**: 456-459.
668. Bailey JM, Schwieger IM, Hug CC, Jr.: **Evaluation of sufentanil anesthesia obtained by a computer-controlled infusion for cardiac surgery.** *Anesth Analg* 1993, **76**: 247-252.
669. Borenstein M, Shupak RC, Barnette RE, Cooney GF, Tzeng T-B: **Cardiovascular effects of different infusion rate of sufentanil (S) in patients undergoing coronary surgery (CS).** *Clin Pharmacol Ther* 1994, **55**: 129.
670. Haynes G, Brahen NH, Hill HF: **Plasma sufentanil concentration after intranasal administration to paediatric outpatients.** *Can J Anaesth* 1993, **40**: 286.
671. Scholz J, Bause H, Schulz M, Klotz U, Krishna DR, Pohl S *et al.*: **Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients.** *Br J Clin Pharmacol* 1994, **38**: 369-372.
672. Paap CM, Nahata MC: **Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction.** *DICP* 1989, **23**: 646-654.
673. Davies NM, Watson MS: **Clinical pharmacokinetics of sulindac. A dynamic old drug.** *Clin Pharmacokinet* 1997, **32**: 437-459.
674. Larsen AK: **Suramin: an anticancer drug with unique biological effects.** *Cancer Chemother Pharmacol* 1993, **32**: 96-98.
675. Hooks MA: **Tacrolimus, a new immunosuppressant--a review of the literature.** *Ann Pharmacother* 1994, **28**: 501-511.
676. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E *et al.*: **Consensus document: therapeutic monitoring of tacrolimus (FK-506).** *Ther Drug Monit* 1995, **17**: 606-614.
677. Mukherjee A, Le K, Lieberman R: **Relevance of preclinical PK-PD to the clinical immunomodulatory (IMMOD) effects of FK-506 in transplantation (TX) and autoimmunity (AI).** *Clin Pharmacol Ther* 1994, **55**: 149.

678. Takahara S, Kokado Y, Kameoka H, Takano Y, Jiang H, Moutabarrik A *et al.*: **Monitoring of FK 506 blood levels in kidney transplant recipients.** *Transplant Proc* 1994, **26**: 2106-2108.
679. Undre N, Moller A: **Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group.** *Transpl Int* 1994, **7 Suppl 1:S15-21.**: S15-S21.
680. Venkataramanan R, Lever J, Jain A, Burckart G, Flowers J, Warty V *et al.*: **FK506: Correlation between trough concentrations and AUC's in transplant patients [abstract].** *Pharm Res* 1993, **10**: S-390.
681. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V *et al.*: **Clinical pharmacokinetics of tacrolimus.** *Clin Pharmacokinet* 1995, **29**: 404-430.
682. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G *et al.*: **Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients.** *J Clin Pharmacol* 2001, **41**: 542-551.
683. Wallemacq PE, Verbeeck RK: **Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients.** *Clin Pharmacokinet* 2001, **40**: 283-295.
684. Winkler M, Christians U: **A risk-benefit assessment of tacrolimus in transplantation.** *Drug Saf* 1995, **12**: 348-357.
685. Terhaag B, Grünert A, Richter K, Bahlmann G, Gloris A: **Zur Effektivität der Hämo-perfusion bei einer Talinolo-l-Intoxikation - ein Fallbericht.** *Z Klin Med* 1987, **42**: 1463-1464.
686. Terhaag B, Möbus U, Oertel R, Richter K, Feller K: **Zur Pharmakokinetik von Talinolo-l (Cordanum(R)) nach wiederholter 7tägiger oraler Gabe am gesunden Probanden.** *Medicamentum* 1992, **2**: 40-44.
687. Janknegt R: **Teicoplanin in perspective. A critical comparison with vancomycin.** *Pharm Weekbl Sci* 1991, **13**: 153-160.
688. Wilson AP: **Clinical pharmacokinetics of teicoplanin.** *Clin Pharmacokinet* 2000, **39**: 167-183.
689. Forrest AR, Marsh I, Bradshaw C, Braich SK: **Fatal temazepam overdoses.** *Lancet* 1986, **2**: 226.
690. Heintz R, Stebler T, Lunell NO, Mueller S, Guentert TW: **Excretion of tenoxicam and 5'-hydroxy-tenoxicam into human milk.** *J Pharm Med* 1993, **3**: 57-64.
691. Nilsen OG: **Clinical pharmacokinetics of tenoxicam.** *Clin Pharmacokinet* 1994, **26**: 16-43.

692. Woosley RL, Chen Y, Freiman JP, Gillis RA: **Mechanism of the cardiotoxic actions of terfenadine.** *JAMA* 1993, **269**: 1532-1536.
693. Brodersen HP, Korsten S, Larbig D: **Eliminationsverfahren bei potentiell letaler Thalliumintoxikation.** *Dtsch Med Wochenschr* 1995, **120**: 1301.
694. Klemm M, Meißner D: **Problematik, Klinik und Beispiele der Spurenelementvergiftung - Thallium.** *Toxichem Krimtech* 2012, **79**: 17-22.
695. Dager WE, Albertson TE: **Impact of therapeutic drug monitoring of intravenous theophylline regimens on serum theophylline concentrations in the medical intensive care unit.** *Ann Pharmacother* 1992, **26**: 1287-1291.
696. Dettloff RW, Touchette MA, Zarowitz BJ: **Vasopressor-resistant hypotension following a massive ingestion of theophylline.** *Ann Pharmacother* 1993, **27**: 781-784.
697. Elias-Jones AC, Larcher VF, Shaw PN: **An investigation into the relationship between liver impairment and theophylline pharmacokinetics in children.** *Pharm Pharmacol Lett* 1992, **2**: 115-118.
698. Hallas J, Davidsen O, Grodum E, Damsbo N, Gram LF: **Drug-related illness as a cause of admission to a department of respiratory medicine.** *Respiration* 1992, **59**: 30-34.
699. Holford N, Black P, Couch R, Kennedy J, Briant R: **Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial.** *Clin Pharmacokinet* 1993, **25**: 495-505.
700. Kirk JK, Dupuis RE, Miles MV, Gaddy GD, Miranda-Massari JR, Williams DM: **Salivary theophylline monitoring: reassessment and clinical considerations.** *Ther Drug Monit* 1994, **16**: 58-66.
701. Phillips BA, Chrystyn H: **The role of bayesian analysis to interpret serum theophylline concentrations in the community sector.** *Pharm J* 1991, **247**: R18.
702. Sanathanan LP, Peck CC: **The randomized concentration-controlled trial: an evaluation of its sample size efficiency.** *Control Clin Trials* 1991, **12**: 780-794.
703. Shannon M: **Predictors of major toxicity after theophylline overdose.** *Ann Intern Med* 1993, **119**: 1161-1167.
704. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J: **Anti-inflammatory effects of low-dose oral theophylline in atopic asthma.** *Lancet* 1994, **343**: 1006-1008.
705. Wessel T, Unger W, Wilhelms E: **Theophyllin: Drug monitoring beim internistischen Patienten sinnvoll? Versuch einer Bewertung für Arzt und Apotheker.** *Krankenhauspharmazie* 1996, **17**: 335-339.

706. Ahearn DJ, Grim CE: **Treatment of malignant hypertension with sodium nitroprusside.** *Arch Intern Med* 1974, **133**: 187-191.
707. Koniaris LG, Zimmers TA, Lubarsky DA, Sheldon JP: **Inadequate anaesthesia in lethal injection for execution.** *Lancet* 2005, **365**: 1412-1414.
708. Adkins JC, Noble S: **Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy.** *Drugs* 1998, **55**: 437-460.
709. Leach JP, Stolarek I, Brodie MJ: **Deliberate overdose with the novel anticonvulsant tiagabine.** *Seizure* 1995, **4**: 155-157.
710. Leach JP, Brodie MJ: **Tiagabine.** *Lancet* 1998, **351**: 203-207.
711. Luer MS, Rhoney DH: **Tiagabine: a novel antiepileptic drug.** *Ann Pharmacother* 1998, **32**: 1173-1180.
712. Perucca E, Bialer M: **The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.** *Clin Pharmacokinet* 1996, **31**: 29-46.
713. Davies NM: **Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.** *Clin Pharmacokinet* 1996, **31**: 331-347.
714. Pottier J, Cousty-Berlin D, Busigny M: **Human pharmacokinetics of tiaprofenic acid.** *Rheumatology (Oxford)* 1982, **7**: 70-77.
715. Brennscheidt U, Brunnmuller U, Proppe D, Thomann P, Seiler KU: **Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment.** *Arzneimittelforschung* 2007, **57**: 106-111.
716. Hajda JP, Jahnchen E, Oie S, Trenk D: **Sequential first-pass metabolism of nortilidine: the active metabolite of the synthetic opioid drug tilidine.** *J Clin Pharmacol* 2002, **42**: 1257-1261.
717. Schwietert HR, Peeters PA, Dingemanse J, Thiercelin JF, Necciari J, de BH et al.: **Multiple dose pharmacokinetics of tiludronate in healthy volunteers.** *Eur J Clin Pharmacol* 1996, **51**: 175-181.
718. Gillet P, Gavrilloff C, Hercelin B, Salles MF, Nicolas A, Netter P: **Pharmacokinetics of tiopronin after repeated oral administration in rheumatoid arthritis.** *Fundam Clin Pharmacol* 1995, **9**: 205-206.
719. Keam SJ, Keating GM: **Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.** *Treat Respir Med* 2004, **3**: 247-268.
720. Barnfield C, Kemmenoe AV: **A sudden death due to tocainide overdose.** *Hum Toxicol* 1986, **5**: 337-340.

721. Latini R, Maggioni AP, Cavalli A: **Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.** *Clin Pharmacokinet* 1990, **18**: 91-103.
722. Barthel W, Hüller G, Böhm C, Haustein K-O: **Tolbutamid: Zwei Präparate im Vergleich.** *Pharm Ztg* 2007, **141**: 4686.
723. Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF: **Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.** *J Clin Oncol* 1996, **14**: 1504-1511.
724. Herben VM, ten Bokkel Huinink WW, Beijnen JH: **Clinical pharmacokinetics of topotecan.** *Clin Pharmacokinet* 1996, **31**: 85-102.
725. Besson JM, Vickers MD: **Tramadol analgesia. Synergy in research and therapy.** *Drugs* 1994, **47 Suppl 1**: 1-2.
726. Lehmann KA, Kratzenberg U, Schroeder-Bark B, Horrichs-Haermeyer G: **Postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimum effective concentrations.** *Clin J Pain* 1990, **6**: 212-220.
727. Iwersen S, Schmoldt A: **One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites.** *J Anal Toxicol* 1996, **20**: 301-304.
728. Meyer FP: **Trapidil (Rocornal).** *Internist Prax* 1993, **33**: 611-614.
729. Ohkubo T, Osanai T, Sugawara K, Ishida M, Otani K, Mihara K *et al.*: **High-performance liquid chromatographic determination of trazodone and 1-m-chlorophenylpiperazine with ultraviolet and electrochemical detector.** *J Pharm Pharmacol* 1995, **47**: 340-344.
730. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ: **Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.** *Clin Pharmacol Ther* 1995, **58**: 127-131.
731. Freeman CD, Quintiliani R, Nightingale CH: **Vancomycin therapeutic drug monitoring: is it necessary?** *Ann Pharmacother* 1993, **27**: 594-598.
732. Leader WG, Chandler MH, Castiglia M: **Pharmacokinetic optimisation of vancomycin therapy.** *Clin Pharmacokinet* 1995, **28**: 327-342.
733. MacGowan A, Lovering A, White L, Reeves D: **Why monitor peak vancomycin concentrations?** *Lancet* 1995, **345**: 645-647.
734. Fernandez de Gatta MD, Calvo MV, Hernandez JM, Caballero D, San Miguel JF, Dominguez-Gil A: **Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.** *Clin Pharmacol Ther* 1996, **60**: 332-340.

735. Pecar A, Lindner W, Mönch V, Münch G, Roos R: **Pharmacokinetics of vancomycin in preterm and term neonates.** *Krankenhauspharmazie* 1992, **13**: 591-593.
736. Welty TE, Copa AK: **Impact of vancomycin therapeutic drug monitoring on patient care.** *Ann Pharmacother* 1994, **28**: 1335-1339.
737. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST: **Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite.** *J Clin Pharmacol* 1992, **32**: 716-724.
738. Lüscher TF, Noll G, Sturmer T, Huser B, Wenk M: **Calcium gluconate in severe verapamil intoxication.** *N Engl J Med* 1994, **330**: 718-720.
739. Schwab M, Oetzel C, Jäggle C, Mörike K, Gleiter CH, Eichelbaum M: **Using generic names is important to prevent iatrogenic drug overdose. A case report [abstract].** *Naunyn-Schmiedeberg's Arch Pharmacol (Suppl)* 2001, **363**: R132.
740. Malabanan A, Veronikis IE, Holick MF: **Redefining vitamin D insufficiency.** *Lancet* 1998, **351**: 805-806.
741. Heaney RP: **Assessing vitamin D status.** *Curr Opin Clin Nutr Metab Care* 2011, **14**: 440-444.
742. Mata-Granados JM, Luque de Castro MD, Quesada Gomez JM: **Inappropriate serum levels of retinol, alpha-tocopherol, 25 hydroxyvitamin D3 and 24,25 dihydroxyvitamin D3 levels in healthy Spanish adults: simultaneous assessment by HPLC.** *Clin Biochem* 2008, **41**: 676-680.
743. Pazaitou-Panayiotou K, Papapetrou PD, Chrisoulidou A, Konstantinidou S, Doumala E, Georgiou E *et al.*: **Height, Whole Body Surface Area, Gender, Working Outdoors, and Sunbathing in Previous Summer are Important Determinants of Serum 25-hydroxyvitamin D Levels.** *Exp Clin Endocrinol Diabetes* 2012, **120**: 14-22.
744. Potoski BA, Brown J: **The safety of voriconazole.** *Clin Infect Dis* 2002, **35**: 1273-1275.
745. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N: **Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities.** *J Clin Pharmacol* 2006, **46**: 235-243.
746. White RH, Zhou H, Romano P, Mungall D: **Changes in plasma warfarin levels and variations in steady-state prothrombin times.** *Clin Pharmacol Ther* 1995, **58**: 588-593.
747. Xu Z-X, Naadimuthu A, Lockwood G, Berger B, Maier G, Dukivic D: **Pharmacokinetic/pharmacodynamic studies of zanoterone [abstract].** *Pharm Res* 1994, **11**: S-334.

748. Fletcher CV, Balfour HH, Jr.: **Variability in zidovudine serum concentrations.** *Pharmacotherapy* 1996, **16**: 1154-1158.
749. Fletcher CV, Acosta EP, Henry K, Page LM, Gross CR, Kawle SP *et al.*: **Concentration-controlled zidovudine therapy.** *Clin Pharmacol Ther* 1998, **64**: 331-338.
750. Hoetelmans RM, Burger DM, Meenhorst PL, Beijnen JH: **Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.** *Clin Pharmacokinet* 1996, **30**: 314-327.
751. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S *et al.*: **Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.** *J Clin Pharmacol* 2002, **42**: 1228-1236.
752. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH, Jr., Ravera C *et al.*: **The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.** *J Clin Pharmacol* 2003, **43**: 154-162.
753. De Luca A., Lamura L, Gallo M, Daniele G, D'Alessio A, Giordano P *et al.*: **Pharmacokinetic evaluation of zoledronic acid.** *Expert Opin Drug Metab Toxicol* 2011, **7**: 911-918.
754. Debailleul G, Khalil FA, Lheureux P: **HPLC quantification of zolpidem and prothipendyl in a voluntary intoxication.** *J Anal Toxicol* 1991, **15**: 35-37.
755. Garnier R, Guerault E, Muzard D, Azoyan P, Chaumet-Riffaud AE, Efthymiou ML: **Acute zolpidem poisoning--analysis of 344 cases.** *J Toxicol Clin Toxicol* 1994, **32**: 391-404.
756. Winek CL, Wahba WW, Janssen JK, Rozin L, Rafizadeh V: **Acute overdose of zolpidem.** *Forensic Sci Int* 1996, **78**: 165-168.
757. Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS: **Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures.** *J Clin Pharmacol* 1998, **38**: 166-171.
758. Mimaki T: **Clinical pharmacology and therapeutic drug monitoring of zonisamide.** *Ther Drug Monit* 1998, **20**: 593-597.
759. Schulz M, Schmoltdt A: **Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.** *Pharmazie* 2003, **58**: 447-474.
760. Bircher J: **Verbesserte Dosierung von Medikamenten durch Messung ihrer Plasmakonzentrationen.** *Ther Umsch* 1977, **34**: 830-834.
761. Bircher J, Sommer W: *Klinisch-pharmakologische Datenbsammlung*, 2 edn. Stuttgart: WVG; 1999.
762. Brosen K: **Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry.** *Ther Drug Monit* 1996, **18**: 393-396.

763. Caccia S, Garattini S: **Formation of active metabolites of psychotropic drugs. An updated review of their significance.** *Clin Pharmacokinet* 1990, **18**: 434-459.
764. Deom A: **L'intoxication d'origine inconnue, l'apport du laboratoire pour le clinicien.** *Ther Umsch* 1986, **43**: 259-268.
765. Deom A: **Valeurs usuelles des taux sanguins, urinaires et autres lors de traitements ou lors d'intoxications chez l'homme.** *Ther Umsch* 1986, **43**: 261-268.
766. Dinovo EC, Gottschalk LA, McGuire FL, Birch H, Heiser JF: **Analysis of results of toxicological examinations performed by coroners' or medical examiners' laboratories in 2000 drug-involved deaths in nine major U. S. cities.** *Clin Chem* 1976, **22**: 847-850.
767. Drayer DE: **Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.** *Clin Pharmacokinet* 1976, **1**: 426-443.
768. Drayer DE: **Problems in therapeutic drug monitoring: the dilemma of enantiomeric drugs in man.** *Ther Drug Monit* 1988, **10**: 1-7.
769. Gottschalk LA, Cravey RH: *Toxicological and pathological studies on psychoactive drug-involved deaths.* Davis: Biomedical Publishing; 1980.
770. Jack DB: *Handbook of clinical pharmacokinetic data.* Basingstoke: Macmillan; 1992.
771. Moffat AC, Jackson JV, Moss MS, Widdop B: *Clarke's isolation and identification of drugs in pharmaceuticals, body fluids, and post-mortem material*, 2 edn. London: Pharmaceutical Press; 1986.
772. Ochs HR, Gugler R: **Drug Monitoring in der Intensivmedizin.** *Internist (Berl)* 1984, **25**: 336-340.
773. Oellerich M, Sybrecht GW, Klein H: **Therapieüberwachung durch Bestimmung von Plasmakonzentrationen im Serum.** *Internist (Berl)* 1982, **23**: 174-181.
774. Paterson SC: **Drug levels found in cases of fatal self-poisoning.** *Forensic Sci Int* 1985, **27**: 129-133.
775. Pentz B, Strubelt O, Gehlhoff C: **Therapeutische, toxische und letale Arzneimittelkonzentrationen im menschlichen Plasma.** *Dt Ärztebl* 1979, **43**: 2815-2820.
776. Roots I: **Wann ist die Bestimmung von Arzneimittelkonzentrationen im Plasma nützlich und notwendig?** *Internist (Berl)* 1986, **27**: 40-52.
777. Rosenkranz B, Frölich JC: **Plasmakonzentrationen von Arzneimitteln: Wann messen, wie interpretieren?** *Dt Ärztebl* 1985, **82**: B-1769-B-1778.

778. Spector R, Park GD, Johnson GF, Vesell ES: **Therapeutic drug monitoring.** *Clin Pharmacol Ther* 1988, **43**: 345-353.
779. Stead AH, Moffat AC: **A collection of therapeutic, toxic and fatal blood drug concentrations in man.** *Hum Toxicol* 1983, **2**: 437-464.